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CHAPTER 1
3, 2, 1 BLAST OFF: A STRUCTURAL ANALYSIS INTERSUBUNIT COMMUNICATION OF
ISOCITRATE DEHYDROGENASE ENZYMES
Introduction
Isocitrate dehydrogenase (ICDH) is an essential enzyme for all aerobic organisms. Its
primary role is catalyzing the oxidative decarboxylation of D-isocitrate (ICT), generating alphaketoglutarate (AKG) along with the concomitant reduction of nicotinamide adenine
dinucleotide (NAD(P)H) (Figure 1).
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Figure 1. Scheme of the overall reaction of ICDH enzymes.
ICDHs either use NAD or NADP as cosubstrates. In eukaryotes the canonical TCA activity is
localized to the mitochondrial matrix where it catalyzes the first oxidative decarboxylation of

1

the TCA cycle. NADP dependent ICDHs are housed in the cytoplasm and supply NADPH and

2

AKG to numerous cellular processes. ICDH enzymes exhibit a variety of structural complexities
from monomeric enzymes found in specific bacteria, to functional hetero-octamers found in
some eukaroyotes.1 The regulation of the activity of the multimeric forms reveals added layers
of structural complexity. The core structure of the multimeric enzymes is a dimer of two
topologically similar or identical protomers. These dimers exhibit conformational heterogeneity
required for intersubunit communication between adjacent catalytic subunits in homodimers
and between regulatory and catalytic subunits in heterodimers. The active/ligand binding sites
are formed at the interface of both dimer subunits providing a direct conformational influence
for both protomers. For simplicity and to avoid the function ambiguity encountered when no
active/ligand site resides exclusively with a given subunit, the subunit that also binds the metal
ion will be described throughout as harboring that site. The tacitly accepted mechanism for
ICDHs is that of an oxidative decarboxylation (Figure 2), in which a hydride derived from the C-2
position of D-ICT is transferred to the nicotinamide C-4 of NAD(P) with the aid of a divalent
metal ion generating oxallosuccinate as an intermediate. This intermediate will then undergo
facile decarboxylation generating the enolic form of AKG that is either released to tautomerize
in solution or is catalytically converted to the keto form. While mechanistically plausible, this
pathway does little to inform how or why higher order oligomers of ICDHs are necessary. It
could well be asserted that homo and heterodimers are the dominant minimal catalytic form of
ICDH enzymes. Though incomplete, the available structural and mechanistic data indicate crossdimer communication is a common characteristic. In some cases, this results in regulatory
communication for the detection of modulating ligands and in other cases it would appear

3

to promote alternating site activity within the dimer.
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Figure 2. Proposed mechanism for ICDH enzymes.
The dimeric human enzymes ICDH1 and ICDH2 are of particular interest, given that variant
hetereodimer forms are associated with several forms of aggressive cancer such as acute
myeloid leukemia, glioblastoma, and chondrosarcomas.2-6 The purpose of this review article is
to catalog the apparent common and distinct communication links between ICDH dimer
protomers. In addition, we will also incorporate a cursory examination of monomeric bacterial
ICDHs that appear to have evolved from the dimeric enzymes but do not have conserved
modulatory conformational processes.
Humans contain three different ICDH enzymes, two homodimeric forms that
Function in the cytosol, ICDH1 and ICDH2, and one hetero tetrameric form that resides

within mitochondria, ICDH3. From a structural topology standpoint these three enzymes are 4
remarkably similar (Figure 3) and with respect to their reactions only differ in their nicotinamide
co-substrate preference.

Figure 3. The overall folds of the three classes of human isocitrate dehydrogenases. The
mitochondrial dimers are shown in burgundy and blue for the αβ dimer and burgundy and teal
for the αγ dimer. The cytosolic dimers are shown in orange and green for ICDH1 and tan and
purple for the ICDH2 dimer. Magnesium ions are shown as lime green spheres, and active
site/allosteric site ligands are also shown in lime green.

The homodimeric forms of ICDH1 have been the subject of intense scientific scrutiny due to
their causative role in numerous cancers. Oncogenic forms harbor an enhancement of function
variation in one of the protomers of the dimer. This alteration of one active site dramatically
enhances the capacity of the enzyme to catalyze the reaction of the nascent products,
AKG and NADPH, to regenerate NADP and the oncometabolite 2-hydroxyglutarate (2HG).

The structural similarity of 2HG to AKG causes inhibition of AKG-dependent dioxygenases

5

(AKGDO). AKGDO that function to demethylate methyl-cytosine and methyl-lysine are
chromatin modifying enzymes that modulate access to the genome.2, 7 Inhibition of these
enzymes results in hyper-methylation of histones and cytosine nucleotides that impedes RNA
polymerase access to genes. Lack of access, particularly to genes that control apoptotic
signaling, is believed to be what contributes to the proliferative behavior in associated cancers.8
This has led to the development of several inhibitors for ICDH1 and 2, designed to specifically to
attenuate the production of 2HG within cells.5, 9-11 These molecules have been developed to
inhibit only the oncogenic activity of variant heterodimer forms, a process which presumably
relies on subunit asymmetry. A fundamental question is how this aberrant activity arises from a
single amino acid change in one of two active sites of the dimer. Here we propose a disruption
in the communications between protomers is what gives rise to aberrant activity of variant
ICDHs and compare the cytosolic forms to ICDH3 in order to attempt to understand the origins
of these intersubunit communications. This analysis is based almost exclusively on examination
of available crystal structures and does not rely significantly on residue conservation to define
intersubunit interactions.
ICDH3
In living systems, the oxidation of glucose to carbon dioxide and water requires
numerous chemical transformations. It is accepted that fermentative eukaryotic progenitors
formed symbiotic associations with bacteria and acquired the capacity to oxidize the three
carbon products of glycolysis to carbon dioxide. These latter transformations are accomplished
by the enzymes of the tricarboxylic acid cycle (TCA), that is housed wholly within vestigial

bacteria/organelles known as mitochondria. This cycle is driven by three exergonic reactions 6
that are each allosterically controlled by energy or carbon status indicators in order to
modulate energy production within the cell.
As part of primary metabolism ICDH3 is the canonical ICDH of eukaryotes. ICDH3
catalyzes the second step of TCA; the oxidative decarboxylation of 2R,3S isocitrate (ICT) with
the concomitant reduction of NAD to form AKG and NADH. The standard state free energy
change for this reaction is -21 kJ/mol and remains distinctly negative under cellular
conditions.12 The NADH produced form this reaction is then utilized as a source of electrons for
oxidative phosphorylation. The enzyme requires an active site divalent metal ion chelated by
three aspartic acid residues. This metal ion is typically magnesium but in many ICDH3 enzymes
manganese functions equally well.13 The chemical mechanism of ICDH enzymes is supported by
a relative paucity of direct evidence but has a well-accepted hypothetical mechanism (Figure 2).
Initially the enzyme activates ICT for hydride transfer by stabilizing the negative charge on the
C1 carboxyl and promoting the reduction of the nicotinamide C4 of the NAD to generate
oxallosuccinate as the first intermediate. The instability of this molecule facilitates the
decarboxylation of the C3 carboxylate, forming the enol form of AKG, at which point the
enzyme can either catalyze the tautomerization by donating a proton from an active site acid,
or release it into solution and allow solvent equilibria to promote the isomerization. A
concerted mechanism is also chemically plausible where both the hydride transfer and the
decarboxylation occur concomitantly. There is evidence for the stepwise reaction however
given the work of Koshland who demonstrated that oxallosuccinate, while not kinetically
competent, is a substrate for the ICDH3 enzyme.14

Structural Analysis of Heterodimers.
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ICDH3 is a tetrameric protein that is formed from two heterodimeric units, an
αβ dimer and an αγ dimer (Figure 4). While the tetramer is referred to as the catalytically
competent enzyme, each of the dimers are capable of catalysis independent of the other with
the αγ dimer being more proficient. 13

Figure 4. Overlay of the inactive and active states of the ICDH3 αγ heterodimer of ICDH3. A.
Overlay of the Inactive and active ag heterodimer. The inactive heterodimer is shown in grey
and the active dimer is in red and teal for a and g respectively. B. Overlay for the active and
inactive αβ heterodimer. The inactive dimer is again shown in grey while the active is in red and
blue for the α and β respectively.
The heterodimeric nature of these enzymes yields a unique ICDH form, relegating the γ and β
protomers to regulatory or vestigial roles respectively, while the α protomers have the catalytic
function. Allosteric control of the ICDH3 dimers is achieved through the γ protomer which has
an allosteric site that mirrors the location of the α protomer’s active site. The β protomer has,
what is described as, a pseudo-allosteric site which does not impart ligand modulatory
influence to its α partner or the adjacent α protomer of the tetramer. As such the tetramer is
regulated primarily by ligand binding to the γ protomer. The β subunit is claimed to be

required only for tetramerization of the two hetero dimers.1 Ligand interactions at the

8

allosteric site of the αγ dimer are transmitted through the dimer interface to the active site via
a series of conformational changes and rearrangements of hydrogen bonds between the
subunits. Sun et al. demonstrated the level of complexity of interaction at this dimer interface,
allowing for the enzyme to perturb its activity based on the ligand state of the allosteric site.1

Figure 5. Intra subunit rearrangements of the αγ heterodimer. The resting
state as well as the residues responsible for rearranging the contour of the interface are shown
in grey. The activated form and those same residues are shown in red and teal for the α and γ
protomers respectively. ADP citrate and Mg are shown in lime green. Clarity has been forgone
to emphasize the complexity of these rearrangements when the activators are present.

Both dimers are also inhibited by the binding of NADH to the α protomer locking the dimer into
an inactive conformation.15 Furthermore the αγ dimer is inhibited by binding ATP binding to the
allosteric site. Activation of the αγ dimer occurs when either citrate or ADP binds at the γprotomer regulatory site, with the greatest level of activation being observed when both
molecules bind simultaneously. Binding of these ligands rearranges the dimer interface,

positioning key residues for favorable interactions with ICT and NAD. As such the

9

concentrations of ADP, ATP, citrate and NADH regulate the TCA cycle through
interactions with ICDH3. Tengfei et al., details the inter-subunit interactions that perturb the
activity of the αγ dimer through the breakage and formation of hydrogen bonds at the dimer
interface 16(Figure 5). These rearranged interactions alter the surfaces of both protomers
inducing a new overall conformation at the α subunit active site (Figure 6). Large changes can
be observed at the interface that bring residue Lysα173 into contact with Asnγ239 and bring
Argα189 within hydrogen bonding distance to Asnγ84 that together with other interactions knit
the two protomers closer to one another. Likewise, Aspα230 and Tyrα126 will move into the
active site and form hydrogen bonds with Lysγ182.

Figure 6. The dimer interface and active site residues for ICDH3 αγ heterodimer.
The ADP and Citrate molecules are associated with the γ protomer of the activated enzyme.
Bond distances shown in black are for the active γ•Mg•CIT•ADP:α•Mg dimer, and bond
distances shown in red are for the γ•Mg•CIT•ADP:α•Mg dimer. Mg ions shown in green are for
both activated and inactive dimers and not duplicated for clarity in the a protomer The Mg for
the γ protomer (right) is only present in the activated protomer.

This orients Lysγ182 from interactions with the γ protomer into the active site of the catalytic 10
protomer where it would appear to direct the leaving carboxyl group of ICT. More hydrogen
bond rearrangements occur between residues within the γ protomer and the α protomer than
occur at the interface of these subunits, suggesting that shape complimentarity and Van der
Waals interactions between the protomers are the dominant energetic contributions that
stabilize the activated state. These changes likely create a more stable binding complex for ICT,
given that activation by both citrate and ADP lowers the KM valuefor ICT.16
The hetero-tetramer also shares this characteristic of lowering the KM for ICT when
either citrate or ADP binds at the γ regulatory site, but the optimal activation is only achieved
when these two molecules act synergistically with one another. Like ADP, ATP at low
concentration has been observed to activate ICDH3 by binding to the γ regulatory site.16 It is not
until higher concentrations of ATP (>3.5 mM) that the triphosphate of ATP begins to compete
for chelation of Mg in solution and prevents the enzyme from achieving the closed
conformation through the acquisition of the metal ion .17 The αγ dimer contains two binding
sites for NADH, one in the γ regulatory site and one in the α active site. Binding of NADH to
either of these sites will inhibit the consumption of ICT by obstructing the binding sites for
activators to the allosteric site, and the nicotinamide co-substrate at active site. The presence
of NADH in the α active site of the αγ dimer has also been observed to alter the conformation
of the α subunit.16
The αβ dimer is not under the same regulatory control as the αγ dimer. The binding site
opposing the active site in the αβ dimer does not have a clear function and so is regarded as a
pseudo-allosteric site. This site does bind Mg, but the presence of citrate or ADP does not alter

the behavior of the enzyme.13 The active site, however, is subject to product inhibition by
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NADH1. The resting or unliganded state of the αβ dimer can become conformationally
asymmetric in that the binding of NADH induces a more compact structure at the α active
site while leaving the β-subunit and pseudo-allosteric site largely unchanged highlighting that
the two protomers do not change conformation in concert but instead acquire local changes in
response to specific ligands (Figure 7)1.

Figure 7. The dimer interface and active site residues for ICDH3 αβ. Bond distances shown in
black are for the active α:β•Mg heterodimer, and residues shown in red are for the inactive
α:β•NADPH. The catalytic Mg ion is shown in green.
The closure of the αβ dimer active site with the binding of NADH recruits
residues that participate in the active site that are from the β protomer rendering the dimer
inactive. Given the apparent lack of communication between the active and pseudo-allosteric
sites in the αβ dimer this review omits a detailed discussion of this heterodimer. Other reasons
for this omission include the similarity in activity observed in vitro for the α2βγ tetramer and the

αγ dimer, both of which have higher rates of turnover relative to the αβ dimer.16 Moreover, 12
the lack of a crystal structure of the αβ dimer with substrates bound and the absence of α2βγ
tetramer structure for human ICDH3 also contribute to this omission.
Disease variants.
Oncogenic variants of ICDH1 and ICDH2 enzymes have spurred interest in the aberrant
activity of human ICDH3. This led to the discovery that mutations in both the α and β
protomers of ICDH3 could lead to the progression of diseases including cancer-associated
fibroblasts which alter cellular metabolism to promote tumor growth.18 It is thought that,
mutated protomers of ICDH3 help to promote disease progression by moving the cells away
from AKG and NADH production. In cancer cells, where cellular proliferation is biased over cell
viability, cells containing specific ICDH3 mutations adapt to favor the glycolytic pathway for
energy production growing largely in a fermentative manner.19 Mutations in the β protomer
have been found to lead to less severe prognoses such as retinitis pigmentosa.20 Unlike ICDH1
and ICDH2, these mutations do not lead to the production of any known oncometabolites, but
instead impede the enzymes ability to function. Unlike the canonical ICDH3, which has a welldefined metabolic role, the cellular functions of dimeric ICDHs are less attributable to a single
cellular role. Their localization outside of the mitochondria, as well as their preference of NADP
over NAD is consistent with a role in secondary metabolism.21 Like ICDH3 both ICDH1 and
ICDH2 utilize D-ICT and Mg and carry out an otherwise identical oxidative decarboxylation.
Unlike ICDH3, ICDH1 and ICDH2 are both functional homodimeric enzymes with two active sites
and there doesn’t appear to be any native allosteric modulators of their function. Like ICDH3,
the active sites of ICDH1 and ICDH2 enzymes are composed of residues arising from both

protomers of each dimeric unit. This results in a set of residues that span the dimer interface, 13
establishing a direct path for communication between the two active sites. Asymmetry could
therefore be a recurring theme for these enzymes, who have been proposed to function in an
alternating sites manner.22 This would yield a mechanism that is reliant on one active site
achieving a post reaction conformation in response to product ligands that influences the
adjacent protomer to progress through its catalytic cycle. Therefore, an essential network of
residues would need to be maintained between the dimers to synchronize the catalytic activity.
Variant forms of homodimeric ICDHs have been documented as causative agents in a
host of cancers.8, 23 Nearly 20 % of acute myeloid leukemias and ~75% of oligodendrogliomas,
and secondary glioblastomas harbor an active site mutation in the dimeric ICDHs7. This is
generally a point mutation that alters an arginine in the active site that forms a charge
interaction with the leaving carboxyl of D-ICT. The Arg132His in ICDH1 and the positionally
equivalent Arg172Gln in ICDH2 result in radically slower native chemistry and an increased

ability to catalyze the production the oncogenic molecule D-2 hydroxyglutarate (2HG) from
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NADPH and AKG (Figure 8).
O

O

O

O
Mg

O
O

H

NAD(P)+

O

O

O

O

O

O

Mg

O
H

O
O

H
O O

O

Mg

O

O
O

O O

N
R

H2N

H
N

H2N

R

ICT

Scheme 3

Mg

NAD(P)H
AKG

Mg

H
O

H

R

O

Mg

Mg

O
H

O O

N

O

O

O

H

H2N

O
H

CO2

O
H

AH
O

H
O O

N
R

H2N

Mg

H
N
R

H2N

2-HG

H

O
H

O
Mg

O

O
O

O O

N
H2N

R

H2N

N
R

Figure 8. Proposed mechanism for the oncogenic chemistry of ICDH1 and 2. The boxed sections
highlights the aberrant activity that arises from the enzyme’s native catalytic cycle.

As stated above, 2HG inhibits cytosine and lysine demethylases of the cell nucleus resulting in
hypermethylation of DNA and histones that spurs proliferative growth cells.4 The consensus
appears to be that the 2HG will accumulate to the highest levels in cells that contain
heterodimeric units (WT:variant) of ICDH1 or 2.24 The exact mechanism by which the
production of 2HG is promoted in the heterodimer is not known. One claim was that channeling
of the product, AKG, occurs between the protomers moving from the WT active site to the
variant active site where the aberrant activity would take place.25 Dexter et.al however,
presented reasonable counter argument based on ligand exchange rates demonstrating that

2HG production is not contingent on channeling, but that the bulk of the 2HG was being
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derived from the conversion of glutamine to AKG and not from the catabolism of glucose.24
Studies have shown that when cells are transfected with a construct that would yield a
homodimeric Arg132 variant of ICDH1 that the 2HG concentration was much less than cells that
contained a monoallelic mutation, implying that the heterodimer is more proficient for the
production of 2HG. This highlights a fundamental alteration in the way the protomers behave
with respect to one another to produce high levels of 2HG suggesting subunit asymmetry is an
indelible component of the ICDH1,2 mechanism. While the mechanism of enhanced 2HG
production has yet to be defined, structural data available for ICDH enzymes provides some
answers. The requirement for a hetero dimer in the oncogenic activity is reminiscent of the way
ICDH3 enzymes are allosterically controlled in that the conformational state of one subnit
directly influences the behavior of the other.
Asymmetry between the protomers of the homodimeric ICDHs has been clearly
demonstrated for ICDH1 and is likely a defining characteristic of the dimeric ICDH enzymes.22
Crystallographic data indicates that ICDH1 has multiple grossly different conformations. In the
absence of Mg and/or ICT the enzyme adopts an open inactive conformation in which the
active site residues provided by the two protomers are an average of 8.6 Å separated from their
positions in the closed, active state. Oddly, the open state has the product, NADP(H), bound
that must be exchanged with NADP+ as the closed active state is formed. Closure and activation
of the enzyme occur when Mg and ICT are present at physiological concentrations which has
led to the assertion that the open state is actually an artifact of recombinant expression and
purification in the absence of these ligands.22 These conformational changes have not yet been

verified in the crystallographic record for ICDH2, perhaps as a result of a dearth of structures 16
that have native ligands bound. In the presence of Mg and D-ICT, ICDH1 adopts the closed
active conformation and releases one half of the bound NADPH and demonstrates asymmetry
in the residues that are responsible for NADP(H) binding. Residues Arg249, Asp253, Glu275, and
Arg314 adopt an open conformation in chain A of the asymmetric dimer (6PAY), which does not
contain NADPH. Asp 252 forms an ionic interaction with the active site metal and is directly
linked to Asp253 which forms part of a “latch” structure that holds the NADP binding site closed
(Figure 9).

Figure 9. Surface representation of the human ICDH1 asymmetric dimer. A Shows the closed
conformation of Arg249 and Glu257 from the NADP bound protomer and Arg314 from the
adjacent protomer in blue and green respectively. B shows the same residues as A but in the
open conformation when NADP is no longer bound. C is the closed conformation of an
ambiguous dimeric ICDH from trypanosoma brucei forming the same NADP latch using residues
Arg248, Asp252, and Arg313, shown in yellow and purple.

17

Asp 252 is also within hydrogen bonding distance of the C-2 hydroxyl group of D-ICT,
creating a direct link from the ICT binding site to the adenosine binding site of the NADP
(Figure 10).

Figure 10. The dimer interface and active site residues for ICDH1. Bond distances showed in red
represent the inactive ICDH1•NADPH complex, bond distances shown in black represent the
active ICDH1•NADPH•ICT•Mg complex. These residues highlight the basis for alternating sites
activity observed for ICDH1.

The other residues involved in forming the NADP latch are derived from the adjacent
protomer with only one of the four being found within the peptide chain bound to the cosubstrate. A short peptide chain, Tyr272-Asp279, forms two bridges that link the dimer active
sites at the dimer interface. Asp275 and Asp279 both form charge interactions with the
magnesium of their respective protomer, while Asn277 forms a hydrogen bond with the

counterpart residue in the adjacent protomer. Tyr272 forms a hydrogen bond with Asp273
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across this interface (Figure 10). This creates a series of interactions between the two
protomers that could influence the behavior of the adjacent protomer based on what is or isn’t
bound to the active site and the current state of the NADPH latch residues. This network of
communication between the protomers manifests itself as an alternating sites mechanism for
ICDH1. Prior to turnover ICDH1 binds to Mg and D-ICT promoting the closure of the enzyme and
priming it for catalysis. During this process 50% of the NADPH bound to the open state of the
enzyme is released allowing for NADP to associate with one active site. This may occur through
the interactions of Asp252, Asp253, Arg249, Glu257, and Arg314. When the Mg and ICT bind,
Asp252 moves ~4 Å to chelate the Mg ion and brings residues Arg249 and Asp253 into contact
with Arg314, forming a bridge between the subunits that holds the NADP in place (Figures 9 &
10). In this state the residues between Tyr272 and Gln277 of the protomer that has NADP+
bound will recruit the helix formed by the same residues in the adjacent protomer, allowing
Arg249, Asp253, Glu257, and Arg314 to adopt a new open conformation which presumably
encourages the dissociation of the pre-bound NADPH product. The mechanism for
communicating which organic acid, either ICT or AKG, resides in the active site is not yet known.
Here we propose that a triad of arginines, Arg100, Arg109, and Arg132, that coordinate around
the leaving carboxyl and C-1 of D-ICT may play a role in ligand recognition. This communication
could then be relayed by Arg132 forming a charge interaction with Asp275, a residue that
through a short peptide chain forms two hydrogen bonds across the interface via Tyr272 and
Asp273. The displacement of the bound NADPH at the opposing active site would then occur
prior to catalysis taking place. Once the decarboxylation step occurs there would be one fewer

negative charges in the active site to hold the three arginine residues in place, encouraging
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the same residues in the adjacent subunit to move and form the D-ICT bounding site in that
active site. This process will then repeat, alternating between co-substrate acquisition and
product release. On this basis disruption of intersubunit communication is expected for the
oncogenic variants as they uniformly diminish the positive character of the active site by one
unit of charge. This may contribute to the adventitious reduction of AKG by NADPH in the active
site as a result of a diminished capacity to sense the state of charge of the ligand occupying the
D-ICT/AKG binding site. While a detailed kinetic analysis of ICDH2 has yet to be done, all of the
necessary machinery appears to be in place to operate in the same alternating sites manner
(Figure 11).

Figure 11. Residues responsible for the alternating-sites activity of Dimeric ICDHs. Residues for
IVDH2 are shown in tan and purple, while residues for ICDH1 are shown in light and dark grey
the two colors representing of of each protomer in the dimer. ICT molecules and Mg ions are
shown in green and NADPH from the structures has been omitted for clarity.

Tyr311-Asp314 make the same interactions bridging between the active site and the dimer
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interface. Arg288-Asp292 also form the same helix that arg249-Asp253 form in ICDH1, with an
aspartic acid, Asp291 and Asp252 in ICDH2 and 1 respectively, that makes contact with the
active site Mg and ICT. The largest deviations in the two structures comes from the NADP
binding site, where the residues responsible for forming the “NADP latch” diverge by several
angstroms in both protomers likely due to the lack of NADP in either protomer of the ICDH2
structure. Altogether the structural similarities in these regions point to a common mechanism
for catalysis, where inter subunit communication becomes the basis for substrate/product
recognition during the catalytic cycle.
There is evidence that this alternating mechanism is not limited to mammalian
enzymes. Dimeric ICDH from Trypanosoma brucie (PDB ID: 6AJB), which cannot be identified
from sequence as distinctly as ICDH1 or 2, displays dimer asymmetry (Figure 9).26 Here we can
see that the active sites were modelled to contain molecule of AKG (which has poor or no
density), but the striking conformational difference between the two protomers can be clearly
observed if one notes the NADP to Mg distances, which differ by ~9 Å. One of them appears to
adopt a conformation with NADPH represented by modest electron density, while the other is
more compact with more well-defined density for the nicotinamide, suggesting that one of the
protomers may in fact be largely devoid of NADP(H). Moreover, the residues responsible for the
intersubunit communication of ICDH1 can also be observed in a similar spatial arrangement,
including the NADP latch, but with one less compact and less liganded protomer.

ICDH2
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ICDH2 is often called mitochondrial isocitrate dehydrogenase given its association with
the intermembrane space of this organelle.27 In this regard it appears to be redundant with
ICDH1 as both provide AKG and NADPH to the cytoplasm. The precise cellular role of ICDH2 is
still a matter of debate, but specific functions have been proposed. ICDH2 has been claimed to
be the source of reducing power for fatty acid biosynthesis.28 Another proposed role is in
providing NADPH for glutathione reductase .29 High levels of reactive oxygen species are
detrimental to cells facilitating a need for a pool of reduced glutathione to compensate.
Neither of these roles is spatially distinct from ICDH1, given that both operate formally within
the cytoplasm.
As stated, ICDH2 is a homodimer with two active sites that reside at the interface
between the protomers. This allows for conformational communication between protomers.
Residues Ile254, Ser253, Leu289, Lys251, and Asp291 arise from the adjacent subunit and play a
role in binding D-ICT (Figure 12). These contacts offer a means to detect the ligand bound in
either protomer, which much like ICDH1, may be an integral part of half site reactivity. Available
structural data for human ICDH2 emphasize complexes with drug candidates designed to inhibit
oncogenic variants to the extent that no inhibitor free structures with native ligands bound
have been deposited. As such, this review will compare the ligand induced conformational
states of Human ICDH2 R100K variant (PDB ID:5SVO), with the WT mouse enzyme (PDB
ID:5F3H), which share 97 % sequence identity. Examination of the topology of these two
structures does not provide any evidence of gross structural changes occurring with the
acquisition of ligands (Figure 12).
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Figure 12. The dimer interface and active site residues for ICDH2. Bond distances in black are
for the presumably active ICDH2•Mg•ICT complex. Bond distances shown in red are from the
open ICDH2•NADP(H) complex. The closed complex has both D-ICT and Mg bound, shown in
black text, while the open dimer has NADPH bound labeled with red text.

By examining specific residues however, we do gain some insight into potential intersubunit
communication mechanisms. Here we observe residues that link the active sites to the dimer
interface. Asp314 coordinates the Mg ion and is linked to Gly313, Asp312 and Tyr311 (directly
analogous to the protomer interface of ICDH1 and homodimeric ICDHs from other species22).
The hydroxyl of the phenol ring of Tyr311 then forms a hydrogen bond with Asp 312 of the
adjacent protomer. This could conceivably be used to relay information between active sites,
perturbing the conformation such that, for example, product dissociation is favored.
Much like ICDH1, variant forms of ICDH2 promote the formation of the
oncometabolite 2HG.8 These enhancement of function mutations involve one of two
active site arginines, Arg140 and Arg172. Both of these arginines have been observed in
crystallographic data to interact in some way with the leaving carboxyl of D-ICT, and alteration

of the size or charge in this location impacts the catalytic cycle. This leads to ICDH2
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preferentially catalyzing hydride transfer between NADPH and AKG allowing for the
adventitious reduction of AKG. Some groups have also suggested that the consumption of
NADPH via this oncogenic activity will remove a source of electrons for glutathione reductase,
allowing for an accumulation of oxidative damage in these cells which in turn would lead to
more mutations.30 Though in regard to causation of cancer, ICDH2 is similarly relevant to ICDH1,
relatively little kinetic or structures including native ligands are available, limiting to some
extent what can be concluded of the function this enzyme.
Monomeric ICDH
Bacteria have similar diversity of ICDH enzymes but in a species-specific manner. These
organisms have the dimeric and tetrameric ICDHs that can have specificity for NADP or NAD.
However, bacteria also have monomeric ICDH enzymes that have a polypeptide chain twice the
length of typical ICDHs and house a single active site. Mention of these enzymes is included
solely for completeness as these enzymes cannot display dimer asymmetry. Monomeric ICDHs
are responsible for the same chemistry as the dimeric enzymes and show similar Vmax and KM
values for their ligands, while preferring to use manganese over magnesium as the divalent
metal ion31. These larger enzymes possess two domains, a large and a small, that come
together to form the active site32 donating residues from both domains to chelate the
ligands necessary for catalysis similar to the interface active/ligand binding sites of ICDH1, 2 &
3. Structurally the monomeric protein is distinct from dimeric enzymes having less that 10%
sequence identity. However, inspection of the active site reveals a similar ligand recognition
motif suggesting they were formed via convergent evolution (Figure 13).
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Figure 13. Structure comparison of dimeric and monomeric ICDHs. Left. Overlay of the dimeric
ICDHs (top) compared with a monomeric form (bottom). Right. A look at the active site for the
three dimeric enzymes as well as the monomeric form. Almost all of the same residues that
have been observed to be catalytically conserved are found arising from a nearly identical
spatial arrangement.

Like the homodimeric enzymes the monomeric forms utilize active site carboxylates and
arginines to bind to the manganese and ICT respectively. The structural similarities between
these two classes of ICDH enzymes have led some groups to conclude that the monomeric
forms evolved from the dimeric;32 while Yasutake et. al. used these features along with
topological studies to conclude that monomeric ICDHs were likely the result of a gene
duplication in organisms that contained a dimeric form. The monomeric forms were then
evolutionarily retained since they conveyed temperature specificity to the production of
NADPH and AKG at 4o C.33

Isocitrate dehydrogenase enzymes are a vital part of cellular metabolism. Variant
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forms of the dimeric human enzymes allow for an enhancement of aberrant chemistry that are
causative in several forms of lethal cancers.2-6 As such, understanding how they are chemically
different from the native enzymes is important from the perspective of treatment
development. The heterodimeric units of the tetramer of ICDH3 are a useful reference for the
functionality of the homodimeric ICDH1 and 2 enzymes. The key difference between the
tertrameric and the dimeric enzymes is that the heterodimeric units that make up the tetramer
only contain one active site in the α protomer. This leaves a γ protomer that binds to activators
to help regulate ICDH activity in the mitochondria, and a β protomer that appears to take on a
structural role aiding in oligomerization. As a result, the interface at which these protomers
interact to form either the αβ or αγ dimers become a vital part of how they modulate their
chemistry. The dimeric enzymes also utilize the interface between protomers to perturb the
activity of their adjacent subunit. However, instead of relegating one protomer to a strictly
regulatory role, the dimeric enzymes seem to sequentially turn over then modulate the
adjacent protomer in an alternating fashion. Insights from the heterodimers as well as the
structural analysis done in this work will be crucial for informing exactly how the two protomers
of dimeric ICDHs communicate, allowing for a detailed elucidation of the catalytic cycle.
Knowing exactly how these enzyme protomers communicate with one another can provide
insight into the variant enzymes, allowing for rationalization of the tumorigenic activity and
helping to drive the development of inhibitor molecules.

CHAPTER 2
TRANSIENT-STATE ANALYSIS OF HUMAN ISOCITRATE DEHYDROGENASE I: ACCOUNTING FOR
THE INTERCONVERSION OF ACTIVE AND NON-ACTIVE CONFORMATIONAL STATES.
Abstract
Human isocitrate dehydrogenase 1 (HsICDH1) is a cytoplasmic homodimeric Mg (II)dependent enzyme that converts D-isocitrate (D-ICT) and NADP+ to alpha-ketoglutarate (AKG),
CO2 and NADPH. The active sites are formed at the subunit interface and incorporate residues
from both protomers. The turnover number titrates hyperbolically from 17.5 s-1 to a minimum
of 7 s-1 with increasing enzyme concentration. As isolated, the enzyme adopts an inactive open
conformation and binds NADPH tightly. The open conformation displaces three of the eight
residues that bind D-ICT and Mg (II). Enzyme activation occurs with the addition of Mg (II) or DICT with a rate constant of 0.12 s-1. The addition of both Mg (II) and D-ICT activates the enzyme
with a rate constant of 0.6 s-1 and displaces half of the bound NADPH. This indicates that
HsICDH1 may have a half-site mechanism in which the active sites alternate in catalysis. The Xray crystal structure of the half-site activated complex reveals asymmetry in the homodimer
with a single NADPH bound. The structure also indicates a pseudo-tetramer interface that
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impedes the egress of NADPH consistent with the suppression of the turnover number at
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high enzyme concentration. When the half-site activated form of the enzyme is reacted with
NADP+, NADPH forms with a rate constant of 204 s-1 followed by a shift in the NADPH
absorption spectrum with a rate constant of 28 s-1. These data indicate the accumulation of two
intermediates states. Once D-ICT is exhausted, HsICDH1 relaxes to the inactive open state with
a rate constant of ~3 s-1.
Introduction
Mammals have three isocitrate dehydrogenase (ICDH) activities that convert Disocitrate (D-ICT) to alpha-ketoglutarate (AKG) and CO2 with concurrent reduction of
nicotinamide adenine dinucleotide (NAD(P)+) (Figure 14).

Figure 14. Chemistry of ICDH Enzymes.
ICDH3 is a matrix mitochondrial enzyme that catalyzes the first oxidative decarboxylation of the
citric acid cycle and has NAD+ as a co-substrate. ICDH1 and ICDH2 preferentially
reduce NADP+, are cytoplasmic and have less defined cellular functions. ICDH2 is associated
with mitochondria and has been suggested to be involved in fatty acid biosynthesis.28, 34-36
ICDH1 diffuses within the cytoplasm and is believed to be an important source of both

NADPH and AKG. Human ICDH1 and ICDH2 have become the subject of intense interest as
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specific variant forms exhibit an increased tendency to catalyze a reaction that consumes both
NADPH and AKG; reducing AKG to D-2-hydroxyglutarate (2HG). In almost all instances the active
site residues altered in such variants are arginines adjacent to the leaving carboxylate. The
dominant alterations involve R132 in ICDH1 and the structurally equivalent R140 in ICDH2. In
80-90% of cases the arginine codon is mutated to yield a histidine codon. This propensity
toward the production of 2HG is analogous to the reverse ICDH reaction chemistry but does not
include the incorporation of CO2.37, 38 2HG has no native metabolic role and can accumulate to
concentrations that induce proliferative cellular behaviors .39 It has been shown that 2HG
inhibits AKG-dependent dioxygenases that control access to the genome by histone
modification .40, 41 This has recently led to the development of drugs that specifically inhibit the
variant forms of these enzymes to halt unchecked cellular division.5, 11, 42-44 The medicinal
imperative to inhibit oncogenic forms of ICDH1 and 2 has superseded the mechanistic
investigation of these enzymes. The consensus is that all ICDHs proceed via the same
mechanism in which hydride transfer from D-ICT C2 reduces NAD(P)+ and the oxalosuccinate
formed is then decarboxylated (Figure 14).45
It is well established that ICDH enzymes exhibit conformational complexity in vitro.46
The most immediate evidence of this is the slow onset or lag that is observed prior to steadystate turnover. Preincubation with both Mg (II) and D-ICT has been shown to eliminate
the lag indicating that these ligands induce conformational changes that bring the
enzyme to an activated state.47 The structural changes that occur between the inactive
resting form and the active state have been described.21 These data show that in the

absence of Mg (II) and D-ICT, ICDH enzymes relax to an open conformation and bind
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NADPH (or NADP+) with high affinity. With respect to D-ICT and Mg (II), the eight first-sphere
liganding residues are contributed by both subunits of the ICDH homodimer: five from one
subunit and three from the other. The open conformation results in numerous changes to the
overall structure of the dimer that withdraw the three residues of the second subunit from the
active site by ~12 Å. Mg (II) and D-ICT can recruit these displaced residues with hydrogen
bonding and charge pairing interactions to reinstate the closed active conformation (Figure 15).

Figure 15. The Open Inactive and Closed Active Structures of HsICDH1. Residues depict the
active site in each conformation.

It is not known if these distinct conformational states of ICDH enzymes have a cellular
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function. It has been suggested the enzyme is self-regulated via these two states ,21 though the
argument offered did not link the conformations to a cellular condition; nor did it consider the
null possibility that the open state is an inconsequential structural oddity that arises only in the
absence of specific native ligands during in vitro isolation.
The open and closed forms add complexity to the systematic biophysical investigation of
ICDH enzymes. This is particularly true with regard to transient-state observations, given that
slow initial events obscure the observation of subsequent relatively fast events. Although the
two states of HsICDH1 have been proposed and described, the extent to which they complicate
observations of catalysis has not. In an effort to make direct observations of the human ICDH1
oxidative decarboxylation reaction we were required to study the events and equilibria that
occur prior to and after catalysis. Our observations are primarily based on spectrophotometric
changes associated with the NADPH dihydronicotinamide. This moiety exhibits perturbations in
fluorescence and absorption transitions in response to HsICDH1 conformational and catalytic
events. We show that pre-incubation with specific reaction components can poise the enzyme
for observation by single turnover, but the path to catalysis from the inactive resting state
involves the added complexity of half-site reactivity in which only one of the two protomers of
the HsICDH1 homo-dimer is immediately available for substrate acquisition and catalysis in the
activated state.

Materials and Methods

32

Materials.
The Miller formulation of LB Broth powder, kanamycin, isopropyl β-D-1thiogalactopyranoside (IPTG), HEPES buffer, NaCl, β-mercaptoethanol (βME), and BD TALON
affinity column packing were purchased from Fisher Scientific. Imidazole and glycerol were
obtained from Acros Organics. NADP+ was purchased from Amresco. NADPH was from Lee
Biosolutions. Competent E. coli BL21 DE3 cells were purchased from New England Biolabs.
DL-isocitrate (DL-ICT) and D-ICT were from Millipore Sigma. DL-ICT was used for all data
presented in this study. Observations relating to half-site reactivity were each repeated with DICT. These include preparation of the 50% NADPH bound form of HsICDH1, transient-state
single turnover observations made with this complex and the X-ray crystal structure of this form
of the enzyme. In each case no significant variation was observed when compared to data
obtained with the racemic mixture.
Enzyme purification.
The gene for HsICDH1 (UniProt: O75874) was synthesized and subcloned into pET41a by
Genscript, Inc. (Piscataway, NJ). The codon bias was optimized for E. coli and the synthesized
DNA incorporated Nde I and Xho I restriction sites at the 5’ and 3’ ends, respectively. The gene
was subcloned into the corresponding restriction sites in plasmid pET41a yielding a construct
that expresses a form of HsICDH1 that is fused to a C-terminal 6His-Tag. This construct,
pHsICDH1, was transformed into competent E. coli BL21 DE3 cells. Cell stocks were prepared by
transferring a single colony to lysogeny broth (LB) containing 25 µg/mL kanamycin and grown at
37 oC with shaking at 225 rpm. The broth culture was grown until the first

signs of turbidity and the cells were combined in precooled microfuge tubes with sterile 50% 33
glycerol to give a final concentration of 20% and then stored at -80 oC.
To express HsICDH1, 100 µL of the thawed cell stock was spread onto an LB agar plates
made with 25 µg/mL kanamycin and grown at 37 oC for 16 hrs. Cell lawns from two plates were
then re-suspended in pre-warmed LB broth and used to inoculate a 1 L flask of the LB broth
with 25 µg/mL kanamycin added. Cells were grown with vigorous shaking (220 rpm) at 37 oC to
an OD600nm of ~0.6 before lowering the temperature to 20 oC. After one hour the culture was
induced with 100 µM IPTG and incubated for an additional ~20 hours. All purification steps
were performed at 4 oC. Cells were harvested with centrifugation for 45 minutes at 2,860 rcf.
The cell pellets were then re-suspended in chilled buffer A (20 mM HEPES, 100 mM NaCl, 10
mM imidazole, 2 mM βME, pH 7.4), 20 mL/L of culture. The cell slurry was lysed by sonication
using a Branson 450 sonifier set to 40 W with two bursts of 3.5 minutes each. The lysate was
centrifuged at 11,630 g for 45 minutes to remove cellular debris and the supernatant was
loaded at 1 mL/min onto a BD TALON affinity column (16 x 110 mm) coupled to a Bio Rad NGC
chromatography system. The column was then washed with 200 mL of buffer A at 1 mL/min.
HsICDH1 was then eluted using a 400 mL linear gradient from 0 to 100% buffer B (20 mM
HEPES, 100 mM NaCl, 300 mM Imidazole, 2 mM βME, pH 7.4) and collected as 5 mL fractions.
Fractions exhibiting ICDH activity were pooled and assessed for purity using SDS-PAGE. The
pooled enzyme sample was then concentrated and exchanged (~1000-fold) into 20 mM HEPES,
100 mM NaCl, 2 mM βME, pH 7.4 by repeated concentration and dilution using Amicon Ultra15, 10 KDa nominal molecular weight cutoff (NMWC) centrifugal filters and then stored at -80
oC.

HsICDH1 eluted from the BD TALON column at near homogeneity and further purification

was not required. HsICDH1 was studied as expressed and was not subject to thrombin
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proteolysis to cleave C-terminal 6His-tag. Enzyme concentration was quantified using a
calculated ε280nm of 65,830 M-1cm-1 that includes the 280 nm absorption contribution (2000 M1cm-1)

of the adenine of the bound NADPH/NADP+ molecules and the yield was calculated using

a molar mass of 46,260. The yield of purified HsICDH1 was ~150 mg of protein per liter of
culture.
Expression and Purification of Old Yellow Enzyme (OYE2).
Saccharomyces cerevisiae OYE2 (ScOYE2) (UniProt: Q03558) was used to convert
HsICDH1•NADPH to HsICDH1•NADP+. The gene for ScOYE2 48, 49 was optimized for expression in
E. coli and cloned into pET28a expression plasmid by Enzymax using Nde I and Xho I restrictions
sites. This cloning strategy fuses the OYE gene to a C-terminal 6His-Tag. Frozen cell stocks were
prepared as described above for pHsICDH1.
For ScOYE2 expression, cell stocks were thawed and 5 L of LB broth (50 µg/mL
kanamycin) were inoculated with 100 µL of the thawed cell stock per liter. Cultures were
incubated at 37 oC with shaking at 220 rpm, until reaching an OD600nm of 0.9. Cultures were then
induced with 100 µM IPTG and incubated for a further 3 hours at 37 oC. The cell suspensions
were then centrifuged at 3,500 rcf and the supernatants were decanted. The pellets were then
resuspended in 100 mL ice-cold 50 mM HEPES, pH 7.5 and placed in a stainless-steel beaker on
ice and sonicated for 12 minutes using a Branson sonifier set to 40 W. The sonicate was then
centrifuged at 11,000 rcf for 45 minutes and the supernatant decanted and retained. The
supernatant was loaded at 1 mL/min onto a BD TALON column (12.5 x 100 mm) preequilibrated with 50 mM HEPES, pH 7.5 coupled to a Bio Rad NGC chromatography system. A

wash step of 200 mL at 1 mL/min of 50 mM HEPES, 10 mM imidazole, pH 7.5 was performed 35
prior to initiating a 400 mL gradient from 10 - 300 mM imidazole in 50 mM HEPES, pH 7.5 to
elute the protein. A single symmetrical peak was observed on the chromatogram.
Yellow, flavin containing, fractions were pooled and the purity was assessed by SDS-PAGE. The
enzyme concentration was measured spectrophotometrically using the measured extinction
coefficient of the flavin at 464 nm (11,300 M-1cm-1). Yields were routinely 12 mg/L of culture.
Imidazole was removed by >100,000-fold buffer exchange into 20 mM HEPES, pH 7.5 using
Amicon-15 10 KDa NMWC filters. The purified enzyme was concentrated to ~500 µM and
divided into aliquots for storage at -80 °C.
Stopped-flow Spectrophotometry.
All steady-state and transient-state observations were made at 20 oC using a Hi-Tech
stopped-flow spectrophotometer (TgK Scientific) in single or double-mixing mode. In all cases a
mixing event involved a 1:1 dilution. The final concentration of reactants is reported in figure
legends.
Preincubation and observation of lag prior to turnover.
To examine the effect of preincubation with substrates and cofactors on lags observed
prior to turnover, HsICDH1 at two concentrations was incubated for defined times with either
D-ICT, Mg (II) or NADP+ and then mixed with the other two reaction components. HsICDH1 was
prepared in 20 mM HEPES, 2 mM βME, 100 mM NaCl, pH 7.4 (hereafter referred to as reaction
buffer) at 400 nM or 8 µM concentration. These solutions were mixed using double mixing
stopped-flow methods with one of D-ICT (8 mM), Mg (II) (20 mM) or NADP+ (1.2 mM). The
reaction was then aged for 0.1, 1 or 70 seconds before being combined with the other two

reaction components (D-ICT (2 mM), Mg (II) (5 mM), NADP+ (0.3 mM) final concentration)
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and the production of NADPH was observed at 340 nm. To evaluate the rate constant
associated with the lag, the data for 0.1 second preincubation with Mg (II), D-ICT, and NADPH
were fit to Equation 1 that describes an exponential event preceding a straight line with an
offset. In this equation, A340nm is the absorbance at 340 nm, Ao340nm is the initial absorbance at t
= zero, ∆A340nm is the amplitude associated with the lag, k is the rate constant for the lag, and m
is the slope of the linear phase.
Equation 1
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Preparation of the HsICDH1•NADP+ complex.
HsICDH1 purifies in the inactive state with predominantly NADPH bound. Treatment of
the HsICDH1•NADPH complex with 1 µM of ScOYE2 resulted in oxidation (observed as a
decrease in absorbance at 340 nm) of the NADPH followed by re-acquisition of the NADP+
formed, to yield the HsICDH1•NADP+ complex. ScOYE2 was then removed chromatographically
by anion exchange. The sample was brought up to 400 mL in reaction buffer and loaded at 1
mL/min onto a Q-sepharose column (2.5 x 20 cm) coupled to a Bio Rad NGC chromatography
system. Separation of the HsICDH1•NADP+, ScOYE2 mixture was achieved using a 400 mL linear
gradient to 500 mM NaCl in the same buffer. The HsICDH1•NADP+ complex was then buffer
exchanged using Amicon Ultra-15, 10 KDa NMWC centrifugal filters as described above to
move the complex into reaction buffer for storage at -80 oC.
Steady-state Measurements.
Steady-state measurements were made by mixing 100 nM HsICDH1 with saturating
concentrations of two of the reaction components and then with varied concentrations of the

third. Data were collected on the stopped-flow spectrophotometer in double mixing mode. 37
HsICDH1, 400 nM, was prepared in reaction buffer and mounted onto the first position
of the instrument. In the first mix, enzyme was combined with a 4-fold saturating concentration
of one substrate and Mg (II) or both substrates. In the second mix the remaining substrate or
metal ion was combined and varied. For titration of NADP+, the concentrations of Mg (II) and DICT were held constant at 5 mM and 1 mM, respectively. The concentration of NADP+ was
varied from 19 µM to 2.5 mM. For titration of Mg (II), D-ICT and NADP+ were added at 1 mM
and 300 µM, respectively, and the Mg (II) concentration was varied from 19 µM to 5 mM. For
titration of D-ICT, the Mg (II) and NADP+ concentrations were held constant at 5 mM and 300
µM, respectively, while the D-ICT concentration ranged from 16 µM to 4 mM. In each case the
reaction was monitored by the increase of absorption at 340 nm with the formation NADPH
(∆ε340 = 6220 M-1cm-1). The slopes of individual traces were determined for the data between
20 seconds and 60 seconds. The dependence of the observed rates was fit either to the
Michaelis–Menten equation (Equation 2) or a modified form that accounts for substrate
inhibition as defined by Ki (Equation 3).
Equation 2
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Equation 3
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The dependence of the observed rate of turnover on the HsICDH1 concentration.
To verify the linearity of the catalytic response of HsICDH1, a range of enzyme
concentrations were combined with saturating substrates and Mg (II) and the rate of turnover
was observed. HsICDH1 (0.097 – 50 µM) in reaction buffer with 5 mM Mg (II) was mixed with 1

mM D-ICT, 150 µM NADP+ and 5 mM Mg (II) in the same buffer using the stopped-flow
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instrument. The reaction was observed at 360 nm in order to remain within the linear range for
the absorbance response of the instrument (∆ε360 = 4240 M-1cm-1). The initial absorption
increases at 360 nm were fit to a straight line to determine the rate of reaction from the slope.
The average turnover number was obtained by dividing these data by the associated enzyme
concentrations. The dependence of the turnover number on the concentration of HsICDH1 was
fit to an inverted hyperbola according to Equation 4, where TN is the average turnover number
and [HsICDH1] is the concentration of HsICDH1.
Equation 4.
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Spectrophotometric Evidence of Half-Site Reactivity.
NADPH bound to the open, inactive form of HsICDH1 binds to a vestige of the NADP
binding site21. This ligand must be released before the enzyme can acquire NADP+ for the
forward reaction chemistry. To measure the extent of NADPH displacement by reaction ligands,
the absorption spectrum of 30 µM HsICDH1•NADPH100% (open complex) was recorded using a
Shimadzu 2600 spectrophotometer. The HsICDH1•NADPH complex was then incubated with DICT (1 mM) and Mg (II) (5 mM) for 10 min and extensively buffer exchanged by repeated
concentration and dilution cycles using Amicon Ultra-15, 10 KDa NMWC centrifugal filters. The
combined factor of dilution achieved was 12 x 106-fold. The enzyme was then diluted to equal
the initial concentration and the spectrum recorded. The fraction of bound NADPH was
determined from the 280:335 nm absorbance ratio and corrected for the contribution of
adenine at 280 nm.

A procedurally equivalent process was undertaken with 7 µM HsICDH1 in order to
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obtain fluorescence emission spectra for three states of NADPH: unbound, HsICDH1•NADPH100%
(open), and HsICDH1•Mg•ICT•NADPH50% (closed).
Fluorescence Changes Associated with Ligand Activation.
Both D-ICT and Mg (II) activate HsICDH1•NADPH21, 47. The dihydronicotinamide of the
NADPH bound to the open inactive form is a fluorophore whose environment changes as the
enzyme closes to the active state. To observe the kinetics of enzyme closure,
HsICDH1•NADPH100% (32 µM with 100 µM EDTA) was mixed with 10 mM Mg (II) and/or 2 mM
D-ICT using the stopped-flow instrument. The sample was excited at 340 nm and the total
emission at 90o beyond a 360 nm cutoff filter was recorded. The data obtained were fit
analytically to either a single or double exponential expression according to Equations 5 and 6.
Where F is the fluorescence at any point in time, Ax is the amplitude of the phase associated
with the rate constant kx and C is the fluorescence at infinite time.
Equation 5
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Equation 6
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The binding isotherm for D-ICT binding to form the HsICDH1•Mg•ICT•NADPH50%
complex was measured by titrating D-ICT to 16 µM HsICDH1•Mg•NADPH. The changes in
fluorescence intensity were used to define the fractional saturation of the enzyme at each
concentration and were fit to Equation 7 where f is fractional saturation, [ICT] is the
concentration of D-ICT and KL is the dissociation constant for D-ICT binding to the
HsICDH1•Mg•ICT•NADPH50% complex.

Equation 7

8=

/09

:;

< /09
7

:=

/09

40

Observation of D-ICT binding and induced NADPH Release.
The binding of D-ICT and the release of NADPH from the preactivated
HsICDH1•Mg•NADPH complex was observed kinetically by monitoring the changes in
fluorescence of the dihydronicotinamide moiety. The HsICDH1•Mg•NADPH complex (32 µM)
was mixed with nine concentrations of D-ICT ranging from 2 to 512 µM (post mixing) in buffer
containing 5 mM Mg (II) using the stopped-flow instrument. The flow cell was excited at 340
nm and total emission was monitored at 90o to the incident light beyond a 360 nm cutoff filter.
The data were fit analytically to Equations 5 and 6 using KaleidaGraph software (Synergy
Software).
Dinucleotide Competition Displacement.
The exchange of NADPH for NADP+ from the inactivated open HsICDH1•NADP+ complex
was observed using the enhancement of fluorescence that occurs when NADPH binds to this
enzyme form. Using the stopped-flow instrument, HsICDH1•NADP+100% (4 µM final) was mixed
with NADPH ranging from 6 to 192 µM. The sample was monitored for 20 seconds post
mixing, with excitation at 340 nm, observing total fluorescence beyond a 360 nm cutoff
filter mounted 90o to the incident light. The data obtained were then fit to a single exponential
according to Equation 5. The converse of this experiment was also undertaken in which 16 µM
NADPH was mixed with varied concentrations of HsICDH1•NADP+100% complex. In this
experiment the increase in fluorescence that occurs when NADPH associates with the resting
enzyme was fit analytically to two exponentials according to Equation 6 to assess the
concentration dependence.

Pre-steady-state single turnover of the HsICDH1•Mg•NADPH50% half-site reactive complex.
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Transient-state single turnover data were collected on the stopped-flow instrument in
single mixing mode. HsICDH1•Mg (II)•ICT•NADPH50% (200 µM HsICDH1, 1 mM D-ICT, 5 mM Mg
(II)) complex was mixed with varied sub-stoichiometric NADP+ concentrations (22.5 to 90 µM
after mixing) in reaction buffer with 5 mM Mg (II). The formation of NADPH and subsequent
processes were observed at 360 nm. The enzymatic reaction initiated in this manner provides a
single turnover for the fraction of the enzyme equivalent to the NADP+ concentration. The data
obtained were fit globally using KinTek Explorer™ software to the model shown in Figure 16
where A represents the HsICDH1•Mg•NADPH50% complex, B is NADP+, and I and II are
intermediate states.

Figure 16. Model Used to Fit Single-Turnover Data.

This model assumes rapid binding of saturating D-ICT and Mg (II) and therefore omits
consideration of binding or depletion of these ligands.
Crystallization and Structure Determination of the Asymmetric HsICDH1•Mg (II)•ICT•NADPH50%
complex.
The HsICDH1•Mg (II)•ICT•NADPH50% complex was crystallized by the hanging drop,
vapor diffusion method. Drops were formed by mixing 2 µL of 625 µM of the HsICDH1•Mg
(II)•ICT•NADPH50% complex in 20 mM HEPES, 2 mM βME, 100 mM NaCl, 2 mM DL-ICT, 5 mM
Mg (II) pH 7.4 with 1 µL of 8% tacsimate, 20% PEG 3350, pH 5.0. Crystals grew in

1-2 days to a size of approximately 50 x 200 x 20 µm. Crystals were cryo-protected for data
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collection by soaking briefly in a solution containing 10% tacsimate, 30 % PEG 3350, 20 %
glycerol, pH 5.0. Crystals were then flash-cooled by plunging in liquid nitrogen.
Diffraction data were collected at 100 K at the Life Science Collaborative Access Team
(LS-CAT) beamline 21-ID-G of the Advanced Photon Source at Argonne National Laboratory. The
beamline was equipped with a MAR 300 CCD detector. Data were collected using an oscillation
angle of 0.5° over a range of 180° and an exposure time of 1 second. The wavelength was fixed
at 0.97856 Å. Diffraction images were processed using HKL2000 [PMID 27754618]. Data
processing statistics are given in Table 1. The structure of the HsICDH1•Mg (II)•ICT•NADPH50%
complex was determined by molecular replacement using PHASER [PMID 19461840] (as
implemented in the PHENIX software suite [PMID 20124702]) with a single chain of the closed
form of HsICDH1 from PDB ID 1T0L as the search model (all ligands and water were removed
from the starting model and all B-factors were set to 20.0). The molecular replacement solution
from PHASER was correct, but the phases were poor (TFZ = 12.7, LLG = 4270) resulting in a
difficult manual rebuild, and the resulting model did not refine well. To improve the phases,
density modification and automated rebuilding were performed using PHENIX.AutoBuild[PMID
18094468].

Table 1. Crystallographic data collection and model refinement statistics for the
HsICDH1•Mg•ICT•NADPH50% complex.
Data collection
Resolution range (Å) (last shell)a
Space Group
a, b, c (Å)
α, β, γ (°)
Rmergea,b
Rmeas
Rpim
CC1/2
Total No. of reflections
No. of unique reflections
Completeness (%)a
Multiplicity
〈 I/σ(I)〉a
Model Refinement

46.50 – 2.20 (2.24 – 2.20)
P 1 21 1
94.6, 74.6, 142.9
90.0, 95.2, 90.0
0.055 (0.444)
0.064 (0.522)
0.033 (0.271)
99.8 (90.3)
379765 (34322)
100492 (6030)
99.3 (89.6)
3.8 (3.6)
12.7 (2.4)

Reflections used in refinement
86422 (5372)
Reflections used for Rfree
1898 (116)
Rcryst (Rfree)
0.224 (0.243)
2
Wilson B-factor (Å )
27.4
Number of TLS groups
19
2
c
Average B factor (Å )
40.3
Protein atoms
40.7
Solvent
32.6
Ligands
18.1
Root-mean-square (RMS) deviations
Bond lengths (Å)
0.004
Bond angles (°)
1.01
Coordinate error (Å)
0.25
Ramachandran statistics
Favored/allowed/outliers (%)
96.4/3.5/0.1
Rotamer outliers (%)
1.9
Clashscore
2.08
aValues in parentheses apply to the high-resolution shell indicated in the resolution row
bR = ∑(||F | − scale ×| F
obs
calc||)/∑|Fobs|.
cIsotropic equivalent B factors, including the contribution from TLS reﬁnement
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The resulting model underwent iterative rounds of restrained refinement in
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PHENIX.Refine[PMID 21041930] and manual model building in COOT[PMID 20383002]. The
final model was validated using MOLPROBITY[PMID 29067766]. Statistics from the
refinement process are given in Table 1. The coordinates and structure factors have been
deposited in the Protein Data Bank with accession code 6PAY.
Pre-steady-state single turnover of HsICDH1•Mg•NADP+ complex.
In order to observe the return of the enzyme to the partially Mg (II) activated
HsICDH1•Mg•NADPH100% complex once D-ICT is exhausted, we utilized the shift in the NADPH
absorption spectrum when bound to the HsICDH1•Mg•NADPH enzyme complex.
HsICDH1•Mg•NADP+ (300 µM) in reaction buffer with 5 mM Mg (II) was mixed either with 200
µM NADP+ and 400 µM D-ICT or 400 µM NADP+ and 200 µM D-ICT. This ratio of reactants
provided a 50 µM excess of enzyme over the limiting substrate ensuring one net turnover. The
former condition exhausts NADP+ and so is expected to retain the enzyme in the activated
closed state (HsICDH1•Mg•NADPH50%•ICT) and the latter condition exhausts isocitrate and thus
will allow the enzyme to acquire available newly formed NADPH and form the
HsICDH1•Mg•NADPH100% complex. To verify the additional phase observed when D-ICT is
consumed is a consequence of the acquisition of NADPH, CCD spectra were recorded for a
similar ratio of enzyme and substrates that exhausts D-ICT. In this experiment 500 spectra were
recorded at a minimum of 30 ms intervals with a logarithmic spacing over a period of 20
seconds.

Results and Discussion
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HsICDH1 is known to adopt open inactive and closed active conformations (Figure 15).21,
38, 39

The enzyme is isolated in the open form that has NADPH tightly bound. To become active,

HsICDH1 must adopt the closed conformation and in order to support the turnover number,
must more rapidly exchange bound NADP molecules. The relatively slow rate of interconversion
of these states is the apparent source of lags observed in the approach to steady-state
turnover, though the events of closure/activation and relaxation/inactivation have not been
measured hitherto. Working with bovine ICDH3, Dalziel et al., demonstrated that preincubation
with Mg (II) and D-ICT abolishes the lag phase and the pre-activated enzyme exhibits a burst of
NADH formation. This indicated that the association of one or both of these ligands converted
the enzyme from an inactive to an active form that has a rate-contributing step subsequent to
NADH formation.50 This has since been corroborated for HsICDH1 by structural studies for
which structures solved with divalent metal and D-ICT (or AKG) bound are closed (PDB IDs:
3INM, 4L04, 5YFN, 1T0L) and, conversely, structures that do not have both metal and isocitrate
are open (PDB IDs: 1T09, 5YFM).21, 38, 39 The conformational switch to the active form involves
gross structural alterations in the HsICDH1 dimer that also form the Mg (II)/D-ICT binding
pocket. The active site residues that participate in binding both the metal and D-ICT are
provided by both subunits of the homodimer (blue and green residues, Figure 15).21 Whilst in
the inactive open state, amino acid residues D252B, K212B and T214B from (what is defined here
as) the B-subunit and are approximately 12 Å distant from the Mg (II)/ICT binding residues in
the A-subunit. These residues move into contact with the substrate and the metal ion in the
closed active form (blue residues, Figure 15).

Out of necessity we have examined the kinetics of interconversion of the two

46

conformational states of HsICDH1 in order to define conditions for transient-state observation
of catalysis. These processes were observed using a variety of kinetic approaches that pivot on
the spectrophotometric signals from NADPH bound to different states of the enzyme.
The HsICDH1 prepared in this study had significant absorption at 335 nm.
Though the inactivated form of HsICDH1 has high affinity for both NADPH and NADP+, the
enzyme was isolated with 100% NADPH bound. This differs from prior reports using the similar
expression methods that reported a 1:2 ratio of NADP+:NADPH in the purified enzyme.38
The identity of the bound ligand was established by heating the enzyme at 70 oC for 5 min
to denature it, followed by centrifugation to remove the protein and analytical HPLC analysis of
the supernatant. The retention time of the ligand was shown to be identical to an NADPH
standard using previously published HPLC conditions 51 (data not shown). Copurification with
NADPH bound to the resting (open) state of the enzyme is a curiosity that has been noted by
other researchers.21, 38 However, no convincing rationale for the existence of this complex has
yet been offered. In order to support the measured turnover number, conformational
activation by the addition of Mg (II) and D-ICT, at a minimum, must enhance the association and
dissociation rates for NADP molecules.
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Figure 17. Steady-state evidence for the inactive/open state of HsICDH1. Colors
indicate which of the three ligands was preincubated with the enzyme using double-mixing
stopped-flow. Traces were manually separated and grouped for clarity. Green is NADP+, black is
D-ICT, blue is Mg (II). Line styles indicate the length of time of preincubation prior to the
addition of the other two reaction components. Solid line is for 70 seconds, dashed line is for 1
second, and dotted line is for 0.1 seconds. The final concentration of all reaction components
were: D-ICT - 2 mM, Mg (II) - 5 mM, NADP+ - 300 µM. A. Is the data obtained with 100 nM
ICDH1. B. Is the data obtained with 2 µM ICDH1. C. Lag analysis of data observed for 0.1 s-1
preincubation with Mg (II) (blue dotted line), D-ICT (black dotted line) and NADPH (green dotted
line) from plot B. The data were fit (red dashed lines) to equation 1 that describes an
exponential curve added to a linear line with an offset. For each ligand, this fit returned a rate
constant for the lag of 0.52 ± 0.01 s-1.
Lags Prior to the Steady-state.
In this study, steady-state Michaelis-Menten analyses were made with 100 nM HsICDH1
(the relevance of this concentration is made clear below). When D-ICT, NADP+ and magnesium
ions are instantaneously combined with the as-isolated resting enzyme, lags are observed prior
to the steady-state (Figure 17). As stated above, this lag was attributed to the relatively slow
conversion from the open/inactive to the closed/active conformation. The steady-state
parameters for the wild type enzyme were 18.4 ± 1.9 s-1 turnover number, with apparent KM
values of 127 ± 10, 30 ± 3, and 23 ± 1 µM for Mg (II), D-ICT, and NADP+, respectively. At 100 nM
enzyme concentration, preincubation with Mg (II), D-ICT, or NADP+ did not eliminate lags prior
to turnover. However, extended incubation with either NADP+ or ICT did result in greater rates

of steady-state turnover (Figure 17A), a phenomenon for which we have no explanation. At 48
relative high enzyme concentration (2 µM) extended preincubation with either Mg (II) or D-ICT
eliminated the lag phase (Figure 17B) in much the same manner as previously observed by
Dalziel for bovine ICDH3 with preincubation of both Mg (II) and D-ICT.47 As might be predicted,
preincubation with NADP+ did not influence the lag phase. Conformational activation by
magnesium ions alone suggests that the relaxation of the enzyme to the open form is largely
irrelevant in the cellular environment where the magnesium concentration is millimolar 52 and
indicates that the open form is an unintended consequence of in vitro preparation as opposed
to a conformation that has a cellular function.21 The Km value for Mg (II) of 127 µM would
predict that in the cell HsICDH1 is maintained ~90% activated by cellular Mg (II) alone. Other
researchers have studied the reverse reaction of HsICDH1, so it is reasonable to assume that
AKG can also transform the resting enzyme to the activated state.38 The combined effect of
cellular magnesium, D-ICT and AKG will likely maintain HsICDH1 in the activated state in vivo.
Only with relatively high enzyme concentrations can either of these ligands induce the
conformational switch to the closed, active state. At low enzyme concentrations
conformational activation is not observed (Figure 17A). Further, at high enzyme concentrations,
the activation was only observed with extended preincubation (70 s) as neither 0.1 nor 1
second preincubation with Mg (II) or D-ICT changed the lag phase appreciably (Figure 17B). The
lag observed with high HsICDH1 concentration could be isolated from the subsequent steady
data by subtraction (Figure 17C). When this residual curvature was fit to an exponential it
returned a rate constant of 0.52 s-1, which presumably represents the rate of activation. This

indicates both that the conformational changes that yield the activated state are relatively
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slow to occur and that higher order dimer-dimer interactions change the behavior of HsICDH1.
Hysteretic Catalytic Response.
Enzyme concentration-dependent changes in the behavior of HsICDH1 enzymes have
not been described previously, though reported limiting rates of turnover typically differ over a
two-fold range from 10-20 s-1. 39 53 38 Here, validation of the catalytic response
of HsICDH1 was made for a wide range of enzyme concentrations. This was achieved by mixing
excess D-ICT (2 mM) and limiting NADP+ (300 µM) with enzyme that had been preincubated
with 5 mM Mg (II) ions and monitoring the formation of NADPH at 360 nm (Figure 18).

Figure 18. The dependence of the apparent turnover number on the concentration of HsICDH1.
A. The changes in absorbance at 360 nm when varied concentrations of HsICDH1 (right to left 0.097, 0.195, 0.39, 0.781, 3.13, 6.25, 12.5, 25, 50 µM) were mixed with 2 mM D,L-ICT and then
300 µM NADP+ (all buffers including 5 mM Mg (II)). The graph shows initial kinetic data in log
time, fit to straight lines to determine the observed rate. B. The dependence of the apparent
turnover number on the concentration of HsICDH1 fit to Equation 4 to obtain TNmax = 17.5 ± 0.6
s-1 , K1/2 = 1.1 ± 0.3 µM and a lower limit of turnover number of 7.3 ± 0.6 s-1.

The data indicate a linear dependence on enzyme concentrations above 10 µM, but at lower 50
concentrations the dependence deviated from linearity. Replotting these data as the apparent
turnover number, TNapp, revealed an inverted hyperbolic shape for the observed dependence.
At low concentrations the enzyme has a maximum turnover rate of 17.5 ± 0.6 s-1 that decreases
with increasing HsICDH1 concentration to an apparent limit of 7.3 ± 0.6 s-1 with a K1/2 of 1.1 ±
0.3 µM (Figure 18B). This hyperbolic dependence indicates a high turnover state at low enzyme
concentration and a low turnover state at high enzyme concentration that may account for
variation in reported TN values. Moreover, this trend is not caused by enzyme denaturation at
high concentration as all enzyme concentrations used in Figure 18 (97 nM – 50 µM) were
prepared from a single ~2 mM HsICDH1•Mg•NADPH stock solution in the same buffer. In
addition, high concentrations of enzymes used in single turnover reactions do not yield data
that suggests the sample is 60% inactive (see below). Here we present a simple explanation for
this hysteretic dependence that is based on the observation of higher order quaternary
structure (see below) from a dimer stacking interface that was not noted in prior available X-ray
crystal or cryo-electron microscopy structures.21, 54
Apparent Half-site Behavior.
We therefore conclude that preincubation of resting HsICDH1 with Mg (II) or D-ICT
activates the enzyme for catalysis. Under the assumption that the closed state has less affinity
for NADP molecules, an attempt was made to remove the NADPH from the as-isolated
HsICDH1•NADPH complex by incubation with 5 mM Mg (II) or D-ICT followed by extensive
buffer exchange. Interestingly, neither Mg (II) or D-ICT alone brought about the net release of
NADPH from the HsICDH1•NADPH complex. Even after a ~12 million-fold buffer exchange all

NADPH was retained by the enzyme in the presence of either one of these ligands. In
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contrast, the addition of both Mg (II) and D-ICT both activated the enzyme and induced the
release of half the bound NADPH (Figure 19A). The retention of precisely half of the NADPH in
the presence of Mg (II) and D-ICT indicates half-site reactivity for the closed state of the
HsICDH1 dimer where one subunit retains the dihydronicotinamide product.

Figure 19. Spectrophotometric evidence of half-site reactivity. The displacement of 50% of the
bound NADPH from the HsICDH1•NADPH complex by added D-ICT and Mg (II).A. Absorption
spectra for various states of bound and free NADPH. B. Relative fluorescence emission spectra
for NADPH complexation states. The black spectra are NADPH in solution, the blue are the
spectra of the HsICDH1•NADPH complex and the green spectra are after the addition of D-ICT
(1 mM) and Mg (II) followed by ~12 x 106-fold buffer exchange in the presence of these ligands.
We established that NADPH fluorescence and absorption provide a sensitive signal for
observation of HsICDH1 dynamic and catalytic processes in real time. NADPH bound to the
inactive open form of the enzyme has an absorption spectrum blue-shifted by ~5 nm (Figure
19A). This shift can be used to observe the dissociation or reacquisition of NADPH. NADPH
bound to the inactive state of the enzyme also has a 4.9-fold more intense emission spectrum
that is shifted to shorter wavelengths by 30 nm and offers a sensitive means to observe

catalytic, binding and release events (Figure 19B). The magnitude of the fluorescence
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changes indicated that ligand induced closure of HsICDH1 may be observable by stopped-flow
methods. Figure 20 depicts the fluorescence changes observed when the inactive
HsICDH1•NADPH complex is mixed with D-ICT, Mg or both. The enzyme was prepared in 100
µM EDTA to preclude metal ion induced changes.

Figure 20. Spectrophotometric evidence of the kinetics of HsICDH1 activation. NADPH
fluorescence intensity changes observed when inactive HsICDH1•NADPH (with 100 µM EDTA)
was combined with Mg (II) ions, D-ICT or both. A. The NADPH fluorescence intensity change
observed when 16 µM HsICDH1•NADPH was combined with 64, 125, 250, 500, 1000 µM D-ICT.
Traces were fit (blue dashes) analytically to a single exponential (Equation 5) to obtain an
average kobs = 0.14 ± 0.04 s-1. The dependence of the amplitude changes (inset) indicate a
dissociation constant for D-ICT of 0.51 ± 0.03 mM. B. The NADPH fluorescence intensity change
observed when 16 µM HsICDH1•NADPH was combined with 640, 1280, 2560, 5120, 10240 µM
Mg (II). Traces were fit (green dashes) analytically to a single exponential (Equation 5) to yield
an average kobs = 0.12 ± 0.05 s-1. The dependence of the amplitude changes indicate weak Mg
(II) binding (inset). C. Comparative NADPH fluorescence intensity changes observed when 16
µM HsICDH1•NADPH was combined with 1 mM D-ICT (blue), 5 mM Mg (II) (green), and 1 mM
D-ICT with 5 mM Mg (II) (red). The trace observed for combined D-ICT and Mg (II) was fit (red
dashes) analytically to a linear combination of two exponentials (Equation 6) to yield kobs1 =
0.59 ± 0.01 s-1, and kobs2 = 0.15 ± 0.01 s-1.

In Figure 20A a ~5% decrease in fluorescence was observed with the association of D-ICT. The
data obtained were fit analytically to a single exponential to reveal an unchanging rate constant

of 0.14 s-1 whose amplitude increased with D-ICT concentration. Similarly, when this form of 53
the enzyme was combined with Mg (II) ions, a slightly larger ~8% decrease in fluorescence was
observed (Figure 20B). These data could also be described by a single exponential with a rate
constant of 0.12 s-1 and an amplitude that was dependent on Mg (II) concentration. We
minimally attribute the similarity in the rate observed to an intrinsic rate of conformational
breathing that oscillates between closed and open states of HsICDH1. The amplitude data
indicate the equilibrium position for each ligand concentration. The dissociation constant
for D-ICT of 0.51 ± 0.03 mM and lack of evidence for saturation by Mg (II) show that neither
binds tightly to the open form (Figure 20 A &B insets). Either ligand can bias the conformational
equilibrium toward the activated state, but neither individually induces the release of NADPH,
as no large decrease in fluorescence accompanies the binding event (Figure 19B). However,
when the HsICDH1•NADPH complex is simultaneously combined with both Mg (II) and D-ICT a
43% decrease in fluorescence is observed (Figure 20C), consistent with the observation that
these two ligands bring about the release of half the pre-bound NADPH (Figure 19B). No initial
increase in fluorescence indicates that the enzyme as isolated has exclusively NADPH bound.
The data obtained with both ligands were fit to a linear combination of two exponentials with
observed rate constants of 0.6 and 0.15 s-1, with the former accounting for 70% of the
amplitude change. This reveals that the combination of both ligands induces a ~4-fold more
rapid rate of activation and that the concentrations of Mg (II) and D-ICT used were insufficient
to saturate this process. The value of 0.6 s-1 is in excellent agreement with the rate constant for
the lag shown in Figure 17C and is consistent with both ligands inducing a more rapid
activation/closure of the enzyme.

To investigate the combined effect of Mg (II) and D-ICT interacting with the enzyme, 54
the association of D-ICT to the Mg (II)-activated form of HsICD1 was studied. The HsICDH1•Mg
(II)•NADPH100% complex was mixed with a range of D-ICT concentrations and the ensuing
changes in NADPH fluorescence were observed (Figure 21).

Figure 21. Fluorescence emission changes observed during the binding of D-ICT to the
HsICDH1•Mg•NADPH complex. A. The changes in fluorescence observed when 32 µM
HsICDH1•Mg•NADPH is mixed with 4, 8, 16, 32, 64, 128, 256, 512 and 1024 µM D-ICT when
excited at 340 nm. The dashed black line delineates what is assigned as D-ICT binding and 50%
NADPH release as indicated. Data for D-ICT concentrations from 4 – 64 µM were fit to equation
6. Data for D-ICT concentrations from 128 – 256 µM had no significant amplitude for D-ICT
binding and were fit to equation 5. The dependence of the kobs values obtained are shown in
the central plots. The upper or k1obs plot was fit to a straight line. The lower plot was not
fit to a specific equation and the line shown is interpolated. B. The fluorescence changes at 432
nm observed when 16 µM HsICDH1•Mg•NADPH is titrated with D-ICT concentrations the same
as those used in A. The inset depicts the emission spectra obtained when excited at 340 nm.
Fractional saturation was calculated from the changes in fluorescence intensity at 432 nm and
the dependence was fit to equation 7 to obtain the overall dissociation constant.
The addition of D-ICT induced two events, a rapid decrease in fluorescence followed by a slower
decrease. While compelling, the data were undermined by the rapid first phase and data offsets
that together dictate that the amplitudes of the first phase cannot be known. This complication
precludes fitting the data using global analysis based on an encompassing kinetic model. For

this reason, the data were fit analytically using exponents to instead provide a descriptive
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summary. In Figure 21A the reaction endpoints were normalized using the equation of the line
obtained from static titration of the HsICDH1•Mg (II)•NADPH100% complex with D-ICT (Figure
21B). This isotherm titration measured a dissociation constant for D-ICT from the HsICDH1•Mg
(II)•ICT•NADPH50% complex of 4.7 ± 0.5 µM. In Figure 21A, the observed rate and amplitude of
the rapid phase titrated with D-ICT concentration. The speed of this process obscured
observation of the event above 64 µM D-ICT. For D-ICT from 2-64 µM, the observed rate
constants have a linear dependence on D-ICT concentration that has a non-zero ordinate
intercept. This suggests that the first phase is direct observation of D-ICT binding with a
dissociation constant for the HsICDH1•Mg (II)•ICT•NADPH100% complex of 1 µM. The rate and
amplitude of the slower second phase also titrated with D-ICT concentration. Though the
dependence was not fit to a specific equation, the rate constants observed show a curved
dependence whose observed maximum correlates well with the 0.6 s-1 measured for NADPH
release in Figure 20C and the lag analysis of Figure 17C. This added to the net change in
fluorescence that is predicted for Mg (II)/D-ICT induced NADPH displacement (Figure 19B),
permitted assignment of this event as release of 50% of the bound NADPH in response to Mg
(II) and D-ICT binding.
Inactive State NADP(H) Exchange.
We were unable to obtain a stable form of the HsICDH1 holoenzyme without NADP
molecules bound and, as such, the dissociation constants for NADP molecules to the open state
could not be measured directly. Other researchers have obtained the apo-enzyme by reacting
the HsICDH1•NADPH complex with substrates for the reverse reaction whilst immobilized to

nickel affinity beads.38 To obtain a relative measure of the exchange of NADP, the
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HsICDH1•Mg•NADP+ complex was mixed with a variety of concentrations of NADPH and the
increase on fluorescence with the association of NADPH was observed (Figure 22A).
These data indicated that slow exchange of the two forms of NADP occurs and that NADPH at
comparable concentrations could effectively compete with the NADP+. These data were fit to a
single exponential.

Figure 22. Exchange of NADP+ and NADPH from the HsICDH1•Mg•NADP+ complex. A. The
increase in fluorescence of NADPH when mixed with 4 µM HsICDH1•Mg•NADP+ complex. The
amplitude decrease observed with concentration is from NADPH inner filter. Red dashed lines
are the analytical fit to Equation 5. The average rate constant derived from this fit was 6.8 ± 0.3
s-1. B. The increase in fluorescence of 8 µM NADPH when mixed with varied concentrations of
HsICDH1•Mg•NADP+91% complex. Red dashed lines are the analytical fit to Equation 6. The
average rate constants derived from this fit were 48 ± 7.0 s-1 and 3.3 ± 0.2 s-1. All buffers
included 5 mM MgCl2.
The observed rate constant for this process was independent of NADPH concentration
indicating that the association of this ligand was contingent on some other event. Given that
both ligands compete for the same binding site, the observed rate constant of 6.8 ± 0.3 s-1 was
assigned to the rate of dissociation of NADP+ from the HsICDH1•Mg•NADP+ complex. We also

conducted this experiment in the converse manner where varied HsICDH•Mg•NADP+
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concentrations were mixed with a fixed amount of NADPH (Figure 22B). These data had
considerably improved signal to noise as they were not impinged by excitation inner filter from
added NADPH. These data were fit analytically to two exponentials. The fit indicated that the
data could be described by two processes: the first with a rate constant of 40-50 s-1 and the
second with a rate constant of 3.0-3.6 s-1. Interestingly, the amplitudes for each of these phases
approximated 50% of the total change in fluorescence at each enzyme concentration, indicative
of half-site reactivity where half the bound NADP+ has a greater propensity to exchange. This is
at least consistent with homodimer subunit asymmetry observed at elevated HsICDH1
concentrations in other experiments.
HsICDH1 Single Turnover.
To determine if the pre-activated Mg (II) and D-ICT-treated enzyme form (i.e.
HsICDH1•Mg (II)•ICT•NADPH50%) is poised for catalysis, this complex was mixed with varied
limiting concentrations of NADP+ (Figure 23) to yield a nested set of single turnover reaction
traces. The formation of NADPH was observed at 360 nm. The data collected at 360 nm were fit
globally to the simple model depicted in Scheme 2. In this scheme A is the
HsICDH1•Mg•ICT•NADPH50% complex, B is NADP+ and AB is the complex of both. I and II
represent intermediate states that form prior to the completion of a single turnover. The fit
indicated a well-defined NADP+ association rate constant of 12.6 ± 0.6 x 106 M-1s-1 and a poorly
defined dissociation rate constant of 0.1-4.0 s-1. This ratio indicates a sub-micromolar
dissociation constant for NADP+ binding to the HsICDH1•Mg•ICT•NADPH50% complex.
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Figure 23. Single turnover kinetics of the pre-activated and exchanged
HsICDH1•Mg•ICT•NADPH50% complex. 200 µM HsICDH1•Mg•ICT•NADPH50% (200 µM HsICDH1,
1 mM D-ICT, 5 mM Mg (II)) complex was mixed with varied NADP+ (5 mM Mg (II) added)
concentrations. From bottom to top, traces shown are for 22.5, 40, 60, 75, 80, and 90 µM
NADP+. Red dashed lines are the global fit to the model shown in Scheme 2.
The association of NADP+ results in a rapid, 205 ± 4 s-1, rate of NADPH formation followed by a
decrease in absorbance that occurred with a rate constant of 28 ± 2 s-1. The rapid rate of
NADPH formation indicates that the HsICDH1•Mg•ICT•NADPH50% complex is an activated form
of the enzyme that exhibits a burst in NADPH production as opposed to a lag observed when
the reaction is initiated with the HsICDH1•NADPH complex (Figure 17). The first phase can be
definitively assigned to hydride transfer and the formation of NADPH. The design of this
experiment was such that the HsICDH1 activity was limited only by NADP+; D-ICT was in excess
and the experiment included 5 mM Mg (II). The enzyme was therefore maintained in the active
state once NADP+ was exhausted. The observed 28 s-1 phase, therefore, reports a change in the
local environment of the newly-formed NADPH that is not relaxation to the open/inactive state.
We have tentatively assigned this phase to the decarboxylation of the intermediate
oxalosuccinate that is formed with hydride transfer from isocitrate to NADP+ in the initial

rapid phase. The 28 s-1 decay of this species is catalytically relevant at 4-fold faster than
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theturnover number at this enzyme concentration (~7 s-1, Figure 18B). This dictates that the
decay of the first transient forms a second intermediate species which is presumably the
product quaternary complex, HsICDH1•Mg (II)•AKG•NADPH, whose multi-step decay is not
evident in this experiment but largely defines the turnover number.
Structure of the Asymmetric Pseudo-tetramer.
To explore the structural basis for the apparent half-site reactivity, the structure of the
HsICDH1•Mg (II)•ICT•NADPH50% complex was determined by single crystal X-ray diffraction.
The 2.2 Å resolution structure contains 4 HsICDH1 molecules in the asymmetric unit, arranged
as two dimers, 4 Mg (II) ions, 4 molecules of D-ICT, and 1 molecule of NADPH. Thus, while all
four chains in the asymmetric unit have both D-ICT and Mg (II) bound, only one of them (chain
A) also has NADPH bound. The HsICDH1•Mg (II)•ICT•NADPH50% dimer (chains A and D) is
asymmetrical. Figure 24A shows that chain D, when superimposed on chain A, gives an RMSD of
1.18 Å.
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Figure 24. Structure of the HsICDH1•Mg (II)•ICT•NADPH50% pseudo-tetramer. A. The ribbon
representation of the A and D chains (a single dimer unit) highlights the asymmetry of the
HsICDH1•Mg (II)•ICT•NADPH50% dimer. The small domain and clasp region of chain A are
colored medium grey and dark grey, while the same structures in chain D are colored light grey.
There is very little difference between the two structures in these regions. The large domain of
chain A is colored blue and that of chain D is colored green. The large domain of chain A is more
closed than in chain D owing to the bound NADP. The helix and loop that help create the
pseudo-tetramer interface is colored red. B. A surface representation showing the interactions
of the chains in the asymmetric unit highlights the ~1000 Å2 pseudo-tetramer interface. The
other crystal contacts in the c-dimension of the unit cell are much smaller, as are those in the
other two dimensions. C. The electron density maps show that there is no evidence for the
presence of the nicotinamide ring of the NADPH added. The 2|Fo|-|Fc| simulated annealing
composite omit map contoured at 1.0 σ is shown as a gold mesh. The 2|Fo|-|Fc| map
contoured at 1.0 σ is shown as a magenta mesh. The |Fo|-|Fc| difference map contoured at
+3.0 σ and -3.0 σ is shown as green and red mesh, respectively. The bound Mg (II) ion is shown
as a silver sphere.
The differences in the two chains are primarily in the relative orientations of the large

domain and the small domain-clasp domain unit. Analysis using the DynDom server[PMID
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12835274] shows that the quaternary complex (chain A) is closed by ~8° relative to chain D,
which is in a semi-closed conformation like the other published ternary complex structure, PDB
ID 5YFN. Put another way, chain A is most similar in conformation to other quaternary complex
structures like 3INM[PMID 19935646] (RMSD = 0.37 Å for 407 Cα atoms), 1T0L[PMID 15173171]
(RMSD = 0.45 Å for 408 Cα atoms), and 4L04[PMID 23731180] (RMSD = 0.48 for 407 Cα atoms).
The conformation of chain D is most like the ternary ICDH·metal·ICT complex (PDB ID 5YFN;
RMSD = 1.02 Å for 408 Cα atoms).
The subunit homodimer interfaces in the asymmetric unit are comprised almost entirely
of residues from the small and clasp domains, and bury an average surface area of 3500 Å2, as
observed in other structures of HsICDH1.21 The two dimers are related by a non-crystallographic
2-fold symmetry axis that creates an interface between the large domains of chains A and B
that buries 1015 Å2 (Figure 9B; all surface areas calculated by PDBe PISA[PMID 17681537]). For
comparison, the crystal contacts that constitute the interactions between neighboring unit cells
in the c-axis of the crystal, also between juxtaposed large domains, bury 153 and 135 Å2 of
surface. The remaining crystal contacts in the a- and b-axes vary between ~20 and ~500 Å2 of
buried surface area. This “pseudo-tetramer” interface is comprised primarily of hydrogen
bonding interactions and van der Waals contacts; there are no salt bridges. Thus, this “pseudotetramer” is unlikely to be physiologically significant, but it may certainly be a factor in in vitro
experiments at high protein concentrations and may explain, at least in part, curious
observations like the reduction in turnover number as the HsICDH1 concentration increases
(Figure 3B). The “pseudo-tetramer” also explains the 4:1 protein:NADPH ratio observed in

these crystals. The segment from Thr311 to Pro329 forms a helix and loop that project out
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from the surface of the large domain (red in Figure 9A). The N-terminal end of the helix and Cterminal end of the loop contact the NADP(H) (Val312, Arg314, His315, Thr327, and Asn328).
This entire segment is brought in toward the center of the protein upon binding of NADP
ligands. The asymmetric HsICDH1•Mg (II)•ICT•NADPH50% dimer may form a stable complex
with an NADPH-depleted (HsICDH1•Mg (II)•ICT) dimer, at least at the high concentrations used
for crystallization, and it is this tetrameric species that crystallizes under these conditions.
Another curious observation in this structure is that the nicotinamide ring of NADPH is
not visible in the electron density (Figure 9C). This is a somewhat puzzling observation, as there
does not appear to be sufficient space in the active site for large “waving” motions of the
nicotinamide ring, but local disorder (i.e. motion) is the only plausible explanation for
why this part of the otherwise solidly represented NADPH molecule is missing from the
electron density. Since NADPH is a product, this disorder may reflect destabilization of NADPH
binding to promote exchange with NADP+ in the closed state.
The initial crystallization conditions include 13.2 mM HEPES, 1.32 mM βME, 66 mM
NaCl, 1.32 mM DL-ICT, 3.2 mM Mg (II), 2.6% tacsimate, 6.6% PEG 3350, pH ~7.0. To confirm that
the dihydronicotinamide was intact in the crystal(s), the HsICDH1•Mg (II)•ICT•NADPH50%
complex was subject to the conditions used for crystallization for 30 hrs and then evaluated
spectrophotometrically for the NADPH chromophore. During this period, no significant loss of
the NADPH absorption was observed. This indicates that the acidic condition of the
crystallization well solution was poorly buffered to pH 5.0 and the 2:1 mixture of well
solution and enzyme buffer had a resulting pH that was largely defined by the

HEPES buffer.Moreover, acid denaturation of NADPH molecules is a highly efficient reaction 63
that results in cyclization of the dihydronicotinamide base with the C2’-OH of the ribose.55 Such
a reaction distorts the shape of the nicotinamide nucleotide. The NADPH observed in the
structure reported is elongated. Collectively this suggests that the dihydronicotinamide of
NADPH is intact in the structure, but is freely rotating and so is averaged to below threshold
density for detection as has been observed previously.56
Relaxation to the Inactive State.
The blue-shift observed in the NADPH absorption spectrum when bound to HsICDH1
was used to gain a measure of the rate of relaxation of the enzyme once D-ICT is exhausted.
The experiments above indicate that in the absence of D-ICT the binding constant for Mg (II) is
relatively weak and does not show evidence of saturation at 10 mM concentration (Figure 20B
inset). Consumption of all D-ICT should therefore promote at least partial relaxation to the
open inactive form in the presence of 5 mM Mg. In this experiment the HsICDH1•Mg•NADP+
complex was prepared and mixed with NADP+ and D-ICT mixtures that had either limiting or
excess D-ICT at ratios that provide single turnover. The reaction was monitored at 360 nm using
photomultiplier and also by charge coupled device detection. The single wavelength traces
obtained indicate that in the presence of excess D-ICT, NADPH is formed and no
spectrophotometric evidence of relaxation to the open state is observed in Figure 25 this
reaction progresses slightly further as a result of the pre-bound NADP+). However, with limiting
D-ICT the reaction abruptly halts and an additional phase that can be fit to single exponential
with a rate constant of 3 s-1 (Figure 25). CCD data indicate that this phase corresponds to a shift

in the NADPH spectrum to shorter wavelengths and a slight diminishment of the absorption 64
intensity, consistent with the open HsICDH1•NADPH state (Figure 19A).

Figure 25. Single turnover kinetics of the HsICDH1•Mg•NADP+ complex. A. 150 µM
HsICDH1•Mg•NADP+29% reacting with limiting NADP+ 143.5 µM (total), D-ICT 200 µM (blue
trace) and limiting D-ICT 100 µM, NADP+ 200 µM (total) (black trace). The red dashed line is
an exponential curve that decays at 3 s-1. B. CCD Spectra recorded prior (solid line), at 3 msec
(dotted line) and 15 seconds (dashed line) for 50 µM HsICDH1•Mg•NADP+91% reacting with with
50 µM NADP+ and 40 µM D-ICT concentration. All buffers included 5 mM MgCl2.

Conclusions
Collectively the above data and analyses reveal that HsICDH1 has considerable
complexity that arises from oscillating conformational states, apparent half-site reactivity and
higher-order dimer-dimer interactions that influence the turnover number. Figure 26 depicts
the behavior of one protomer of the homodimer at relative high enzyme concentration and as
such does not include observed half-site complexity. In this scheme it is shown that the
heterologously expressed, as-isolated enzyme has an inactive/open conformation that has
NADPH tightly associated. This form of the enzyme is activated relatively slowly by the addition
of Mg (II) or D-ICT.
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Figure 26. Kinetics and Equilibria of High Concentration ICDH1

The addition of either one of these ligands activates the enzyme, presumably to a closed state,
but only with the addition of both does the enzyme release of half of the bound NADPH. When
mixed with NADP+, this half-sites HsICDH1•Mg•D-ICT•NADPH50% complex affords the direct
observation of transient-state catalytic events in the absence of lags. The activated enzyme will
remain closed and in turnover until D-ICT is exhausted. Once all available D-ICT is consumed the
enzyme relaxes slowly and reforms the inactive resting state HsICDH1•NADPH complex. It is
assumed that the balance of slow activation and slow inactivation ensures that the enzyme
remains in the active form even at low D-ICT and/or Mg (II) concentrations.
The kinetic observation of the enzyme is further complicated by a non-linear catalytic
response curve that shows a ~3-fold decrease in the turnover number at relative high enzyme

concentration. This phenomenon is also not accounted for in Figure 26. The structure of the 66
activated HsICDH1•Mg•D-ICT•NADPH50% complex revealed the basis of the observed hysteretic
catalytic response curve. This structure exhibits dimer subunit asymmetry at a pseudo-tetramer
interface interaction. This interface apparently impedes the exchange of NADP molecules
consistent with a diminishing turnover number at high enzyme concentration
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CHAPTER 3
INSIGHTS INTO THE KINETIC MECHANISM OF HETERODIMERIC ISOCITRATE DEHYDROGENASE
1
Introduction
Isocitrate dehydrogenase (ICDH) enzymes exist as three distinct isomers each with
unique roles in humans.27, 57 They function to catalyze the oxidative decarboxylation of Disocitrate (D-ICT) to alpha-ketoglutarate (AKG) with the concomitant reduction of nicotinamide
adenine dinucleotide (phosphate) (NAD(P)). ICDH3 functions in the matrix of mitochondria and
preferentially uses NAD as a substrate, whereas ICDH1 and 2 both function in the cytosol and
use NADP as a substrate (Figure 27).

Figure 27. Overall reaction of ICDH enzymes.
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Variants of the dimeric forms of ICDH1 and ICDH2 have been identified as causative agents in 68
several forms of cancers.7, 8, 23 ICDH1 in particular is causative in approximately 90% of
secondary glioblastomas through the activity of the Arg132His variant.58 This mutated form
gains an enhancement in its ability to catalyze the conversion of the products of its native
chemistry, AKG and NADPH, into 2-hydroxyglutarate (2HG) and NADP+. 2HG mimics AKG,
leading to the inhibition of cytosine and lysine demethylases that are responsible for grooming
access to the genome.59 This leads to hypermethylation of chromatin and the proliferative
behavior of cancer cells. The inhibition of causative ICDH variant enzymes is a validated
approach to cancer theraphy.10, 58, 60-62 ICDH1 and 2 inhibitors target the heterodimer
(WT:variant) that arises from mono-allelic mutations as it is this form that is responsible for the
large quantities of 2HG produced by certain cancers.63 It has been demonstrated that when a
cell line is transfected with a plasmid that expresses an R132H homodimer variant of ICDH1,
substantially lower concentrations of intercellular 2HG were observed relative to cell lines
harboring a plasmid that expresses the heterodimeric form (WT:variant).24 The mechanism by
which this heterodimer generates such a large pool of the 2HG oncometabolite is poorly
understood but may be crucial in determining the best route for inhibition in the treatment of
cancers. Here we attempt to use recent findings on the WT homodimer of ICDH1 to assess
whether the heterodimer utilizes an alternating sites reaction22 and propose a mechanism
where the enol tautomer of AKG is in fact the preferred substrate for this aberrant activity.

Materials and Methods
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Protein Expression and Purification.
The gene for HsICDH1 (UniProt entry O75874) and the Arg132His mutant were
synthesized and subcloned into pET-DUET by Genscript, Inc. (Piscataway, NJ). The codon bias
was optimized for E. coli, and the synthesized DNA incorporated NdeI and XhoI restriction sites
for both genes at the 5′ and 3′ ends, respectively. The gene was subcloned into the
corresponding restriction sites in the pET-DUET plasmid yielding a construct that expresses the
WT HsICDH1 protomer and the variant Arg132His protomer fused to a C-terminal 6-His tag. The
construct for the heterodimeric ICDH1 WT:Arg132H, henceforth referred to as DUET, was
transformed into chemically competent BL21-DE3 cells (New England Biolabs® Inc.). Single
colonies were then used to inoculate starter cultures consisting of 20 mL of sterile Lysogeny
Broth (LB) (Fisher ScientificTM) with 100 µg/mL ampicillin. Cells were grown at 37 oC until
turbidity was observed, then aliquoted with sterile 50% glycerol (3:2) to give a final
concentration of 20% glycerol and stored at -80 oC.
The 1 mL cell stocks were thawed and spread at a rate of 100 µL/plate onto 8 LB agar
plates containing 100 µg/mL ampicillin. Plates were incubated at 37 oC for 14-16 hours. Lawns
of cells were then resuspended using 5 mL/plate of warm LB broth. Resuspended cells were
combined and used to inoculate four liters of Sterile LB (100 µg/mL ampicillin) evenly
partitioned into four 2 L Erlenmeyer flasks. Cells were then grown with shaking (220 rpm)
at 37 oC to an optical density of 0.6 at 600 nm. The temperature was lowered to 22 oC ,
and the cultures were cooled for 1 and a half hours. Once cooled cells were induced

with 100 µM Isopropyl β-d-1-thiogalactopyranoside(IPTG) and expressed for 20 hours. Cells 70
expressing the DUET plasmid were pelleted by centrifugation at 4000 g for 45 minutes. The
supernatant was discarded and the cells were resuspended in 20 mL/L of culture with ice cold
buffer A (20 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES), 100 mM
NaCl, 2 mM β-mercaptoethanol (BME), 10 mM imidazole pH 7.4). The resuspended cells were
placed in a stainless-steel beaker in an ice and water slurry and then lysed with sonication at 40
W in 2 bursts of 3.5 minutes, ensuring the temperature did not exceed 10 oC. Lysed cells were
then centrifuged at 10,000 g for 45 minutes to remove cellular debris prior to loading onto a BD
TALON column pre-equilibrated with buffer A. The column was then washed with 100 mL of
buffer A prior to eluting the enzyme with a 400 mL linear gradient from buffer A to buffer B (20
mM HEPES, 100 mM NaCl, 2 mM BME, 180 mM imidazole pH 7.4). Fractions (5 mL) were
collected throughout the gradient elution. The elution contained two peaks, the first contained
DUET while the later consisted of the homodimer variant, the first two-thirds of the first peak
(determined by fitting each peak independently to a gaussian according to equation 7) were
collected for buffer exchanging and storage, consisting of centrifuging using Amicon Ultra 15 mL
10 KDa cutoff filters to a >1000-fold factor of dilution into buffer C (20 mM HEPES, 100 mM
NaCl, 2 mM BME pH 7.4). The sample was then concentrated to between 1.5-2.5 mM,
partitioned into 100 µL aliquots and stored at -80 oC. The center of the two peaks were pooled
and diluted to a sufficiently low imidazole concentration (<20 mM) and loaded back onto the
column for a second elution identical to the first. Once again two peaks were obtained,
and the process repeated for the first two thirds of the first peak.

Equation 7
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Steady-State.
Steady state assays were performed to compare the native and tumorigenic activity of
all three forms of ICDH1, the homodimer WT (WT:WT), the homodimer mutant (R132H:R132H),
and the heterodimer (WT:R132H). Unless otherwise stated, all titrations were performed using
a buffer consisting of: 20 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid (HEPES),
100 mM NaCl, 2 mM β-mercaptoethanol (BME) pH 7.4 Data for the titrations with ICT were
performed on TgK stopped flow spectrophotometer in double mixing mode, monitoring the
formation of NADPH (ε340 = 6,220 M-1cm-1) at 340 nm. The WT:WT enzyme (prepared as
described in Chapter 2) (at 400 nM) was first mixed with 20 mM MgSO4 and 300 µM NADP+ and
allowed to age for 1s before being mixed with a concentration of D-ICT ranging from 31.2 to
1000 µM. Similar titrations were done for the R132H:R132H homodimer (8µM) , and the
WT:R132H heterodimer (4 µM) keeping the concentrations of MgSO4 and NADP+ the same while
varying the concentration of D-ICT from 4 to 1024 µM. The steady-state portions (4 to 15
seconds) of the data were fit to straight lines, used to build a Michaelis curve and fit according
to (Equation8)
Equation 8:
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Steady-state titrations for all three forms of the enzyme were also performed titrating AKG.
8 µM WT, 6 µM DUET, and 6 µM R132H homodimer were made in buffer C containing 400 µM
NADPH. This solution was then mixed on the stopped flow in single mixing mode with buffer C
containing 10 mM Mg (II) and AKG concentrations ranging from 0.078 to 37.5 µM. Data were

collected for 40 seconds monitoring the consumption of NADPH at 340 nm and data was
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analyzed as described above.
DUET Dual Reaction.
Steady-state analysis was performed on the DUET enzyme to determine if, like the WT
enzyme (see chapter 2), there was a dependence of the turnover number on the enzyme
concentration. In these reactions 400 µM NADP and 1.2 mM D, L-ICT were made up in buffer C
prior to mixing with DUET at 2.5, 5, 10, 20, and 40 µM on the stopped flow. Reactions were
monitored for 1000 seconds at 340 nm for both the production and consumption of NADPH.
For each concentration of the enzyme the linear portions of the increase at 340 nm as well as
the linear portions of the decrease at 340 nm were used to determine the turnover number at
those concentrations. Plots of the turnover values vs the enzyme concentration were made to
evaluate whether there was any dependence on the enzyme concentration for kcat.
Isolation of NADP Bound Form.
Attempts to observe transient event in the DUET enzyme required the removal
of bound NADPH. This was accomplished by treating the enzyme with 5 mM AKG and 5
mM Mg to induce the oncogenic activity. NADPH concentrations were monitored using the
absorbance of the co-substrate at 340 nm on a Perking-Elmer Lambda 350 spectrophotometer.
Once the absorbance at 340 nm was at baseline the sample was exchanged into fresh buffer (20
mM HEPES, 100 mM NaCl, 2 mM BME, 100 µM EDTA) by centrifugation using Amicon Ultra 15
mL 10 KDa cutoff filters to remove excess ligands. The buffer contained 100 µM EDTA to ensure
minimal metal content of the exchanged protein. The sample was then assessed for NADP+
content by assaying with 2 mM D,L ICT and 5 mM Mg without any additional NADP+,

monitoring the increase in absorbance at 340 nm on a Shimadzu UV-Vis spectrophotometer. 73
The sample was then separated into 150 µL aliquots and stored at -80oC.
NADPH Release.
Our previous work on the WT ICDH1 (Chapter 2) demonstrated that the addition of ICT
and Mg could be used to induce the release of NADPH. To ascertain whether this was true for
the heterodimer it was first incubated (on ice) with 50 µM NADPH to ensure full occupancy of
the active sites. This sample was then filtered, as above, and washed with fresh buffer C to
remove the excess NADPH. The concentrated DUET was then used to prepare a 32 µM sample
in buffer C containing 5 mM Mg (II). The DUET•Mg•NADPH complex was then mixed in a 1:1
ratio on a TgK Stopped flow spectrophotometer in fluorescence with D,L ICT ranging from 2-256
µM (final concentrations) prepared in buffer C containing 5 mM Mg (II). Changes in
fluorescence were monitored for 200 seconds beyond a 360 nm cutoff filter, exciting at 340 nm.
Data were fit to a linear combination of two exponentials for the concentrations of ICT
below 64 µM and single exponentials for concentrations above 128 µM according to
equations 9 and 10 respectively.
Equation 9:
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Transient-state (DUET•NADPH73% vs Limiting AKG).
Single turnover experiments were done for the 73% NADPH bound form of DUET
(post ICT and Mg (II) treatment) using stopped flow spectrophotometry.
DUET•NADPH73% (300 µM) was prepared in buffer C containing 10 mM Mg (II) before being
mixed with limiting and excess concentrations of AKG ranging from 6.25 to 800 µM. Oxidation

of NADPH was monitored at 340 nm for 100s, for limiting concentrations, and 200s, for
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excess concentrations. The concentration of NADPH was fixed by the amount bound to the
enzyme, ensuring that only a net single turnover occurred. Data for all AKG concentrations
were fit to single exponentials according to equation 10. Observed rate constants were plotted
against the concentrations of AKG to get a dependence curve which was in turn fit to an
inverted hyperbola according to equation 11. Where TN is the apparent turnover number
[DUET] is the concentration of DUET and k½ is the concentration of enzyme at half the minimal
turnover number.
Equation 11:

$%&'' = $%

&)

−L

∆+,∗ MNO+
3

MNO+

P

Transient-state (NADP Form).
The NADP bound form of DUET was to measure the intrinsic rate of hydride transfer for
the oncogenic activity using stopped flow spectrophotometry. DUET (300 µM, 90% NADP+
bound) was prepared in buffer C containing 2 mM AKG and 5 mM Mg (II). To avoid precipitation
of this inherently unstable form of the enzyme, it was kept on ice for the duration of the
experiment. NADPH stocks ranging in concentration from 4.4-140 µM, were prepared in the
same buffer as the enzyme with 5 mM Mg (II) added. These samples were loaded onto the
stopped flow 1 mL at a time and warmed to 20 oC for 5 minutes prior to mixing. Reactions were
monitored for NADPH consumption at 340 nm over 200 seconds. Data were fit to two
exponentials according to equation 9, and secondary plots of the dependencies for both the
amplitudes and observed rate constants were generated.
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Enol AKG.

To establish if the tautomer of AKG preferentially consumed by the DUET enzyme, enol
AKG was formed by pre-incubation with metal ions. Yang et.al demonstrated that certain
metals were capable of shifting the AKG enol-keto equilibrium toward the enol form64,
providing a means to assess this tautomer as a substrate. AKG (10 mM) was mixed with 15 mM
Mg (II) and aged for 10 minute increments in buffer C prior to being mixed with the same buffer
containing both 10 µM DUET•NADPH100% and 200 µM NADPH. The reaction was monitored for
NADPH consumption at 340 nm for 100 seconds.
Double mixing stopped flow provided a way to distinguish equilibrium driven
accumulation of the enol form, from enzyme catalyzed tautomerization. DUET (80 µM)
prepared in buffer C was mixed with the same buffer containing 4 mM AKG and 20 mM Mg (II).
This solution was then aged from 0.1 up to 500 seconds before being mixed with 300 µM
NADPH. The reaction was observed for 200 seconds at 340 nm for the consumption of NADPH.
Data were then fit to an exponential followed by a straight line according to equation 12 in
order to determine both the extent of the burst as well as the steady state rate for each age
time.
Equation 12
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NMR.
In order to definitively determine the source of the burst, C-13 spectra were obtained
on a Bruker Avance NEO 500 MHz NMR spectrophotometer. Per-13C labeled AKG was diluted
into 100% D2O to a concentration of 10.3 mM. Puratronic MgSO4 was prepared in D2O to a
concentration of 500 mM. These stocks were used to make a sample consisting of 5 mM

Mg (II), 1 mM C-13 AKG, 1.2 mM DUET and brought up to volume a final volume of 600 µL
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with D2O. This sample was then placed into the NMR and 1028 scans were acquired with proton
decoupling to determine the C-13 connectivity for the AKG molecule when bound to the
enzyme.
Results
Expression and Purification.
Seperation of the three forms of ICDH1 was achieved by using a relatively low gradient
of Imidazole (180 mM). Given that only one of the two protomers being expressed possessed a
6-His tag the different species of ICDH1 were distinguishable on the chromatogram (Figure 28
left). Extrapolation of the peaks using a gaussian distribution (Equation 7) assured us that the
fractions we pooled were pure DUET (Figure 28 right).

Figure 28. Chromatogram of ICDH1 DUET. Imidazole gradient for the DUET on a BD TALON
column. Left. A is the non-His-tagged WT:WT dimer, B is the WT:R132H heterodimer, and C is
the R132H:R132H homodimer. Right. Extrapolated peaks for both species to demonstrate the
extent of” contamination” each peak contains.

Steady-state.
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Steady state data for the native chemistry of ICDH1 demonstrated how all the forms,
WT:WT R1132H:R132H and DUET, differed in their abilities to sequester and convert D-ICT. The
WT enzyme demonstrated the highest rate of turnover at 17.6 ± 0.79 s-1 with a KMDICT value of
41.8 ± 6.75 µM. Both the homodimer variant and the DUET enzyme demonstrated similar
binding affinity for D-ICT at 102.99 ± 12.89 and 111.84 ± 7.10 µM respectively but had
dramatically different turnover numbers at 0.0048 ± .00022 and 4.54 ± 0.11 s-1. Similar
observations for 2HG production were also observed with the three forms of ICDH1, with the
homodimer variant demonstrating the highest rate of turnover with respect to AKG, followed
by DUET and WT at 0.48 ± 0.014, 0.24 ± .00062, and 0.013 ± .0012 s-1 respectively. The KMAKG
value were unexpected however, with the WT showing the weakest affinity followed by the
homodimer variant and DUET at 17.94 ± 4.37, 6.71 ± 0.65, and 0.21 ± 0.031 mM respectively
(Figure 29).

Figure 29. Steady-state plots for the three forms of ICDH1. A show the native chemistry
varying the [D-ICT] from 2-512 µM. B shows the tumorigenic activity all three forms varying the
[AKG] from 0.078-37.5 µM. While the DUET enzyme generates 2HG at a rate two-fold lower

than the homodimer mutant, the catalytic efficiency of the DUET enzyme is 17-fold higher
given the relatively tight binding with kcat/KM values of 71.23 µM-1s-1 and 1177.38 µM-1s-1
respectively.
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Figure 30. Steady state titration of the DUET enzyme. Concentrations of DUET are 3.13, 6.25,
12.5, 25 and 50 µM. The increase in absorbance is the native chemistry of ICDH1 where ICT and
NADP are converted into AKG and NADPH, the plateau is an equilibrium for both the WT and
tumorigenic activities, and the decrease in absorbance is the tumorigenic activity where NADPH
and AKG are converted into NADP and 2HG. The arrow indicates the direction in which the
concentration of enzyme is increasing.
The bi-functional assay while titrating the DUET enzyme revealed that DUET is capable of
preforming both chemistries simultaneously, but ultimately failed to demonstrate any
dependence on the enzyme concentration for either process (Figure 30)
NADPH Release
ICDH1 enzymes purify with a full complement of NADPH bound in the active site. Our
study of the WT ICDH1 (see Chapter 2) demonstrated that the half of that NADPH could be
displaced by the addition of ICT and Mg (II) priming the enzyme for an alternating sites
mechanism22. The DUET enzyme appears to be functioning via a different mechanism however

where initially the data suggest NADPH is being released but appears as though it is rebinding 79
to the enzyme (Figure 31). Not until higher concentrations of ICT do we get traces that
demonstrate a non-reversible release of NADPH from DUET. The latter phase has tentatively
been attributed to the rate of NADPH rebinding, but without proper endpoints and verification
experiments this cannot be stated with surety. The rate constants determined the first phase
do not titrate and appear to have an average rate constant of 0.13 ± 0.0017 s-1, ~ 5-fold lower
than what was observed for the WT enzyme at 0.6 s-1. The amplitudes, when plotted against
the [ICT] suggest a binding constant for D-ICT of 4.2 µM to the activated form of the DUET

enzyme which is in good agreement with the 1 µm Kd observed for the WT enzyme.

Figure 31. Presumptive evidence for NADPH release by 16 µM of the DUET enzyme. A. 16 µM of
the 100% NADPH bound DUET enzyme titrated with D-ICT at 2,4,8,16,32,64,128, and 256 µM in
the presence of 5 mM Mg (II). The decrease in fluorescence is assumed to indicate release of
NADPH as the enzyme adopts the active conformation. Fluorescence was monitored by exciting
at 340 nm and observing the total emissions beyond a 360 nm cutoff filter. the first 6 traces are
fit to two exponentials to capture the amplitudes of those phases with a rate constant fixed to
what is observed for the two pseudo-first-order traces (128 and 256 µM - 0.13 s-1) which are
both fit to a single exponential. B. Dependence of the amplitudes of the first phase plotted

against the [D-ICT] amplitudes and rate constants for the second phase are ignored due a lack80
of defined endpoint.

Together these observations seem to indicate that ICT binds more slowly to the DUET
form of the enzyme, we postulate this may be due to a disruption of conformational changes
reliant on intersubunit communications. ICDH enzymes rely on these interactions for
communicating ligand states that in turn drive the half site activity of these enzymes.
Transient-State (NADP Form).
Single turnover data for DUET•NADP+90% were observed by single mixing stopped flow,
titrating NADPH and monitoring the oxidation of the co-substrate at 340 nm.

Figure 32. Single-turnover for DUET•NADP+90% vs NADPH. A. 300 µM DUET with 2 mM AKG and
5 mM Mg (II) mixed with limiting NADPH at 4.375, 8.75, 17.5, 35, 70, and 140 µM in buffer
containing 5 mM Mg (II), traces were fit to two exponentials (green dashed lines). B. (top)
changes in the amplitude of the first phase plotted against the concentration of NADPH. B.
(bottom) The first observed rate constant plotted against NADPH. C. (top) Changes in the
amplitude for the second phase. C. (bottom) The second observed rate constant.

These data indicate biphasic NADPH oxidation (Figure 32) in which the first phase had an
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amplitude that increased almost linearly with the concentration of the co-substrate from 0.016
to 0.07 AU. These values indicate at most 11 µM NADPH oxidation in this phase, approximately
3% of the enzyme concentration. The observed rate constant for this first event was also faster
than turnover decreasing from 0.9 s-1 to around 0.3 s-1 suggesting a transient event
preceding chemistry or an alternate pathway. The reason for the decreasing rate is not
evident but could be the result of a pseudo tetrameric form of DUET altering the way NADPH
interactswith its binding site (see Chapter 2). As such this phase is tentatively assigned to
spectral perturbations that occur with NADPH binding and not resulting from NADPH oxidation.
The second phase has an average rate constant of around 0.03 s-1, a value ~ 10-fold lower than
the turnover number for this enzyme. The amplitude of this phase does correlate well with the
amount of NADPH added, with each amplitude corresponding to ~89% of the expected
absorbance change. As such we have tentatively assigned this as NADPH consumption.
Transient-state (DUET•NADPH73% vs Limiting AKG).

Single-turnover experiments limiting the concentration of AKG were performed on
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the ICT Mg (II) treated DUET enzyme. The WT enzyme revealed an alternate set of rates when
prepared in the same way, leading to the identification of an activated state (Chapter 2). A
similar titration performed with DUET yielded a set of traces were that fit to single exponentials
(Figure 33). The observed rate constants for these traces decreased with higher concentrations
of AKG, starting at a maximum of 0.08 s-1 and decreasing hyperbolically to 0.03 s-1.

Figure 33. Net single-turnover for the ICT and Mg (II) treated DUET. A. 300 µM
DUET•NADPH73% was prepared in a buffer C containing 5 mM Mg (II), this sample was then
mixed with limiting AKG at 6.25, 12.5, 25, 50, and 200 µM as well as AKG in excess at 200, 400,
and 800 µM without the addition of any NADPH to ensure single turnover under all conditions.
B. Dependence of the observed rate constant for each concentration of AKG. Interestingly the
value decreases with higher concentration, and even the maximum rate observed lies well
below the TN of 0.25 s-1.
This was a puzzling phenomenon for two reasons, the first was that the turnover number for
the DUET enzyme is 0.25 s-1 in the direction of consuming AKG, the second was we did not
anticipate AKG having an inhibitory effect on the DUET protein. The amplitudes for this
experiment did not align with expectations either. In every case the amount of AKG that was
consumed, according to the decrease in absorbance at 340 nm and assuming 1:1 stoichiometry
for NADPH:AKG, was half the concentration of added AKG.

Enol AKG.
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Early steady-state titrations for the consumption of AKG by the DUET enzyme contained
small burts prior to turnover. In order to elucidate the source of these burts AKG was incubated
with either Mg (II) alone or both Mg (II) and the DUET enzyme. A small burst in NADPH
oxidation could be observed initially (Figure 34a) reaching its maximum amplitude at around
140 minutes as the AKG and Mg (II) were aged. Data suggest the accumulation of the enol of
AKG is observed as the burst that is largely ended at the beginning of data collection.
Extrapolating to the starting concentration of NADPH in solution of 140 µM indicates 17 µM
NADPH consumed in the burst phase, ~ 10% of the total available ligand.

Figure 34. Tautomerization trials of AKG in the presence of Mg(II). A. 10 µM of the R132H
homodimer mixed against a solution of 15 mM AKG and 20 mM Mg (II). Shots were taken every
10 minutes and monitored at 340 nm for 100 s. B. Enzyme induced tautomerization using 20
µM DUET•NADP mixed first with 1 mM AKG and 5 mM Mg(II), aged for 0.1, 0.2, 0.8, 2, 4, 8, 16,
32, 64, 128, 256, and 500 seconds before being mixed with 150 µM NADPH. B inset. Fits of the
early times of the traces shown in B. The lag that diminishes over time is likely the result of
conformational changes in the enzyme as ligands associate having an average rate
constant of 0.05 s-1.

The double mixing stopped flow experiments didn’t reveal a noticeable accumulation 84
of the “burst inducing substrate” either. Even at 500s age time with a relatively high
concentration of DUET there was almost no observable burst (Figure 34b). The total absorbance
at the beginning of data collection is ~1.08, yielding a 173 µM NADPH signal at 340 nm which
correlates well with the 20 µM DUET•NADPH + 150 µM NADPH added indicating no
consumption of the substrate had occurred in the dead time of the instrument. The rate of the
steady-state consumption of AKG does increase but may be due to conformational changes in
the enzyme with ligand acquisition rather than a new kinetic phenomenon. More work is
required in order to confirm if an enolic form of AKG is the true substrate for the heterodimeric
ICDH.
NMR
In order to capture the enolic AKG in the active site of DUET, 13C NMR was done with a
sample that contained no NADPH a fully labeled AKG and Mg (II). Preliminary attempts at
obtaining this spectrum for the AKG bound to DUET proved to be fruitless. The Enzyme in the
NADP-bound form was not stable at room temperature. Preparation of the sample often lead
to a slight precipitation of the enzyme obscuring the peaks of interest around the 100-ppm
range, the peaks were further obscured by natural abundance 13C observed from the HEPES
buffer used to stabilize the enzyme. Initial observations for a control did reveal a portion of the
keto AKG disappearing with time, without any formation of a unique enol peak arising from the
sp3 to sp2 hybridization change between C-2 and C-3 of AKG. There was also an observation of a
discernable yellow color when the enzyme Mg (II) and AKG were allowed to age for a short
period of time a room temperature. This color disappeared once the sample was brought back

to 4 oC. This associated change in pH could alter the protonation state or the acidity of one of 85
the protons in the active site of DUET, promoting the tautomerization of AKG. Conjugation
within the enol form would lead to absorption of light, potentially accounting for the color
observed.
Discussion
Specific variant forms of ICDH1 play a direct role in the development of several forms of
aggressive cancers. This necessitates a study of how they behave relative to the wildtype
enzyme, in order to understand their function in the context of cancer metabolism. WT ICDH1
presented a unique mechanism where half site reactivity and intersubunit communications, as
well as a pseudo-tetramer all played a role in dictating its behavior22. Presumably these same
machineries would dictate how the heterodimer enzyme behaves. By performing similar
experiments with the DUET enzyme that were performed with the WT, we hoped to compare
the kinetic parameters and binding constants between the two systems in order to elucidate
how the mechanism had changed. Our goal was to define how the change in arginine to
histidine promoted such a profound enhancement of the production of 2HG. Steady-state data
for both the DUET and WT enzymes revealed a nearly 3-fold decrease in the TN for the native
chemistry with a similar increase for the KM with respect to ICT. In regard to the ICDH1 activity
that converts AKG and NADPH to 2HG and NADP+, of all three forms of ICD1 are different in the
steady-state, with DUET showing the highest proficiency for the oncogenic activity (Figure 29).
The first chapter of this thesis discusses in detail the dimer interface of ICDH enzymes and how
they play a crucial role in determining the catalytic routes these enzymes take to generate their
products. We surmise that those same interactions are what gives rise to the enhancement of

the oncogenic activity of ICDH1 variants. These communications, when disrupted, could
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contribute to less specific binding of ligands in either of the active sites of the heterodimer.
Having one fewer positive charges localized in the active site of the Arg132His protomer is
qualitatively consistent with 2-fold decrease of the KM for ICT in the DUET enzyme compared to
the WT. The 13-fold decrease in the KM for AKG may arise from compromised communications
that normally link the two active sites through the interface. The available data supports an
alternating sites model in which catalysis at one subunit yields a new ligand set that induces
substrate acquisition and catalysis in the opposing subunit (Chapter 2). However, the precise
mechanism cannot at this time be known and what follows are speculative ideas that relate to
the role of Arg132 in the alternating sites mechanism.
When ICDH1 performs the decarboxylation of the putative oxallosuccinate
intermediate, Arg132 would experience less charge interaction. This could be translated to the
opposing active site through the residues identified in Chapter 1, where the conformation
changes would promote hydride transfer, leaving the enol form of AKG in the active site.
Logically, if the enzyme tautomerizes enol AKG into its keto form, we would expect ICDH1 to
have a relatively high affinity for the enol compared to keto AKG, at least until the opposing
active site had performed its chemistry. Alternatively, the enol form could be released into
solution immediately following the decarboxylation. In this case, cation pi interactions between
the alkene bond of the enol AKG and the positive charge of the guanidinium of Arg132 would
be lost and this information could be transmitted to the opposing active site. At which point a
second decarboxylation could occur in that active site thereby restoring the conformation of
the original active site designed to bind ICT. Creating a sort of Newton’s cradle for the two

active sites where one was always conformationally poised to react with ICT, and the other
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poised to release or tautomerize the enol AKG in the presence of excess substrates. By breaking
this communication through alteration of the ligand interactions at the interface, the enzyme
may become locked in a conformation that is inefficient at transmitting information once the
decarboxylation takes place or when ICT/AKG binds/dissociates. This would result in a protomer
that is locked into a state with a higher affinity for either tautomer of AKG relative to the native
active site.
This inability to recognize substrates/products properly could impact the latch for the
nicotinamide co-substrate that was identified in an asymmetric structure of ICDH1 (Chapter 1).
Arginine132 forms ionic interactions with Asp275, a residue that is covalently linked to the latch
for NADP(H). When ICT binds to ICDH1, it attains the fully active state with a lower affinity for
NADP(H) (Chapter 2). The latch motif possibly exists to aid in binding and release of the
nicotinamide co-substrate while in this lower affinity state. If correct this assumption helps
explain the ICT induced release of NADPH by DUET, where low concentrations of ICT initially
encourage the release of NADPH, before rebinding after ~ 20 seconds indicated by the increase
in fluorescence (Figure 31) presuming the same events as the WT enzyme are being observed.
Having an altered dimer interface could leave the enzyme with a diminished capacity to
maintain the low affinity state with respect to NADPH. Interestingly the overall fluorescence
change, even at the highest concentrations of ICT, was only about 25% of the total fluorescence
as opposed to 50% observed with the WT homodimer. Possibly the result of a tendency for
ICDH1 to form pseudo tetramers in solution, a phenomenon which imparts changes in the
catalytic behavior of the enzyme. If this is true for DUET, the relatively high concentration of

enzyme would result in a tetramer with a unique interface where only one of the two dimers 88
that oligomerize are capable of achieving a conformation that is capable of releasing NADPH.
The formation of a pseudo tetramer and altered interface may help explain the
inconsistencies with our single turnover data as well. When DUET•NADPH73% was used in single
turnover experiments the observed rate constant was consistently much lower than the
turnover number we obtained for the oncogenic activity (Figure 33). The observed rate
constant for this experiment decreases as the concentration of AKG increases, suggesting that
the substrate for this reaction is in some way inhibitory to the enzyme. This inhibition could
arise from the variant protomer’s altered ability to distinguish ICT from AKG, potentially leaving
one of the protomers in a conformation that was unable to exchange the co-substrate. This
would not only encourage the reaction between AKG and NADPH in one of the two protomers
but, under high AKG concentrations, may inhibit the release of NADP+ from that same subunit
(Figure 35).
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Figure 35. Representation of the proposed alternating sites reactivity of ICDH1. From top left,
the as isolated enzyme with NADPH bound in both active sites, ICT will then bind and displace
one of the NADPH molecules. NADP will then bind at the site vacated and induce closure of the
latch (represented by green and blue surface to represent the two protomers making up this
site). Catalysis will take place prompting the latch in the adjacent subunit to open allowing the
dissociation of NADPH and AKG. NADP will then bind and the cycle will repeat alternating
between the formation of AKG and release of NADPH to the binding NADP. Ligands in the
protomer in the rear as well as products released from that site are shown as transparent.The
Enol AKG is shown dissociating from the enzyme but does not indicate the true product of this
reaction.

The interaction of the dimers at the tetramer interface likely perturbs the enzymes
behavior in the single turnover experiments performed starting with the NADP+ bound form
(Figure 32). The high concentrations of AKG in this experiment may contribute to a large pool of
the enzyme being stuck in the low activity state. Consistent with the average kobs for the NADPH
consumption remaining constant at 0.03 ± 0.00013 s-1, the same as the minimum value reached
during the single-turnover experiment titrating AKG (Figure 33b). The steady decrease in the

rate of NADPH binding is still enigmatic at this point and will need further experiments to
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elucidate how this is occurring.
The possibility of the enol form of AKG being the actual product of ICT consumption
remains unaddressed in the literature, leading us to question whether the preferred substrate
for the oncogenic activity of ICDHs is in fact the enol tautomer of AKG. Early observations of the
steady state at relatively high concentrations of enzyme reveled a burst in activity (Figure 34).
While the burst could be the rapid consumption of substrate as a function of a particular step in
the reaction it seems unlikely given that the amplitudes of this phase were far too small to
correlate with the enzyme concentration. Another possibility was having a preferred substrate
as a contaminant in our sample of AKG. Yang et.al had previously demonstrated the
tautomerization of alpha-keto acids by metals under acidic conditions64. Further testing of this
enol form measured if the enzyme itself was catalyzing the tautomerization of this species or if
it was equilibrium driven (Figure 34b). The amplitude of the burst did not increase
proportionally to the age time of the enzyme with Mg and AKG. Increases in the rate of NADPH
consumption were observed but have been tentatively assigned as an abolishment of a lag that
ICDH enzymes exhibit prior to catalysis (Chapter 2). While yet unproven we assume that in the
presence of MG (II) and AKG the enzyme is capable of achieving the same activated state
as it does in the presence of ICT. Bursts were not observed in this experiment,
but this may be due to flaws in the design of the experiment. The literature discusses the need
for the native chemistry in order to get higher levels of the tumorigenic activity, having a small
amount of ICT in the assay may encourage the proper conformation for enol binding (DEX ref).
We are currently unsure of what ligand ensemble will encourage the greatest enol AKG

accumulation. Evidence for a new species was observed however, when attempting to collect 91
NMR data for the DUET•NADP•AKG•Mg complex the formation of a colored species was
observed. When adding AKG and Mg (II) to the NADP bound enzyme, the solution turned bright
yellow. Attempts to capture this species spectrophotometrically proved futile but revealed a
temperature dependence on its accumulation. At ~ 20 oC the color was rather prevalent but
cooling the solution down to 4 oC dissipated the color entirely. Whether this is the result of the
conjugation of the enol form of AKG is yet to be determined.
Elucidation of the ICDH DUET mechanism is by no means complete, further analysis will
be required to answer some of the oddities observed in this study. A few noteworthy
experiments to be done are:
1. Site directed mutagenesis of some of the key residues identified in the first chapter of this
thesis. While the mechanism of the single mutant is daunting, further mutations may help
validate the precise alternating sites nature of these dimeric enzymes.
2. Kinetically monitoring the accumulation of the yellow color, then seeing how it decays upon
the addition of NADPH. This would give insight into how quickly the enzyme is tautomerizing
AKG.
3. AKG induced release of NADPH. Similar to how ICT can cause NADPH to be released from
DUET, to an extent, I suspect that AKG may do the same given the disrupted communication
between the protomers.
4. Single turnover experiments for the forward reaction. It would be nice to know if it is the
decarboxylation step that is being impaired by this mutation. Do we see a reduction in the 30 s-1
rate when using DUET•NADPH73%.

5. Attempting the NMR experiments with the NADPH bound enzyme in the presence
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of EDTA. This may give us the spectrum that we want and would do it with a more stable form
of the enzyme.
6. Single turnover for the two forms of DUET presented here but limiting the other ligand,
DUET•NADPH73% vs limiting NAPH…. Which it naturally has; and the DUET•NADP+ with limiting
AKG to see if the observed rate constants get closer to the 0.15 s-1 observed for the steady
state.
With these observations in hand, elucidation of the DUET mechanism may be possible
and would provide needed insight into how these variant forms of this vital enzyme contribute
to disease.
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CHAPTER 4
TRMFO CANNOT BE OBSERVED TO METHYLATE U54 OF TRNAPHE AT MICROMOLAR REACTANT
CONCENTRATIONS
Intro
The post transcriptional modification of tRNA is a widely accepted means to confer
structural stability to the secondary structure of the nucleotide chain. There does not appear to
be any necessity for these modifications to occur with all but three modifications having little to
no impact on cell viability from among approximately 100 known post transcriptional
modifications.65, 66 The successive order and chemistry of these modifications is generally
poorly understood. Methylation is a common modification, appearing on Adenine, Cytosine,
and Uracil. The methylation Uracil 54 to form thymine in the T-Ψ arm of transfer RNAs is of
note as it is ubiquitous to all kingdoms of life65 The C5 methyl group transferred to the uracil is
typically derived from the electrophilic methyl of S-adenosyl methionine (SAM).67 However, in
some organisms this methyl group can also come from methylenetetrahydrofolate (MeTHF), as
is the case for thymidylate synthase enzymes.68, 69 However, this modification is to the base of a
nucleotide prior to incorporation in nucleic acid. Bjork et al. noted that the folate pool could
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also be utilized for the methylation of RNA arising from the identification of a flavin
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dependent enzyme that transferred the methylene from MeTHF to the C5 position of
tRNA U-54.70
BsTrmFO and TtTrmFo are proposed to be U-54 tRNA methyltransferases from bacillus
subtilis and thermus thermophilus respectively. These enzymes were projected to function
similarly to the thymidylate synthase (ThyA and ThyX) enzymes.71 72 This claim was based on
data from a radiometric assay designed to follow the signal of a 32P-labeled tRNA using cell free
extracts incubated in the presence of MeTHF and NADPH.72 This assay was later modified to use
serine hydroxy methyltransferase (SHMT) and 14C-labeled serine along with THF to generate a
14C

MeTHF, that affords monitoring methyl transfer as a function of TrmFO activity.73 These

assays, while useful for obtaining binary results, fail to take into consideration the complex
mixtures being generated and lack the proper controls to help substantiate the claims being
made. Binary results are also incapable of revealing the true pathway molecules take on their
way to becoming products. Though Urbonavicius et al. noted that a direct mechanistic
comparison between TrmFO and ThyX could not be made based on these results, several
groups carried forward with these methods and, rather unfortunately, have defined the
standard of observation for these enzymes.71, 73-78 Another fundamental flaw in the TrmFO
record is the lack of evidence for catalysis in the form of multiple turnovers. The consensus is
that TrmFO is isolated with a covalently bridged methylene in the form FAD-CH2-C226. And that
this adduct is capable of methylating tRNAs and is not influenced by exogenous NADPH and/or
MeTHF.78 Moreover, it has also been asserted that once this reaction has taken place that the
enzyme is no longer capable of modifying tRNA; defying the definition of catalytic turnover.

Other evidence suggests, in addition, that when the enzyme is allowed to oxidize (over the 95
course of ~20 hours) it loses the ability to perform methyl transfer.75, 78
TrmFO enzymes contain an active site flavin, and every mechanism proposed alludes to
NADPH being the source of a hydride required for the reduction of an exocyclic methylene that
forms the methyl of thymine.79 If true, this would provide a sensitive means to observe the
turnover of TrmFO spectrophotometrically. Our objective was to use this and the chromophoric
characteristics of FAD and NADPH to observe catalysis directly and elucidate the chemical
mechanism of TrmFO enzymes.
Materials and Methods
Materials.
Sodium chloride, 2-[4-(2-hydroxyethyl) piperazin-1-yl] ethanesulfonic acid (HEPES), βmercaptoethanol (BME), prime RNase inhibitor, and TRITON X-100 were purchased from Fisher
Scientific. Adenosine triphosphate (ATP), cytidine triphosphate (CTP), guanosine trisphosphate
(GTP), uridine triphosphate (UTP), magnesium chloride, and spermidine were purchased from
Millipore Sigma. Methylenetetrahydrofolate (MeTHF) and tetrahydrofolate (THF) were
purchased from MERK & CIE (Germany). PCR master mix as well as inorganic pyrophosphatase
were purchased from New England Biolabs. Nicotinamide adenine dinucleotide phosphate
reduced (NADPH) was purchased from LEE Biolabs and the oxidized form (NADP+) was
purchased from AMRESCO. Expression plasmid containing the genes for the Bacillus subtilis,
and the Thermus thermophilus forms of TrmFO were both purchased from Enzymax LLC,
and the plasmid containing the sequence for unmodified tRNAphe was a gift from Dr. Eugene
Mueller (University of Louisville).

Expression and Purification of BsTrmFO, TtTrmFO and T-7 polymerase.
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BsTrmFO. The gene for Bacillus subtilis U54 tRNA methyltransferase (BsTrmFO) was
synthesized by Enzymax and incorporated Nde I and Xho I restriction sites at the 5’ and 3’ ends
respectively. The gene was subcloned into the corresponding restriction sites in plasmid pET28a
yielding a construct that would fuse the gene to an N-terminal 6xHis-Tag. This construct,
pBsTrmFO, was transformed into chemically competent E. coli (BL21 DE3) (New England
Biolabs). Cell stocks were prepared by transferring a single colony to Lysogeny Broth (LB) broth
containing 25 µg/mL kanamycin and grown at 37o C with shaking at 220 rpm. The broth culture
was grown until the first signs of turbidity and the cells were mixed with 50% glycerol to give a
final concentration of 20%, aliquoted to precooled microfuge tubes and stored at -80o C. To
express BsTrmFO, 100 µL of the thawed cell stock was spread onto LB agar, 25 µg/mL
kanamycin and grown at 37o C for 16 hrs (two plates per liter of expression culture). Cells were
then re-suspended in warm LB broth and used to inoculate one-liter volumes of LB broth each
in a 2L Erlenmeyer flask with kanamycin added to 25 µg/mL. Cells were grown with vigorous
shaking (220 rpm) at 37o C to an optical density of ~0.6 at 600 nm before lowering the
temperature to 28o C. After one hour at this temperature the culture was induced with 100 µM
Isopropyl β-D-1-thiogalactopyranoside (IPTG) for ~20 hours. All subsequent purification
procedures were undertaken at 4o C. Cells were harvested with centrifugation for 45
minutes at 4000 g. Cell pellets were then re-suspended in 20 mL/L of culture of chilled buffer A
(50 mM potassium phosphate, 300 mM NaCl, 10 mM imidazole, 2 mM 2-mercaptoethanol
(BME), pH 7.0) before being lysed using a Branson 450 sonifier set to 40 W with two bursts of
3.5 minutes. The lysate was centrifuged at 10,000 g for 45 minutes to remove cellular debris

and the supernatant was loaded at 1 mL/min onto a BD TALON affinity column coupled to a 97
Biologic LP chromatography system. The bound sample was then washed with a 200 mL of
buffer A. BsTrmFO was then eluted using a 400 mL linear gradient from 0 to 100% buffer B (50
mM potassium phosphate, 300 mM NaCl, 300 mM imidazole, 2 mM BME, pH 7.0) and collected
as 5 mL fractions. Fractions exhibiting characteristic flavin absorption were assessed for purity
using SDS-PAGE and fractions containing pure BsTrmFO were pooled. The pooled enzyme
sample was then concentrated and exchanged into buffer C (20 mM sodium phosphate, 100
mM NaCl, 2 mM BME, pH 7.0) using Amicon Ultra-15, 10 kDa nominal molecular weight cutoff
centrifugal filters. Typically, the enzyme was concentrated and diluted sufficiently to achieve a
~1000-fold buffer exchange. The concentrated enzyme was then stored at -80o C.
TtTrmFO. The construct of the Thermus thermophilus TrmFO was synthesized and
subcloned similarly to the B. subtilis enzyme with the exception that it was subcloned into the
plasmid pET17b, which does not fuse the sequence to a purification tag. This construct was
transformed into chemically competent E. coli (BL21 DE3). 100 µL of cells containing the
plasmid for TtTrmFO were spread onto LB agar plates supplemented with 100 µg/mL
ampicillin and left to incubate overnight at 37o C. These cells were then resuspended prewarmed LB and the cells from 2 plates were used to inoculate each liter of LB that included 100
µg/mL ampicillin. Cells were grown at 37o C to an OD600 of 0.6 before the temperature was
lowered to 20o C. Cells were then cooled for an hour before being induced with 100 µM IPTG at
which point they were left to express with shaking for ~20 hours. Cells were harvested by
centrifugation at 4,000 g for 35 minutes and pelleted cells were then resuspended in buffer
D (10 mM Tris, 1 mM dithiothreitol (DTT) pH 8.0) using 20 mL of buffer per liter of

culture. Cells were lysed by two bursts of 3.5 minutes of sonication using a Branson 450
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sonifier set to 40W. Cellular debris were then removed by centrifuging at 10,000 g for 45
minutes. The lysate was then incubated at 70o C for 30 minutes to precipitate the majority of
contaminant proteins. The heat-treated lysate was then centrifuged at 10,000 rpm for 30
minutes before loading the supernatant at 1 mL/min onto a Q-sepharose column (Bio-Rad) preequilibrated with buffer D. Elution of TtTrmFO was accomplished by first washing the column
with 200 mL of buffer D followed by a linear gradient of 0 to 100 % E (10 mM Tris, 1 mM DTT,
500 mM NaCl pH 8.0) with fractions collected every 5 minutes. Fractions containing the
characteristic yellow color of flavin were assessed by SDS-PAGE and fraction having greatest
TtTrmFO purity were pooled and concentrated by centrifugation to <10 mL and loaded onto a
SephacrylTM S-300 gel filtration column. Pure TtTrmFO was then eluted with 400 mL of buffer D.
Fractions containing pure TtTrmFO were pooled and concentrated to ~500 µM before being
stored at -80o C.
T-7 polymerase. The gene for the bacteriophage T-7 RNA polymerase was purchased
from GenScript® and incorporated Nde I and Xho I restriction sites at the 5’ and 3’ ends
respectively. This gene was subcloned into the pET28a+ expression plasmid to form the
pT7RNAPol expression construct that produces T7-RNA polymerase fused to an N-terminal
6xHis tag. pT7RNAPol was transformed into competent BL21 DE3 cells and aliquoted and stored
at -80 oC. Cells were thawed and spread (100 µL/plate) on LB agar containing 25 µg/mL
kanamycin were cultured overnight at 37 oC, these cells were then resuspended and used to
inoculate one-liter LB containing 25 µg/mL kanamycin and shaken (220 rpm) at 37 oC. Cultures
were grown to an OD600 of 0.6 before cooling to 20 oC for ~1 hour. The cells

were then induced with 100 µM IPTG and shaken for an additional ~20 hours. Cells were

99

harvested by centrifugation at 4,000 g and resuspended in pre-cooled buffer F:(100 mM
tris(hydroxymethyl)aminomethane (Tris), 200 mM NaCl, 10 mM Imidazole pH 8.0).
Resuspended cells were lysed by sonication on ice using 2 bursts at 20 W for 4 minutes.
Cellular debris were removed by centrifugation at 10,000 g for 45 minutes and the supernatant
was decanted and loaded onto a BD TALON cobalt affinity column at 1 mL/min. Buffer F (200
mL) was used to wash the column before T-7 polymerase was eluted using a linear gradient of 0
to 100% Buffer G (100 mM Tris, 200 mM NaCl, 300 mM Imidazole pH 8.0). Fractions containing
the T-7 polymerase were pooled and exchanged into buffer H (100 mM Tris, 200 mM NaCl, 20
mM Dithiothreitol (DTT), 2 mM Ethylenediaminetetraacetic acid (EDTA), 5% glycerol pH 8.0).
using centrifugal concentrators. Concentrated T-7 polymerase was then mixed in a 1:1 ratio
with 100% glycerol prior to storing at -80o C.
Air Oxidation of Semiquinone Species from BsTrmFO.
BsTrmFO waqss isolated as a mixture that included reduced and anionic semiquinone
flavin species. In order to regenerate the presumed active oxidized cofactor, the mixture of
enzyme was incubated in air equilibrated buffer at 4o C for ~10 hours prior to concentration and
storage. The reoxidation of the semiquinone was observed by collecting spectra from 200-750
nm, every 20 mins during this period.
FAD Binding.
The T. thermophilus form of the TrmFO did not retain the flavin cofactor during
purification. In order to establish a binding constant, the enzyme (27 µM) was titrated with a
range of concentrations of FAD, 0.3 to 380 µM. Spectra between 200 and 750 nm were

taken using a Shimadzu UV-Vis 2600 spectrophotometer. These measurements recorded
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changes in the FAD spectrum indicative of binding. All spectra were normalized using the 450
nm extinction coefficient for FAD (11,300 M-1cm-1). In this way the data record shifts in the FAD
spectrum that arise from being predominantly bond to TtTrmFO at low concentration to
predominantly free at high concentration. The initial contribution of the enzyme was
subtracted from each spectrum. The wavelength of maximal absorption around 450 nm was
then plotted relative to the FAD concentration as a measure of ligand occupancy. The data
were fit to a rectangular hyperbola (Equation 14) to determine the binding constant.
Equation 14
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The Reduction of TrmFO by NADPH.
The reduction of the TrmFO flavin can be observed by combining the enzyme with
NADPH under anaerobic conditions. The oxidized BsTrmFO enzyme, 16.6 µM, prepared
anaerobically as described above, was mixed with NADPH pseudo-first order concentrations
ranging from 222 to 7100 µM. The change in absorbance was monitored at 454 nm for 10,000s.
Data were fit to Equation 15 and the rate constants (kobs) determined were plotted against the
concentration of NADPH. The secondary plot data were fit to a rectangular hyperbola
dependence according to Equation 16 to determine the limiting rate of reduction and the
binding constant for NADPH to the oxidized enzyme.
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Reoxidation of Reduced TrmFO in the Presence of Dioxygen.

The oxidation of BsTrmFO was observed using the stopped flow in conjunction with a
Hansatech oxygraph electrode. BsTrmFO was first artificially reduced using a xanthine/xanthine
oxidase system that provides electrons to the reduce the enzyme-bound flavin via methyl
viologen as a mediator. This sample was prepared in a tonometer with two side arms, one
containing 300 µM xanthine and the other 20 U m of glucose oxidase (Ref Massey). The body of
the tonometer had 20 µM BsTrmFO, 2 µM xanthine oxidase and 5 µM methyl viologen in buffer
(20 mM HEPES, 300 mM NaCl, 2 mM BME, 1 mM glucose, pH 7.5) to a final volume of 4 mL.
Once anaerobic all solutions were combined and the sample was incubated at 4 oC for 16 hrs.
To determine the concentration of molecular oxygen a Maxtec gas blender was used to mix
oxygen and nitrogen, this mixture was then sparged over a calibrated Clarke type platinum
electrode that reported the concentration of O2. Once the desired dioxygen concentration was
achieved the blend was then used to sparge a buffer solution (20 mM HEPES, 300 mM NaCl, 2
mM BME, pH 7.5) in an inverted glass syringe. This buffer was then sparged for 5 minutes
before being mounted onto the stopped flow instrument and mixed against the reduced
enzyme. Oxidation of the flavin was monitored at 445 nm over 10 seconds for seven post
mixing concentrations of O2 ranging from 62 to 555 µM. The traces obtained were then fit to
Equation 17 and the observed rate constants were plotted against the concentration of
molecular oxygen. The plot obtained was then fit to Equation 18 that describes a straight line
with a slope corresponding to the second order rate constant for reoxidation by dioxygen.
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Preparation of Folates.
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Methylenetetrahydrofolate (MeTHF) and tetrahydrofolate (THF) were both prepared in
a 3 mL Wheaton® V vial fitted with a rubber septum cap. Two 16G needles inserted through the
septum were used to allow constant argon flow over the folate solutions. Small amounts
(usually between 2 and 15 mg) were added to the vial as a powder before the cap was sealed
and the sample equilibrated with argon. Within 5 minutes buffer (5 mM TAPS pH 9.0 pre
sparged with argon) was added to bring the volume to 0.5 to 1 mL before a small volume was
withdrawn and diluted to measure the concentration via absorption at 295 nm for MeTHF (ε295
= 25,000 M-1cm-1) and 298 nm for THF (ε298 = 25,000 M-1cm-1). Solutions were then diluted
further to achieve the desired concentration before being drawn into a Hamilton® 500 µL
gastight threaded plunger syringe.
Methylenetetrahydrofolate Binding Titrations.
MeTHF was titrated to the oxidized, FAD loaded form of the BsTrmFO and TtTrmFO
enzymes to determine binding constants. In each case, 20 µM of enzyme was prepared in an
anaerobic cuvette with glucose oxidase to give a diluted activity of 2 U/mL in one of the side
arms. The vessel was sealed, and 45 exchanges of vacuum and argon were applied to
achieve anaerobiosis20. Anaerobic MeTHF in the threaded plunger syringe was mounted to the
aerobic cuvette via modified stopcock consisting of one ground glass joint and a compression
bushing that can be tighten against syringe the barrel. This allowed for the MeTHF to be
introduced into the body of the cuvette in a defined manner without the introduction of
atmospheric dioxygen. Five additional exchanges were then applied, taking care to ensure the

meniscus of the MeTHF solution remained within the tubing attached to the syringe needle. 103
The plunger of the syringe was then used to add MeTHF to the enzyme solution(s)
(5.28 µL per turn). Scans were taken between 200 and 700 nm on a Shimadzu® UV-Vis 2600
spectrophotometer, allowing 5 minutes of equilibration after each addition before taking the
scans. Concentrations of MeTHF for both BsTrmFO and TtTrmFO ranged from 20 µM to 2.4 mM.
Analysis of these data consisted of generating a difference spectrum for each concentration of
MeTHF, where the ∆Abs = Af -Ao with Ao representing the enzyme spectrum prior to the
addition of ligand. The wavelength with the most pronounced ∆Abs was used to build a
dependence plot. Data were and fit to a quadratic binding equation (Equation 19) to determine
the KdMETHF.A similar titration was performed using THF and BsTrmFO, with concentrations of
the THF ranging from 1.9 to 219 µM. Data were interpreted in the same way as described
above.
Redox Potential Determination.
Redox potential for the BsTrmFO enzyme was determined according to the Massey
method.80 Anaerobic cuvettes were assembled as described above with the body containing 10
µM BsTrmFO, 10 µM hydroxyphenazine or both in the presence of 250 nM xanthine oxidase,
and 5 µM methyl viologen brought to 2 mL in 20 mM potassium phosphate pH 7.5. The side
arm for this vessel contained 300 µM xanthine that was added to initiate the reaction once the
sample was made anaerobic. As such the reduction of the enzyme and the dye were observed
separately and when combined. The reduction reactions were observed using a Shimadzu UVvis 2600 spectrophotometer by collecting spectra (200 and 750 nm) every 30 seconds for half

an hour. For the combined reduction reaction, the fractional reduction of the dye was
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determined at 370 nm by subtracting out the contribution of the enzyme bound flavin
at this wavelength based on the extent of reduction at 445 nm according to Equation 20 where
∆εTrmFO is the change in extinction coefficient for the FAD bound to the enzyme and F(HPox) is
the fraction of oxidized hydroxyphenazine. The fraction of reduced enzyme was calculated
at445 nm from Equation 21, where F(TrmFOox) is the fraction oxidized enzyme in solution. Ao
and AF are respectively the absorbance values, initially, and after the reduction. The log of
[oxidized]/[reduced] for the enzyme and dye was calculated using equations 22 and 23 and
these values were plotted against one another to yield a straight line. The midpoint potential
was determined from the y-intercept of this line and substituted into the Nernst equation
(Equation 24) using the known redox potential of hydroxy phenazine of -0.18 V and an overall
two-electron transfer.
Equation 20
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Preparation of Runoff-Transcription Plasmid for tRNA Synthesis.
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Unmodified tRNA was synthesized via in vitro transcription. A portion of a pUC-18
plasmid containing the sequence for a tRNAphe from B. subtilis was amplified using PCR.
Reactions mixture consisted of 200 ng of the forward and reverse primers, 100 ng of the
template plasmid, and 50 µL of PCR Master Mix® (NEB). The reverse primer was complementary
to the 5’ end of the tRNAphe sequence. The reaction mixes were placed in a Perkin Elmer
GeneAmp 2400 thermocycler. Cycle parameters were as follows: melting temperature
of 98 oC for 10 seconds, annealing temp of 54o C for 30 seconds, and an extension temp of 72 oC
for 45 seconds. After 33 cycles the mixtures were pooled together, brought to 300 mM sodium
acetate, mixed thoroughly and then ethanol was added to 70% v/v before being stored at -20o C
overnight. The precipitated template was then centrifuged at 13,000 rpm for 35 minutes and
the supernatant was decanted. Pellets were then dried for 45 minutes. Each pellet was then
reddissolved in 40 µL of nuclease free water (Qiagen) and stored.
In-vitro Transcription of Unmodified tRNAphe.
In vitro transcription reactions consisted of: the amplified template (50 ng), 4 mM UTP,
4 mM GTP, 2 mM ATP, 2 mM CTP, and 16 mM GMP, 1 mM spermidine, 0.01 % TRITON X-100,
24 mM MgCl2, 5 mM DTT, 50 U RNase inhibitor, 10 U of inorganic pyrophosphatase, and buffer
(40 mM Tris-Base pH 8.0) to give a final volume of 1 mL. The reaction was then initiated with 50
U of T-7 polymerase. This reaction was incubated overnight at 370C. tRNA was then harvested
by following the Qiagen RNeasy midi kit protocol, eluting with two 40 µL aliquots of nuclease
free water before being stored at -800C.

Single-Turnover Attempts with TrmFO Enzymes.
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Observations of enzyme turnover were attempted using stopped flow
spectrophotometry in double mixing mode. TtTrmFO (15.5 µM) was prepared anaerobically and
mixed initially with 60 µM NADPH, 60 µM MeTHF (pre-sparged for 5 minutes with
argon in 5 mM TAPS, 1 mM glucose pH 9.0). This was aged for 5 seconds to allow equilibration
before being mixed with either buffer (20 mM Tris, 2 mM DTT, 1 mM glucose pH 8.0) or 20 µM
unmodified tRNAphe (in 20 mM Tris, 1 mM glucose pH 8.0). The reactions for both tRNAphe and
control were monitored for 200s at 340 nm and 444 nm; wavelengths that report changes in
NADPH and flavin respectively.
Results and Discussion
The idea that TrmFO enzymes were preforming a methylation reaction utilizing a folate
as well as NADPH was based on sequence similarities to the Gid family of proteins and several
reported activities from radiolabeled substrates and TrmFO gene knockout assays72. While valid
and powerful methods for deriving a binary result, they tell us little about the specific
transformations taking place during the catalytic cycle. Having FAD as a cofactor provides a
versatile spectrophotometric reporter to monitor individual steps of catalysis. Our objective
was to utilize the chromophoric character of the flavin to observe TrmFO chemistry directly.
Hamdane et al. showed that as isolated TrmFO was capable of methylating a tRNAALA in the
absence of both a methyl donor and source of hydride and it proposed that the active site FAD
of TrmFO stabilized an N-5 methylene adduct used in the methyl transfer step74, 75, 81. These
observations suggest that the methyl group is installed within cells by a process that has not yet

been duplicated in vitro. As such TrmFO has not been observed to do multiple turnovers in 107
continuous assay75, 78, which is a major deficit in the study of this activity.
Yields for the b. subtillis enzyme were typically ~ 20 mg per liter of culture but was
eluted as a green protein comprised of a mixture of both oxidized and neutral blue
semiquinone FAD. This form of the enzyme was quasi-stable, slowly oxidizing over the course of
20 hours (Figure 36).

Figure 36. Air oxidation of BsTrmFO following elution from the cobalt affinity column. Spectra
were taken every 20 minutes over the course of 10 hours. The green spectrum represents the
enzyme immediately following its elution from the column while the yellow spectrum is the
fully oxidized cofactor.
Whether this semiquinone species is catalytically relevant was not ascertained in this study
given the difficulty of isolating it from the fully oxidized species. Furthermore, we were unable
to regenerate this form of the flavin by the addition of its proposed substrates and as such
presume it may be an artifact of purifying in the presence of cobalt and a reducing agent (BME).
Similar yields were obtained for the t. thermophilus enzyme but no semiquinone was observed,
this variant was prone to releasing the FAD during purification and was isolated with at most a
~20 % compliment of the cofactor. The FAD could be added exogenously however,

and this was used to estimate binding from a sample containing 19% bound FAD (Figure 37). 108

Figure 37. FAD binding titration to TtTrmFO. A. Changes in the λMAX for the FAD Bound to
TtTrmFO, normalized at 450 nm to the extinction coefficient of FAD, 11,300 M-1cm-1. B.
Dependence of the λMAX on the concentration of FAD. Data was fit to a quadradic binding curve
to determine an approximate binding constant for FAD to TtTrmFO•FAD19%.
If the proposed mechanism is correct (Figure 38) the FAD cofactor would accept electrons from
NADPH. These reducing equivalents would then transfer to the exocyclic methylene that was
generated prior to folate elimination. Such a scenario suggests that the resting state of
TrmFO enzymes is the oxidized form as opposed to the reduced or semiquinone forms.
As such, it was necessary to obtain fully oxidized, cofactor bound forms of both BsTrmFO

and TtTrmFO in order to assess their full catalytic cycles.
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Figure 38. Proposed mechanism for the formation of methylated tRNA U-54 by TrmFO enzymes.
Dissociation constants (KD) were acquired for the proposed ligands by observing the
perturbation of the flavin absorbance signal as a function of ligand association (Figure 39).

Figure 39. Binding titration for BsTrmFO. Example of the data that were used to determine
binding constants for the folates to the oxidized TrmFO enzymes. A. Example of the difference
spectra that were obtained post reaction. Data were corrected for dilution prior to
subtraction of the initial spectrum from each subsequent spectrum. The flat bolded line is the 0
spectra subtracted from itself while the other bolded line is the final spectrum once all THF had

been added. The arrow indicates the wavelength used to generate the dependence plot. B. 110
Binding isotherm of THF to the oxidized BsTrmFO enzyme.
Concentrations of THF are 1.99, 3.99, 7.96, 15.85, 31.37, 61.51, 118.29, and 219.70 µM
These values were then used to ensure saturation of the enzymes by their ligands for use in
single turnover experiments. The KD for MeTHF and NADPH were 0.45 and 4.50 mM
respectively; the relatively high KD for NADPH may be a function of it adding to the incorrect
state when titrated in the absence of other ligands. Similarly, it may be necessary to have either
the tRNA and/or NADP+ in the active site to observe catalytically relevant MeTHF binding.

Figure 40. Reductive half reaction for BsTrmFO. A. Traces for the decrease in absorbance at 444
nm to reduction of the active site flavin. Concentrations of NADPH from left to right are:
221.875, 443.75, 887.5, 1775, 3550, and 7100 µM. B. Dependance on the observed rate
constant on the concentration of NADPH. Data were fit to a quadratic binding curve to
determine the rate of reduction as well as binding constant to the enzyme with respect to
NADPH.
Evidence that productive NADPH binding requires other ligands is the slow rate of
reduction of the active site flavin by NADPH (Figure 40) that occurs with a limiting rate constant
of 0.003 s-1. However, attempts in the presence of the MeTHF did not increase the rate of
reduction by NADPH (data not shown) suggesting that additional components are required. The
slow rate of NADPH consumption may be attributed to a conservation of reductive power in the
absence of all required substrates to avoid futile flavin oxidation by molecular oxygen (Figure

41) that was observed to occur with a bimolecular rate constant of 13,500 M-1 s-1. In this
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way TrmFO is shielded from diaphorase activity. Molecular oxygen presents additional
complications when interpreting data from other researchers. Folates degrade in the presence
of molecular oxygen into compounds that cannot be enzymatically utilized82. This fact
compromises previous observations that report tRNA methylation given that reactions were
observed for more than 20 minutes at 37 oC in the presence of atmospheric dioxygen without
performing, or at least reporting proper controls.69, 72, 73, 77

Figure 41. Oxygen dependence of BsTrmFO. A. Traces fit to single exponentials, shown as green
dashes, for reduced TrmFO reacting with molecular oxygen at 99.5, 206, 296, 408, and 584 µM
increasing in concentration from right to left. B. The dependence for the rate of reoxidation on
the concentration of oxygen fit to a straight line to obtain the bimolecular rate constant for
reoxidation of TrmFO by O2.
The Massey method for determination of the redox potential of soluble enzymes
was used to determine the reduction potential for BsTrmFO of -0.187 V, well above the
reduction potential for NADPH (Figure 42). This allowed us to conclude that reduction by
NADPH is not thermodynamically impeded and reinforcing the notion that the enzyme

needs the correct ensemble of ligands bound for catalytic reduction of the flavin cofactor.
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Figure 42. Determination of BsTrmFO reduction potential. A is the simultaneous reduction
spectra of BsTrmFO and HP. The arrow on the left shows the wavelength where the combined
reduction was monitored, the arrow on the right shows where the pure reduction of the
enzyme cofactor was observed. Solid lines represent the beginning of the data collection (top)
and the final spectrum post reduction (Bottom). B. Linear portion of the reduction curve for
both species in solution from which the midpoint was derived.
Oxygen dependent degradation of folates and reduced flavins pose a set of
challenges when observing the enzymatic formation of methylated tRNA using TrmFO enzymes.
The reported long incubation times for assays and the common use of 2-D TLC to determine the
final products of the reaction that are also reliant on hydrolysis by RNase create considerable
uncertainty in the routine observation of methylation by TrmFO.71, 73-78 Moreover, the assays
involving SHMT to regenerate MeTHF (as opposed to anaerobic technique) also incubated
the reaction mixture for 30 minutes before assaing for methylation.73 This approach
ameliorates the degradation of MeTHF to some extent but ignores the oxygen sensitivity of the
reduced flavin. Compounding these apparent limitations is the failure to account for the folateindependent activity of SHMT, which produces 14C-labeled formaldehyde from 14C-labeled

serine.83 Formaldehyde is a highly reactive molecule that incorporates a methyl group onto 113
amines and other moieties independent of TrmFO. This glaring oversight is further
compounded by the fact that 50 µM of the 14C-labeled serine was used with only 5 µM
tetrahydrofolate,73 so that potentially ~45 µM 14C formaldehyde was available to react with the
tRNA that is subsequently assayed for radiolabel. That proper controls were not incorporated or
reported places significant doubt on the veracity of the activity claims for TrmFO enzymes.
In order to remedy these oversights, we attempted to carry out direct transient state
observation of TrmFO in the absence of molecular oxygen utilizing NADPH, MeTHF and tRNAPhe
as substrates. Two different wavelengths were used to monitor either the consumption of
NADPH at 340 nm or the reduction of the enzyme’s flavin cofactor at 444 nm (Figure 43).

Figure 43. Single turnover experiment for TtTrmFO. Left. The spectra of all molecules in solution
at the concentrations used. 3.9 µM enzyme, 15 µM NADPH and 15 µM MeTHF were mixed and
aged for 5s prior to being mixed with 10 µM tRNAPhe. The blue arrow shows the NADPH
spectrum while the black arrow shows the FAD of TtTrmFO. Right. The traces for 200s of the
reaction described here. The two blue lines represent the reaction and control for 339 nm,
while the black lines are the same for 444 nm.

Expected absorption changes for the consumption of NADPH and reduction of flavin were
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estimated to be ~0.09 and 0.04 respectively, but after 200s less than 0.001 AU changes were
observed when compared to a control containing no tRNA. Altogether we found no evidence
for turnover relative to controls suggesting that TrmFO enzymes do not carry out the proposed
methylation of immature tRNAs. While not definitive, these data suggest that the long held
belief that TrmFO enzymes can methylate immature tRNA molecules is deficient and that the
foundation of this belief is undermined by experimental design that promotes adventitious
methylation.
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Abstract
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The hydroaromatic compounds quinate and shikimate can be used as sole carbon sources by
some fungi and bacteria. Dehydroshikimate dehydratase (DSD) plays a central role in this
process, catalyzing the conversion of 3-dehydroshikimate to protocatchuate, a common
intermediate of aromatic degradation pathways. DSD has valuable applications in metabolic
engineering for the production of protocatechuate-derived molecules including muconate, a
compound that can be used in making bioplastics. Although a number of Gram-negative
bacteria are known to degrade quinate and shikimate, only limited information exists on the
identity and properties of the quinate/shikimate catabolic enzymes in these organisms. Here,
we show that the Pseudomonas putida protein, PP_2554, has in vitro DSD activity and produces
protocatechuate when heterologously expressed in quinate-fed Escherichia coli cells. Analysis
of a knock-out of the orthologous protein from P. aeruginosa demonstrates that it is essential
for growth on either quinate or shikimate. PP_2554 is not related by sequence with previously
identified DSDs from the Gram-negative genus, Acinetobacter, but instead shows limited
sequence identity in its N-terminal half with fungal DSDs. The crystal structure of PP_2554
reveals that the protein is in fact a fusion of two distinct modules: an N-terminal sugar
phosphate isomerase-like domain and a C-terminal hydroxyphenylpyruvate dioxygenase
(HPPD)-like domain. Structural and biochemical analyses verify that DSD activity is associated
with the N-terminal domain, which forms a TIM barrel fold containing a novel collection of
active site residues for DSD activity. The enigmatic C-terminal domain exhibits a vicinal oxygen
chelate fold typical of HPPD, but does not appear to possess in vitro HPPD activity. The
presence of this large secondary domain defines a new class of bacterial DSDs and

highlights the considerable diversity of enzymes known to participate in the catabolic
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quinate pathways of different microbes. Based on the analysis presented here, previous
notions regarding the distribution of quinate pathway enzyme variants should be revisited.
Soil-dwelling bacteria and fungi are a metabolically diverse group of microbes capable of
producing and consuming a vast array of compounds. These organisms play a particularly
important role in preserving the nutrient balance in the soil by recycling chemicals deposited by
plants and animals. Quinate and shikimate are two molecules that are readily mineralized by a
number of soil-borne microbes. Both compounds are produced in considerable quantities in
many plants, where they used in the biosynthesis of the cell wall component, lignin. 84
Shikimate is also generated as an intermediate in the production of a number of aromatic
molecules, while quinate may serve an additional role as a carbon store for aromatic
biosynthesis in the early stages of plant development. 85-87
Quinate and shikimate are both degraded by microbes via the so-called quinate pathway.
During this process, the compounds are first oxidized to dehydroquinate and dehydroshikimate,
a reaction catalyzed by a bifunctional quinate/shikimate dehydrogenase (Q/SDH; Figure 1) 88.
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Figure 1. The quinate pathway. In different organisms, either an NAD+- or PQQ-dependent
dehydrogenase catalyzes the initial reaction.

Dehydroquinate generated by this reaction is subsequently converted to dehydroshikimate by
the enzyme, dehydroquinase (DHQ). Finally, dehydroshikimate dehydratase (DSD) catalyzes the
dehydration and aromatization of dehydroshikimate to form protocatechuate, a compound
that can later be degraded to intermediates of central metabolism via the ß-ketoadipate
pathway.
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The activity of DSD has been exploited as part of engineered systems to produce a

variety of protocatechuate-derived molecules including catechol, 90 vanillin, 91, 92 and the
bioplastic-precursor, muconate.93-96
The structural and biochemical properties of the quinate pathway enzymes vary greatly
between different microbes. Fungi, such as Neurospora crassa 97, 98 and Aspergillus nidulans, 88,
99

as well Gram-positive bacteria, including Corynebacterium glutamicum,100 utilize an NAD+-

dependent Q/SDH and a ‘type II’ DHQ. In contrast, members of the genus Acinetobacter, which

has represented a model for quinate degradation among Gram-negative bacteria, 101, 102 use 120
a pyrroloquinoline quinone (PQQ)-dependent Q/SDH and a ‘type I’ DHQ. 102, 103 Additionally,
the DSD found in Acinetobacter species appears to be structurally unrelated to those from fungi
and Gram-positive bacteria.
Quinate and shikimate can also be used as sole carbon sources by some members of the
Gram-negative genus, Pseudomonas, although little biochemical information exists on the
enzymes involved. 104, 105 Here, we confirm previous speculations 104, 106 that these enzymes
differ from those found in Acinetobacter. In particular, we show that P. putida KT2440 encodes
a novel type of DSD that is more closely related to DSDs from fungi, but which is also
differentiated from the fungal enzymes by the presence of a large C-terminal secondary
domain. Based on the high level of activity of the P. putida DSD, this enzyme may have useful
biotechnological applications in the production of protocatechuate-derived compounds. When
combined with our analysis of the remaining quinate pathway enzymes found in P. putida and
other pseudomonads, our results highlight the extensive diversity in the enzymes available for
the degradation of heterocyclic molecules in different microbes.
Materials and methods
Cloning and site-directed mutagenesis.
The gene encoding PP_2554 (NP_744699) from P. putida KT2440 was originally cloned
into the NdeI/BamHI sites of a modified version of the pET28 vector containing a C-terminal
6xHIS/TEV cleavage site (pET28 MOD; Structural Genomics Consortium, Toronto, Canada)
using primers listed in Table 1. However, this construct failed to yield a sufficient quantity
of protein for biochemical studies. The gene was therefore excised from pET28 MOD

at NdeI and BamHI sites and inserted into the equivalent restriction sites of the pET28a
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vector containing an N-terminal 6xHIS/thrombin cleavage site (Novagen, Gibbstown, New
Jersey). A C-terminal stop codon was introduced at the end of the protein-coding sequence by
site-directed mutagenesis. To test the effects of isolating the N-terminal domain of the protein,
the codon encoding Pro278 of the protein was mutated to an early stop codon. In the structure
of PP_2554, Pro278 is found just prior to the linker region connecting the N- and C-terminal
domains of the protein. Site-directed mutagenesis was performed as per the protocol provided
with the QuikChange mutagenesis kit (Agilent Technologies, Santa Clara, California). Primers
used to generate site-directed mutagenesis constructs are shown in Table 1. All constructs
were verified by DNA sequencing.
For complementation studies in a P. aeruginosa DSD knock-out strain (described below),
the gene encoding PP_2554 was amplified from the PP_2554-pET28a construct and cloned into
the BamHI/HindIII sites of a gentamicin-resistant variant of the pUCp20 broad host-range
expression vector (pUCp20g) using primers shown in Table 1.
Table 1. Primers, expression vectors and constructs used in this study.
Primers

Sequence

Cloning Primersa
PP_2554-pET28 MOD

5´-GGACTCATATGCAACGTTCGATCGCTA-3´

forward
PP_2554-pET28 MOD
reverse

5´-GATGAGGATCCCAGAACCGGCTTGCG-3´

PP_2554-pUCp20g

5´-GACTCGGATCCATGCAACGTTCGATCGCTACCG-3´

forward
PP_2554-pUCp20g

5´-CAGTTAAGCTTTCACAGAACCGGTTTGCGCG-3´

reverse

Site-Directed
Mutagenesis Primersb,c
pET28a stop codon

5´-CGCAAGCCGGTTCTGTGATCCGAATTCGAGC-3´

forward
H168A forward

5´-TGATCCTCGACAGCTTCGCCACCTTGTCGCTCAAAG-3´

S206A forward

5´-GATGTGCTGGAGTGGGCCCGCCACTTTCGCTG-3´

R207A forward

5´-GCTGGAGTGGAGCGCCCACTTTCGCTGC-3´

R210A forward

5´-GGAGCCGCCACTTTGCCTGCTTCCCGGG-3´

P278 stop codon forward

5´-GGAGCAGGAGAACACGTAGATCGAACCTGGCGTG-3´

E356A forward

5´-CCACAACTTCTTCGCGGCCCATGGCCCAT-3´

Expression vectors

Description and source

pET28 MOD

Modified version of the pET28a expression vector with a Cterminal 6xHIS/TEV cleavage site (Structural Genomics
Consortion, Toronto, Canada)

pET28a

Expression vector with an N-terminal 6xHIS/thrombin
cleavage site (Novagen, Gibbstown, New Jersey)
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pUCp20g

Gentamicin-resistant variant of the broad-host range
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expression vector pUCp20 107 (Centre for the Analysis of
Genome Evolution and Function, Toronto, Canada)

Constructs

Description and source

pET28 MOD-PP_2554

pET28 MOD vector containing the full-length NP_74699
gene (expressing full-length PP_2554; this study)

pET28a-PP_2554

pET28a vector containing the full-length NP_74699 gene
(expressing full-length PP_2554; this study)

pET28a-PP_2554-N

pET28a vector containing the full-length NP_74699 gene
with an internal stop codon (expressing only the PP_2554 Nterminal domain; this study)

pUCp20g-PP_2554

pUCp20g vector containing the full-length NP_74699 gene
(expressing full-length PP_2554; this study)

pUCp20g-PP_2554-N

pUCp20g vector containing the full-length NP_74699 gene
with an internal stop codon (expressing only the PP_2554 Nterminal domain; this study)

aBases

complementary to the P. putida genomic DNA sequence are underlined. bReverse site-

directed mutagenesis primers are complementary to forward primers shown. cIntroduced base
mutations are bolded.
The full-length gene containing the early stop codon (expressing only the N-terminal
domain of PP_2554) was similarly cloned into the pUCp20g vector.

Analysis of DSD function in P. aeruginosa.
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The P. aeruginosa PAO1 protein, PA0242, sharing 78% sequence identity with the P.
putida protein PP_2554 was identified by a BLAST search. A PA0242 knockout strain (strain
1433, genotype PA0242-F10::ISphoA/hah) (should the insertion position be given to ensure the
reader understands that the DSD sequence was disrupted?) was ordered from the Manoil Lab
P. aeruginosa PAO1 Two Allele Library 108. Wild-type P. aeruginosa and the transposon
knockout strain were tested for their ability to utilize quinate or shikimate as a sole carbon
source. Overnight starter cultures of the strains were grown in Luria Bertani (LB) media at 30°C.
These cultures were pelleted, washed twice in M9 minimal media, and resuspended in the
same media. The resuspended cultures were then used to inoculate 100 µL volumes of M9
minimal media (starting OD600 of 0.1) supplemented with 25 mM quinate, shikimate, or glucose
in a 96-well microplate. The OD600 of cultures in individual wells was monitored at 30°C over 24
hours with orbital shaking (258 rpm, 2.5 mm amplitude) using a TECAN Infinite M1000 PRO
microplate reader (Tecan Group, Männedorf, Switzerland). All growth curves were generated
in triplicate and averaged. Concurrently, the resuspended overnight cultures were streaked on
agar plates containing minimal media containing 25 mM quinate, shikimate or glucose. After
24 hours of incubation at 30°C, plates were examined for bacterial growth. A P. aeruginosa
knock-out of a predicted Q/SDH (strain 1437, genotype PA0244-B11::ISphoA/hah) was analyzed
using the same protocol.
For complementation studies in the P. aeruginosa PW1433 knock-out background,
pUCp20g constructs containing either the gene expressing the full length PP_2554 protein or
the gene expressing the truncated N-terminal half of the protein were transformed into the

PW1433 strain by electroporation and grown on LB-agar plates containing 15 µg/mL
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gentamicin. The empty pUCp20g vector was also transformed into the PW1433 strain as a
control. Growth experiments in minimal media were performed as described above for the P.
aeruginosa wild-type and knockout strains, but with the addition of 15 µg/mL gentamicin to all
starter cultures.
Protein expression and purification.
Recombinant protein expression was performed in Escherichia coli BL21 CodonPlus
(Agilent Technologies, Santa Clara, California). 50 mL overnight starter cultures grown in LB
supplemented with 50 µg/mL kanamycin and 33 µg/mL chloramphenicol were used to seed
fresh 1 L cultures containing kanamycin alone. Cells were grown with shaking at 37°C to an
OD600 of 0.6, at which point the temperature of the shaker was lowered to 18°C. Once the
culture had equilibrated to the temperature of the shaker, protein expression was induced by
the addition of 0.4 mM isopropyl ß-D-thiogalactopyranosid (IPTG). After a 4-5 hour induction
period, cells were harvested by centrifugation and resuspended in binding buffer (50 mM Tris
pH 7.5, 500 mM NaCl, 5% glycerol, 5 mM imidazole). Cells were then lysed using a French press
followed by sonication, after which insoluble cellular materials were removed by centrifugation.
The recombinant protein was purified by nickel nitrilotriacetic acid affinity
chromatography. Wash steps were preformed using buffer containing 30 mM imidazole, prior
to elution with buffer containing 250 mM imidazole. Following purification, the protein was
incubated with 10 mM EDTA and then dialyzed overnight at 4°C in buffer containing 50 mM Tris
pH 7.5, 500 mM NaCl, and 5% glycerol. The 6xHIS tag was removed via overnight incubation
with thrombin at 4°C. The protein was then separated from the cleaved 6xHIS tag by

passage through a nickel nitrilotriacetic acid column.
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Thrombin was removed from the cleaved sample by gel filtration using an AKTA purifier (GE
Healthcare, Uppsala, Sweden) with a HiLoad 16/60 Superdex 75 column. Mutant proteins were
purified in a similar fashion.
To purify PP_2554 for analysis of potential 4-hydroxyphenylpyruvate dioxygenase
(HPPD) and protocatechuate dioxygenase (PCD) activities, the lysate from E. coli cells expressing
the protein was loaded onto a 12 mm × 100 mm TALON column at a flow rate of 1 mL/min. The
column was then washed with 200 mL of buffer (20 mM HEPES pH 7.5, 5 mM imidazole) to
remove any nonspecifically bound contaminants. Finally, the enzyme was eluted using a 400
mL linear gradient of 20 mM HEPES pH 7.5 with 150 mM imidazole.
Enzyme activity assays.
N-terminal DSD domain activity assays. DSD activity of PP_2554 was initially detected
during heterologous expression of the protein in quinate-fed E. coli. Briefly, a 50 mL culture of
E. coli BL21 CodonPlus carrying the gene encoding PP_2554 on the pET28a expression vector
was grown in LB media supplemented with 15 mM quinate at 37°C to an OD600 of 0.6,
whereupon expression of PP_2554 was induced by the addition of 0.4 mM IPTG for 4 hours.
Metabolites were extracted from the culture (as well as from a control culture carrying the
empty pET28a vector) with two volumes of ethyl acetate, dried in vacuo and resuspended in
100 μM methanol. The metabolites were then separated by high pressure liquid
chromatography (HPLC) using an Agilent 1200 series system equipped with a
4.6 mm × 150 mm Zorbax 3.5 µm reverse phase C18 column (Agilent Technologies, Santa Clara,
California) at a flow rate of 0.7 mL/min in a linear gradient of 95:5 to 0:100 water:methanol

with 0.1% formic acid. The DSD reaction product was identified by comparison to a

127

protocatechuate standard (Sigma-Aldrich, Oakville, Canada).
The DSD activity of PP_2554 was verified with a spectrophotometric analysis using the
purified recombinant protein. The purified enzyme (~50 nM) was incubated in a 1 mL cuvette
with 50 μM dehydroshikimate (Sigma-Aldrich, Oakville, Canada) and 2 mM CoCl2 for ~30
minutes. Product identification was performed via a spectral trace using a Varian Cary 50 Bio
UV-visible spectrophotometer (Varian, Mulgrave, Australia) by comparison to the UV spectrum
of a bona fide protocatechuate standard. The identity of the in vitro reaction product was
further confirmed using HPLC analysis to verify coelution of the reaction product with a
protocatechaute standard. HPLC analysis was performed as described above, except prior to
loading, 5% formic acid was added to the reaction and the enzyme was removed by
centrifugation. The reaction mixture lacking the enzyme was used as a negative control.
The kinetic properties of the PP_2554 wild-type and mutant enzymes were measured by
following the production of protocatechuate (ε290 = 3.89 x 103 M-1 cm-1) (note superscript)(a
delta ext coef should be used at 290 nm to include the loss of the dehydroshikimate
contribution) at 290 nm using the procedure described by Strøman et al. 109. Dehydroshikimate
stocks were prepared in deionized water and quanitified using ε234 = 11.9 x 103 M-1 cm-1(note
superscript). Reactions were prepared in 1 mL volumes and monitored at 25°C. Typical
reactions contained 15 nM purified protein, 50 mM HEPES pH 7.5, 150 mM NaCl, 10 mM
CoCl2, and between 0.01 mM and 3 mM dehydroshikimate and the rate was determined from a
linear fit to the change in absorption measured in the first X seconds. All reactions were
performed at least in triplicate using three or more independently purified protein

preparations. Vmax and KM values were determined by varying the concentration of
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dehydroshikimate and fitting the
data to the following equation, using the program GraFit 110:

Equation 1

v = Vmax[S]/(KM + [S])

where v is the initial velocity and [S] is the concentration of the substrate.
Metal ion dependence was evaluated by monitoring the reaction in the presence of up
to 5 mM of the following compounds: CaCl2, CoCl2, MgCl2, MnCl2, NiCl2, and ZnSO4. To remove
metal ions copurified with the enzyme, the protein was first incubated with 10 mM EDTA and
then dialyzed overnight.
C-terminal HPPD-like domain activity assays. PP_2554 was tested for HPPD and PCD
activity using a dioxygen electrode assay, spectrophotometetric coupled assay methods, and by
HPLC product analysis. The dioxygen electrode assay consisted of 0.1 M potassium phosphate,
2 mM 2-mercaptoethanol, 40 μM ferrous sulfate, and five concentrations of the PP_2554
enzyme (4, 8, 12, 16, and 20 μM) to determine whether or not the rate of oxygen consumption
increased proportionally to the amount of enzyme present. Each reaction was initiated with
the addition of 250 μM 4-hydroxyphenylpyruvate (Sigma-Aldrich) and allowed to react for ~8
minutes while the level of oxygen in the vessel was monitored.
A single coupled reaction was also preformed to monitor HPPD activity
spectrophotometrically. For this reaction, 20 mM HEPES pH 7.5 was mixed with 40 μM ferrous

sulfate, 2 mM 2-mercaptoethanol, 15 μM PP_2554 enzyme, and an estimated excess (1-2

129

µM) of the coupling enzyme, homogentisate 1,2 dioxygenase (HGD) from P. aeruginosa
(turnover number ~90 s-1). The reaction was initiated with 250 μM 4-hydroxyphenylpyruvate
and the absorbance was monitored at 321 nm for the formation of the HGD product,
maleylacetoacetate.
To test for PCD activity, an increase in absorbance at 375 nm was monitored in the
presence of protocatechuate and the cofactor Fe2+. A buffer of 0.1 M potassium phosphate pH
7.5 was mixed with 40 μM ferrous sulfate, 2 mM 2-mercaptoethanol, and 1.8, 3.6, 7.3, 14.7,
29.4 µM of PP_2554 enzyme. Each reaction was initiated with 200 μM protocatechuate and
the change in absorbance was monitored for 300 seconds. The reaction conditions were
replicated and then used to observe the consumption of molecular oxygen as the enzyme
turned over, using an oxygen electrode.
The formation of the expected products for the two potential activities was further
assessed using HPLC analysis. Reactions were designed to observe the reaction mixture at an
initial and a final point in time (before and after the addition of enzyme). The T=0 injections for
both the HPPD and PCD assays contained 40 µM ferrous sulfate, 2 mM 2-mercaptoethanol, 250
µM substrate (either 4-hydroxyphenylpyruvate or protocatechuate) and 10 mM potassium
phosphate pH 7.5 in a total volume of 986 mL. The reaction was then initiated with 20 µM of
enzyme and allowed to react for ~20 minutes, at which point 100 µL of the reaction mixture
was withdrawn, added to a 0.5 mL 10 kDa nominal molecular weight limit Amicon
ultracentrifugal filter (EMD Millipore, Billerica, Massachusetts), and centrifuged at 14,000 g for

7 minutes to remove the enzyme. The same reactions were prepared without enzyme as
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substrate stability controls, and subsamples were collected and frozen every five minutes
for a total of 20 minutes. The resulting filtrates, as well as the T=0 and control samples, were
chromatographed using a Waters 600E HPLC system fitted with a 4.6 mm × 150 mm Waters 3.5
µm Xterra reverse phase C18 column (Waters Corporation, Milford, Massachusetts). The
column was run under isocratic conditions at 0.8 mL/min with a mobile phase consisting of 10
mM potassium phosphate pH 2.0 and 0.5% acetonitrile. Elution was monitored at 220 and 276
nm using a Waters 2487 dual wavelength detector. Individual substrates and products were
identified by coelution with standards for each.
Protein crystallography and structural analysis.
PP_2554 crystals were grown using the hanging drop vapor diffusion method over a well
solution composed of 100 mM Tris pH 7.5, 0.1 M LiSO4, and 25% PEG3350. Crystallization drops
contained a 1:1 ratio of PP_2554 (20 mg/mL) and well solution. Crystals were cryoprotected in
25% ethylene glycol and flash frozen prior to data collection at the Advanced Proton Source
(Argonne, IL), beamline 19-ID. Data were processed and scaled using HKL2000 111 and Se atoms
were located using Phenix 112. Automated model building was performed using Phenix
Autobuild, followed by manual building using Coot 113 with refinements performed by Phenix
Refine. Crystallographic structural data are summarized in Table 2.
Results
Identity of putative quinate pathway enzymes in different pseudomonads.
Early studies hinted at potential differences in the quinate pathways of some
pseudomonads compared to other Gram-negative bacteria. 104, 106 To explore this possibility,

we identified putative quinate pathway enzymes encoded by different pseudomonads and 131
compared them to those previously identified in Acinetobacter calcoaceticus 101, 102 and other
microbes. For simplicity, we will refer to proteins encoded by P. putida KT2440 by their gene
locus IDs (PP_####).
At least two structurally unrelated variants of the first enzyme in the quinate pathway,
Q/SDH, exist. The first is a soluble ~30 kDa NAD+-dependent enzyme present in fungi such as
Aspergillus nidulans 114, 115 and Neurospora crassa. 98 This type of Q/SDH is also found in Grampositive bacteria including C. glutamicum 116, 117 and Rhodococcus rhodochrous. 118 The second
Q/SDH class is an ~88 kDa membrane-associated PQQ-dependent dehydrogenase that has been
identified in certain species of Acinetobacter 101, 103 and Gluconobacter. 119, 120
Although P. putida KT2440 encodes a protein (PP_3569) that shares 61% sequence
identity with the PQQ-dependent Q/SDH from A. calcoaceticus, it also encodes a second
candidate Q/SDH (PP_2406), which exhibits 22% and 51% sequence identity with the NAD+dependent Q/SDHs from A. nidulans and C. glutamicum, respectively (Table 3). While the
activity of PP_3569 has not been verified, we have shown previously that PP_2406 catalyzes the
NAD+-dependent oxidation of both quinate and shikimate in vitro. 121 P. syringae pv. tomato
str. DC3000 also encodes both an NAD+-dependent Q/SDH ortholog and a putative PQQdependent Q/SDH, while P. aeruginosa PAO1 and P. protogens Pf-5 encode only the NAD+dependent variant (Table 3). A transposon-based knock-out of the P. aeruginosa protein
prevents growth of the bacterium on quinate or shikimate (Figure S1), demonstrating an
essential role for an NAD+-dependent Q/SDH in the quinate pathways of some pseudomonads.

Dehydroquinate produced by the Q/SDH-catalyzed oxidation of quinate is

132

subsequently converted to dehydroshikimate by the enzyme, DHQ. Like Q/SDH, two types of
DHQs exist. The two types appear to have arisen by convergent evolution, as the enzymes are
structurally unrelated and utilize dissimilar catalytic mechanisms.122-124 We were not able to
identify a protein similar to the quinate degradation-associated type I DHQ from A.
calcoaceticus in P. putida KT2440. However, a P. putida protein (PP_2407) sharing 53%
sequence identity with catabolic type II DHQ from A. nidulans and 59% identity with the type II
enzyme from C. glutamicum is encoded by a gene situated immediately adjacent to the gene
for PP_2406, the NAD+-dependent Q/SDH (Table 3) (is it co-transcribed??). This genomic
organization is also maintained in P. aeruginosa PAO1 and P. protogens Pf-5 and is suggestive of
a related function for the gene products. A similar clustering of the quinate catabolic genes has
also been observed in the genomes of quinate-degrading fungi (Table 3).
The third reaction in the quinate pathway, the formation of protocatechuate from
dehydroshikimate, is catalyzed by DSD. Fungal DSDs are soluble enzymes approximately 350
amino acids in length. These fungal proteins do not show significant sequence similarity with
the ~490 amino acid DSD from A. calcoaceticus. An additional type of DSD, designated AsbF,
has been identified in some species of Bacillus, but is not associated with quinate degradation.
125, 126

Instead, AsbF is involved in the production of protocatechuate for use in the biosynthesis

of the virulence-associated siderophore, petrobactin. B. anthracis AsbF is 280 amino acids long
and exhibits only 16% sequence identity with the fungal DSD from A. nidulans, but lacks
sequence similarity with A. calcoaceticus DSD.

While some P. putida strains, including GB-1 and W619, possess a protein with a
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high level of sequence identity with A. calcoaceticus DSD, this protein is not encoded by the
KT2440 strain (Table 3). A possible candidate to function as a DSD in this strain is a ~635 amino
acid protein, PP_2554, which exhibits ~25% sequence identity in its N-terminal half with A.
nidulans DSD (Table 3). The PP_2554 N-terminal domain shows only limited sequence identity
(~15%) with B. anthracis AsbF. The C-terminal half of the protein has ~30% sequence identity
with P. fluorescens 4-hydroxyphenylpyruvate dioxygenase (HPPD), an enzyme normally
associated with tyrosine degradation (Table 3). The distinctive fusion of domains is not
observed in fungal DSDs or AsbF proteins.
Although the genomic context of the gene encoding PP_2554 is not immediately
suggestive of its function, orthologous proteins in other pseudomonads are encoded by genes
in the vicinity of the remaining quinate pathway genes (Table 3). A knock-out of the PP_2554
ortholog from P. aeruginosa PAO1 resulted in an inability of the bacterium to utilize quinate or
shikimate as a sole carbon source (Figure 2), demonstrating that the putative two-domain DSD
plays a critical role in the catabolism of these compounds. This growth impairment could be
reversed by plasmid-based expression of PP_2554 (Figure 2). BLAST analysis reveals that the
novel two-domain enzyme is also present in a number of other pseudomonads as well as a
variety of other Gram-negative bacteria including Burkholderia cenocepacia and Klebsiella
pneumoniae, and Gram-positive quinate-degrading species such as C. glutamicum and R.
rhodochrous. The gene encoding the corresponding C. glutamicum protein, qsuB, is situated
in an operon that has been shown to be associated with quinate usage by this organism. 100
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Figure 2. The PP_2554 ortholog, PA0242, is essential for the growth of P. aeruginosa on
quinate or shikimate. The 1437 knock-out strain contains a transposon disrupting the gene
locus, PA0242, encoding an ortholog of PP_2554. Growth was monitored on agar plates (left)
or in liquid media (right) supplemented with A) glucose, B) quinate, and C) quinate. WT, wildtype. For liquid media growth curves: P. aeruginosa wild-type ( ), 1433 knock-out strain ( ),
1433 + PP_2554 ( ), 1433 + PP_2554 N-term ( ), 1433 + empty vector ( ).

Recently, expression of qsuB in the plant, Arabidopsis thaliana, has been shown to lead to
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the accumulation of protocatechuate, 127 although the product of the gene has not been
characterized in vitro.
Analysis of PP_2554 DSD activity.
Our sequence analysis suggested that some bacteria might utilize a novel class of DSDs
for quinate catabolism. To explore this possibility further, we performed a detailed biochemical
analysis of PP_2554. For this analysis, the protein was produced recombinantly in Escherichia
coli. While E. coli already encodes a Q/SDH and a DHQ, it does not naturally possess a DSD or
proteins capable of degrading the DSD reaction product, protocatechuate. Hence, we
rationalized that exogenous quinate supplied to E. coli would be converted only to
dehydroshikimate by the native E. coli Q/SDH and DHQ. Heterologous expression of an active
DSD would then convert the dehydroshikimate to protocatechuate, which would accumulate in
the media. Indeed, ethyl acetate extracts from quinate-fed E. coli cells expressing PP_2554
revealed the accumulation of significant quantities of protocatechuate, suggesting that
PP_2554 encodes an active DSD (Figure 3A). To verify the activity of PP_2554, the protein was
purified (Figure S2) and used in a spectrophotometric activity assay. This analysis
demonstrated that PP_2554 readily catalyzes the production of protocatechuate from
dehydroshikimate in vitro (Figure 3B). The identity of the reaction product was further
confirmed using HPLC by comparison to a protocatechuate standard (Figure 3C).

136

Figure 3. Detection of DSD activity of recombinant PP_2554. A) HPLC traces indicating the
production of protocatechuate by quinate-fed E. coli BL21 cells expressing PP_2554. B) UV and
C) HPLC traces of dehydroshikimate, protocatechuate, and the PP_2554 reaction product

To determine the kinetic parameters for the DSD activity of PP_2554, we monitored the
formation of protocatechuate at 290 nm in the presence of the purified enzyme and various
concentrations of dehydroshikimate. Similar to previous reports for fungal DSDs 109, 128 and
AsbF 125, 126, PP_2554 DSD activity is dependent on a divalent cation and EDTA inactivates the
enzyme. Under the reaction conditions,

we found that the enzyme has maximal activity when supplied with Co2+ (Figure S3). Activity 137
is reduced more than 5-fold when Ni2+, Mn2+, or Mg2+ is used and is lower still using Zn2+ or Ca2+.
In the presence of 10 mM CoCl2, we measured a kcat of 163.6 ± 8.5 s-1 and a KM for
dehydroshikimate of 331 ± 51 μM (Table 3).
Functional analysis of the PP_2554 C-terminal domain.
PP_2554 is differentiated from fungal DSDs and the siderophore biosynthesis-associated
AsbF by the presence of a large C-terminal extension. This portion of the protein exhibits
significant sequence identity with HPPD, an Fe2+-dependent α-keto acid oxygenase that
catalyzes the conversion of 4-hydroxyphenylpyruvate to homogentisate during the (note: HPPD
is found in all kingdoms) degradation of tyrosine. 129 We therefore tested whether PP_2554 has
HPPD activity.
HPPD is a member of the vicinal oxygen chelate (VOC) superfamily, of which the Fe2+dependent members also include several extradiol dioxygenases. 130 Given that
protocatechuate is a reaction product generated via the DSD activity of PP_2554, and because
protocatechuate normally undergoes a dioxygenase-catalyzed ring cleavage during its
degradation,89 we also tested whether PP_2554 has protocatechuate dioxygenase (PCD)
activity.
Both HPPD and PCD activities were tested for using an oxygen-sensing electrode to
monitor the consumption of molecular oxygen by PP_2554 in the presence of Fe2+ and either 4hydrophenylpyruvate or protocatechuate. We also performed an HPLC analysis to determine
whether 4-hydroxyphenylpyruvate or protocatechaute could be consumed in the presence of
PP_2554. Finally, both

activities were monitored using spectrophotometric methods, with HPPD activity coupled to 138
homogentisate 1,2-dioxygenase from P. aeruginosa to observe the production of
maleylacetoacetate at 321 nm, and PCD activity evaluated by monitoring an increase in
absorbance at 375 nm associated with the production of the protocatechuate cleavage product.
In all cases, however, we did not detect enzymatic activity.
In the absence of measurable HPPD or PCD activity, we examined the relevance of the
PP_2554 C-terminal domain to the DSD activity of the protein. For this analysis, the C-terminal
domain was removed entirely by mutating the codon specifying Pro278 to an early stop codon
(Figure S2). Pro278 is found immediately prior to the linker that connects the N- and C-terminal
domains of the protein (as described later). Following purification, we found that the isolated
N-terminal domain still possessed DSD activity. We measured a kcat of 61.2 ± 2.5 s-1 for the
truncated protein, representing only a modest 2.7-fold reduction compared to full-length
PP_2554 (Table 4). The KM for dehydroshikimate of the isolated N-terminal domain was 205 ±
30 μM, which is very similar to that of the full-length protein.
To evaluate the significance of the C-terminal domain to quinate and shikimate
degradation in vivo, we tested whether plasmid-based expression of the isolated PP_2554 Nterminal domain could restore growth of the P. aeruginosa 1433 knock-out strain on quinate
and shikimate. When expressing only the N-terminal domain, the knock-out strain could use
either quinate or shikimate as a sole carbon source, albeit with a reduction in growth compared
to the knock-out strain expressing full-length PP_2554 (Figure 2). When taken together, these
data suggest that the C-terminal HPPD-like domain of PP_2554 is not essential for the DSD

activity of PP_2554, although co-evolution of the fused domains may have entwined their
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functional contribution to promote maximal DSD activity.
Structural analysis of PP_2554.
Representative crystallographic structures have been determined for a number of
quinate pathway enzymes, including the NAD+-dependent Q/SDH (e.g., PDB ID: 2NLO) and both
the type I and type II DHQ (e.g., PDB IDs: 1QFE and 2DHQ). In addition, the crystal structure of
the siderophore biosynthesis-associated AsbF from B. anthracis has been determined in
complex with protocatechuate (PDB ID: 3DX5). However, a representative crystal structure of a
quinate pathway DSD is lacking. In light of the relatively low sequence identity between the
PP_2554 N-terminal domain and AsbF (~15%), and given the presence of the novel PP_2554 Cterminal domain, we predicted that a crystal structure of PP_2554 would reveal a number of
novel features.
Crystals of PP_2554 diffracted to 2.37 Å resolution and belonged to the P 63 space
group (Table 2). The crystallographic unit cell had dimensions of 262.5 Å x 262.5 Å x 139.6 Å,
with six molecules present in the asymmetric unit. The structure of PP_2554 was solved by SAD
phasing from data collected using a selenomethionine-derivatized crystal. Density for residues
__ was not observed and therefore, these residues were omitted from the final model, which
was refined to R and Rfree respectively.
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Figure 4. Crystal structure of PP_2554. A) PP_2554 dimer. N- and C-terminal domains are
shown in dark and light teal, respectively, for the first molecule in the dimer (dark and light gray
for the second molecule). Select secondary structures are labeled for reference. B) PP_2554
protomer. Metal ions present in each domain are shown as spheres. The location of Pro278,
the site at which an early stop codon was introduced to remove the C-terminal domain, is
indicated.

The six molecules in the PP_2554 asymmetric unit are arranged in three dimers. In each dimer,
the N-terminal domain associates mainly with the C-terminal module found in the adjacent

molecule and forms fewer contacts with the second N-terminal domain (Figure 4A). This
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arrangement results is a pinwheel-like topology in which the N- and C-terminal domains of the
protein alternate. Each N-terminal domain active site (identifiable by the presence of a bound
metal ion) is separated from either of the C-terminal domain active sites by a distance of ~40 Å.
Analysis by size exclusion chromatography suggests that PP_2554 is also dimeric in solution
(Figure S4). We therefore hypothesize that the mode of dimerization observed in the crystal
structure represents the biological assembly of this protein. While AsbF also forms a dimer, the
two molecules associate in a distinct orientation due to the absence of an HPPD-like domain. 126
In contrast to these proteins, the fungal DSD from A. nidulans has been reported to be
monomeric in solution.109
In a PP_2554 protomer, the N-terminal domain spans ~275 amino acids and forms a TIM
barrel consisting of eight ß-strands interwoven with an equal number of α-helical regions
(Figure 4B). The TIM barrel architecture is shared with a large number of other proteins,
including xylose isomerase (e.g., PDB ID 5XIN) and the type I DHQ (e.g., PDB ID: 1QFE). AsbF
also belongs to the TIM barrel family.126 However, a superimposition of the structures of B.
anthracis AsbF and the PP_2554 N-terminal domain generates an RMSD of 3.03 Å, implying that
notable structural variations are likely exist between the two proteins. A closer comparison of
the proteins reveals that a long AsbF α-helix that partially caps the active site is replaced by two
smaller α-helices in the PP_2554 N-terminal domain, α9 and α13’, which are oriented in a much
different manner than the AsbF α-helix (Figure 5A).
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Figure 5. A) Superimposition of the PP_2554 N-terminal (DSD) domain (teal) with B. anthracis
AsbF (brown; PDB ID: 3DX5). A cobalt ion in the PP_2554 structure is shown as a pink sphere. A
manganese ion present in the AsbF structure is shown as a purple sphere. Protocatechuate
present in the AsbF crystal structure is shown in stick form. The α-helix, α13’, is found on the Cterminal domain of the second molecule of the PP_2554 dimer and is shown in isolation for
clarity. Refer to Figure 4A for the location of secondary structures in the PP_2554 dimer. B)
Superimposition of the active sites of the PP_2554 N-terminal (DSD) domain and AsbF in
complex with protocatechuate. AsbF residues occupying the same position as PP_2554 Arg207
and Arg210 are not observed. Metal-coordinating bonds are shown as yellow dashes in the
PP_2554 structure. Bonds in the AsbF structure are shown as white dashes. C)

Partial multiple sequence alignment of the PP_2554 N-terminal (DSD) domain with the N- 143
terminal domains from other putative two-domain DSDs, fungal DSDs and AsbF proteins.
Identical residues are outlined in black; similar residues are outlined in gray. Black numbering
corresponds with the PP_ 2554 sequence. Teal numbering indicates PP_2554 active site
residues shown in panel B). Brown numbering indicates B. anthracis AsbF active site residues.

Interestingly, α13’ is found on the C-terminal domain of the second molecule of the PP_2554
dimer. In addition to this difference, we observed that PP_2554 α3 and α5 are shorter than the
corresponding α-helices in the AsbF structure and do not bend toward the active site (Figure
5A). Furthermore, PP_2554 α11 is shifted compared the position of the equivalent AsbF αhelix, while a disordered region beneath α11 is substituted with a short α-helix in the AsbF
structure.
The C-terminal domain of PP_2554 encompasses ~325 residues and adopts a VOC fold
that bears significant structural resemblance to HPPD. The VOC fold is typically formed by two
incomplete barrels, each comprised of a pair of ßαßßß modules. The active site is contained by
the C-terminal half of the molecule, while the N-terminal region appears to be a vestigial
structural domain resulting from a gene duplication event.130, 131 Comparison of the PP_2554 Cterminal domain with the bona fide HPPD from P. fluorescens (PDB ID: 1CJX) reveals a virtually
identical overall fold, with nearly complete conservation of secondary structural elements
(Figure 6A). Indeed, a superimposition of the two structures yields an RMSD of only 1.46 Å.
However, we noted a few key differences between the two proteins.
In the PP_2554 N-terminal domain, α16 exhibits a large shift away from the active

site relative to the position of the corresponding α-helix in the HPPD structure, so that it is 144
instead wedged into the cleft between the N- and C-terminal domains of the second molecule
of the PP_2554 dimer (Figures 4A, 6A).

Figure 6. A) Superimposition of the PP_2554 N-terminal (HPPD-like) domain (teal) with P.
fluorescens HPPD (blue; PDB ID: 1CJX). Refer to Figure 4A for the location of secondary
structures in the PP_2554 dimer. Differences in the position of secondary structures between
the PP_2554 and HPPD structures are indicated with red arrows. Non-heme iron is shown as a
brown sphere in the PP_2554 structure or a blue sphere in the HPPD structure. B)
Superimposition of the active sites of the PP_2554 C-terminal (HPPD-like) domain and P.
fluorescens HPPD. Acetate is present in the P. fluorescens HPPD structure. Metal-coordinating
bonds are shown as yellow dashes in the PP_2554 structure or white dashes in the HPPD

145
structure. C) Partial multiple sequence alignment of the PP_2554 C-terminal (HPPD-like)
domain with the C-terminal domain from other putative two-domain DSDs and bona fide
HPPDs. Identical residues are outlined in black; similar residues are outlined in gray. Black
numbering corresponds with the PP_ 2554 sequence. Teal numbering indicates PP_2554 active
site residues shown in panel B). Blue numbering indicates P. fluorescens HPPD active site
residues.

The repositioning of α16 allows the nearby α9’ of the second PP_2554 molecule to approach
the C-terminal active site. In addition, a disordered loop in the PP_2554 structure replaces a
pair of ß-strands lining the opening of the HPPD active site (Figure 6A). This loop is also shifted
away from the active site compared to the HPPD ß-strands due to the influence of α16’ from
the second molecule in the PP_2554 dimer. Discontinuous density in portions of the PP_2554
disordered loop suggest that this region of the structure may exhibit conformational flexibility.
As a consequence of these features, the active site of the PP_2554 C-terminal domain exhibits a
more ‘open’ conformation than the HPPD active site. Finally, we noted differences in the
relative positions of α-helices at the extreme C-termini of the PP_2554 C-terminal domain and
P. fluorescens HPPD (Figure 6A). This region has been observed to exhibit a significant level of
mobility in other HPPD structures, and may serve a gating function for active site ligands. 132, 133
The N- and C-terminal domains of PP_2554 are joined by a ~20 amino acid linker that
does not show significant sequence similarity with any previously characterized proteins. The
linker also exhibits variability among orthologs of PP_2554. The equivalent stretch of amino
acids between the predicted N- and C-terminal domains of the PP_2554 ortholog from
Burkholderia thailandensis appears to be more than three times longer. The PP_2554 linker
includes a total of five proline residues, including three in succession (Pro287-Pro289).

These residues lend structural rigidity to the linker and may help stabilize the interaction
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between the N- and C-terminal domains of the protein.
Analysis of the PP_2554 N-terminal DSD domain active site.
The PP_2554 DSD active site is located at the center of the N-terminal TIM barrel, and is
formed by residues including, Arg64, Leu97, Glu134, Leu136, His168, Asp165, Gln191, Ser206,
Arg210, and Glu239. We compared the active sites of the PP_2554 N-terminal domain and B.
anthracis AsbF (PDB ID: 3DX5) by superimposition of the two structures (Figure 5B) and probed
the function of specific PP_2554 residues by generating a series of site-directed mutants (Table
4, Figure S2).
Like AsbF and a number of other TIM barrel proteins, our kinetic analysis of PP_2554
revealed that the activity of the enzyme requires a divalent cation. In the PP_2554 DSD active
site, we observe strong metal density coordinated with the residues, Glu134, Asp165, Gln191,
and Glu239, all of which are conserved in the sequences of DSDs from the fungi A. nidulans, N.
crassa, and P. anserina (Figure 5C). These residues are also present in the structure of AsbF,
with the exception of Gln191, which is substituted with a histidine (Figure 5B). In the AsbF
active site, the residues are bound to a manganese ion that is proposed to stabilize a catalytic
intermediate.126 In the structure of xylose isomerase (PDB ID: 5XIN), another TIM barrel
protein, the corresponding residues are a Glu-Glu-Asp-Asp motif that binds an ion of
magnesium.
Although the PP_2554 N-terminal domain and AsbF both catalyze the same overall
reaction, we noted a large number of variations among residues forming the substrate binding
sites of the enzymes. In the AsbF-protocatechuate complex, the C1 carboxyl group of the

reaction product forms hydrogen bonds with the side chains of an arginine (Arg102) and
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two tyrosine residues (Tyr70 and Tyr217; Figure 5B). Simultaneous mutation of the two
tyrosines led to a ~10-fold increase in the KM of AsbF for dehydroshikimate, suggesting an
important role for these residues in substrate binding or solvent exclusion.126 However, none
of these residues is conserved in the PP_2554 N-terminal domain active site. Sequence
alignment suggests that these residues may also be different in fungal DSDs (Figure 5C). In the
structural alignment shown in Figure 5B, AsbF Arg102 corresponds with PP_2554 Leu97, while
the first AsbF Try70 is found in the same position as PP_2554 Arg64 (Figure 5B). The second
AsbF tyrosine, Try217, is located on a long α-helix that partially caps the enzyme’s active site. In
the PP_2554 structure, the long α-helix is replaced with the much shorter α9, while a glutamate
(Glu256) contributed by α13’ of the C-terminal domain of the second molecule of the PP_2554
dimer occupies roughly the same position as the AsbF Tyr217 side chain. Mutation of PP_2554
Glu256 to an alanine did not significantly alter the activity of the enzyme (Table 4), suggesting
this residue plays a different functional role than Asb Tyr217. Given the location of Glu356 at
the interface of two molecules in the PP_2554 dimer, we also explored the effect of the alanine
mutation on the oligomeric state of the protein. However, gel filtration studies demonstrate
that the mutation does not affect the dimeric assembly of PP_2554 (Figure S4). Mutation of a
nearby strictly conserved arginine (PP_2554 Arg207) resulted in a large increase in the KM for
dehydroshikimate, but also appeared to have additional effects on the conformation of the
protein, as determined by gel filtration analysis (Table 4, Figure S4). Similarly, mutation of a
second PP_2554 active site arginine (Arg210) also appeared to affect the tertiary structure of
the protein (Figure S4). The side chain of the latter arginine extends into a position occupied by

the side chain of the AsbF active site residue, Lys200 (the main chain of AsbF Lys200
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corresponds with PP_2554 Ala193; Figure 5B).
Other residues in the vicinity of the predicted binding site of the substrate hydroxyl
groups are presumed to participate in the reaction chemistry. However, these residues also
show significant variability between PP_2554 and AsbF. Catalysis by AsbF has been proposed to
be initiated by the removal of a proton from the aliphatic C4 atom of dehydroshikimate.126 This
role was attributed to AsbF His144, as this residue is strictly conserved among AsbF proteins
(Figure 5C) and its mutation completely inactivated the enzyme from B. anthracis. Intriguingly,
this histidine is not conserved in the PP_2554 structure, nor is it present in the sequences of
fungal DSDs (Figure 5C). In its place, PP_2554 contains a leucine (Leu136), a residue that is
unable to participate in the proposed proton abstraction step of the reaction. As an alternative,
we considered the possibility that a neighboring histidine in the PP_2554 structure, His168,
could function in this process. PP_2554 His168 is conserved in both siderophore biosynthesisand quinate degradation-associated bacterial DSDs, however it is replaced with an asparagine
or glutamine in fungal sequences (Figure 5C). We found that an alanine mutant of PP_2554
His168 still retained a significant level of activity (kcat ~8 s-1; Table 4). Therefore, while this
residue may be important for obtaining maximal turnover, it does not appear to be a critical
catalytic group. In agreement with this finding, an alanine mutant of the corresponding
histidine from AsbF (His175) retained trace activity, suggesting that this residue is also not
catalytically essential among siderophore biosynthesis-associated DSDs.126
In the proposed AsbF reaction mechanism, removal of the C4 proton is followed by

the formation of a non-covalent enolate that is stabilized by the active site metal.126 In a

149

subsequent step, the main chain carbonyl of AsbF Phe211 is predicted to act as an acid to
remove the C5 hydroxyl of the substrate, leading to the formation of protocatechuate after
aromatization of the reaction intermediate. Due to significant differences in the position of
secondary structures in this region of the active site, a residue corresponding with Phe211 is
not found in the PP_2554 structure (Figure 5A, B). A residue aligning with AsbF Phe211 is also
unidentifiable in fungal DSD sequences (Figure 5B). Mutation of a nearby PP_2554 serine
(Ser206), a residue that is strictly conserved in DSDs outside of the AsbF class (Figure 5C),
resulted in a ~10-fold increase in the KM of the enzyme for dehydroshikimate, but no change in
kcat (Table 4). This finding suggests that the serine may play an important role in binding the
substrate, although it unlikely to be required for the catalytic chemistry used by the enzyme.
When taken together, our results demonstrate that the PP_2554 N-terminal domain contains a
novel collection of residues for DSD activity and implies that the enzyme may employ a
different substrate binding mode and catalytic mechanism than AsbF.
Analysis of the PP_2554 C-terminal HPPD-like domain active site.
In the PP_2554 C-terminal domain, a putative active site is found in the second of the
two incomplete barrels that forms the VOC fold. The active site of P. fluorescens HPPD (PDB ID:
1CJX) is centered around a ferrous ion bound by a 2-His-1-carboxylate facial triad. We
identified an equivalent set of metal binding residues in the PP_2554 C-terminal domain
(His443, His521, Glu599; Figure 6B). While these residues appear to be conserved in C-terminal
module of most two-domain DSDs, the second histidine is substituted with a glutamine is
the PP_2554 ortholog from R. rhodochrous (Figure 6C).

An HPPD has yet to be structurally characterized in complex with the substrate, 4-
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hydroxyphenylpyruvate, or product, homogentisate. However, a number of residues important
to the overall chemistry used by this enzyme have been identified by site-directed mutagenesis.
The substrate binding site of P. fluorescens HPPD is formed by residues that include Ser201,
Pro214, Asn216, Phe337 and Phe341. Mutation of any of these residues results in a reduction
in HPPD activity and/or a change in hydroxylation regiospecificity.134-136 In the HPPD active site,
Ser201 is proposed to bind the C4-hydroxyl of 4-hydroxyphenylpyruvate. The corresponding
PP_2554 residue, Ser483, is found on the disordered loop that replaces a pair of ß-strands seen
in the HPPD structure (Figure 6A). A shift in the location of the PP_2554 disordered loop
compared to the HPPD ß-strands results in a difference in the position of the PP_2554 and
HPPD serine side chain hydroxyls of more than 4 Å (Figure 6B). In addition, we note that an
equivalent serine is not conserved in the sequences of some PP_2554 orthologs from Grampositive bacteria, including C. glutamicum and R. rhodochrous (Figure 6C).
Of the remaining HPPD active site residues, Pro214 and Asn216 are conserved in
PP_2554 (as Pro496 and Asn498), but not in all PP_2554 orthologs (Figure 6B, C). Sequence
alignment suggests that HPPD Phe341 and Phe337 are replaced in PP_2554 with Val615 and
Leu619 (Figure 6C), although due to the apparent conformational mobility of this region, the
position of these residues differs somewhat in each structure (Figure 6A, B). PP_2554 orthologs
from other bacteria possess a valine or alanine at the first position, while a leucine is strictly
conserved at the second position (Figure 6C). F337I and F341Y mutants of P. fluorescens HPPD
showed 150- and 6-fold decreases in HPPD activity, respectively (Gunsior et al., 2004).
Therefore, substitution of these residues with Val615 and Leu619 may impair the ability of

the PP_2554 C-terminal domain to catalyze the HPPD reaction. When taken together, the
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presence of the active site variations described here may explain the lack of HPPD activity we
have observed in our in vitro analysis of PP_2554.
Discussion
Diversity of enzymes involved in quinate and shikimate catabolism.
Soil-associated microbes possess versatile metabolic capacities. P. putida, in particular,
is well-known for its ability to degrade a large number of aromatics, including benzoate,
caffeate, nicotinate, phenylalanine, tyrosine, vanillate, and the hydroaromatic molecules,
quinate and shikimate.106, 137 Both quinate and shikimate are produced in significant quantities
by many plants.138, 139 Quinate alone is estimated to represent ~10% of the leaf litter by weight.
88

It is therefore logical that quinate and shikimate have also been found to act as

chemoattractants that draw microbes including P. putida to the rhizosphere.140-142
The microbial quinate pathway consists of three conserved overall reactions. However,
a number of structurally distinct enzyme variants are capable of catalyzing each step. These
enzymes include the NAD+- and PQQ-dependent Q/SDHs, the type I and type II DHQs, and the
soluble and membrane-associated DSDs. We have demonstrated here that P. putida and a
number of other bacteria encode a novel two-domain DSD variant. A transposon-based
knockout of a two-domain DSD from P. aeruginosa PAO1 resulted in the inability of this
organism to grow on either quinate or shikimate, demonstrating the essential nature of these
proteins in the quinate pathway (Figure 2).
Based on the analysis presented here, we can now delineate at least four DSD classes.
Three of these classes – the fungal single-domain DSDs, the siderophore biosynthesis-

associated AsbF orthologs, and the novel two-domain DSDs -- share at least a low level of
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sequence relatedness (Figure 7). The fourth group includes structurally unrelated proteins
typified by DSDs found in species of Acinetobacter. An additional DSD variant may be present in
the plant, Vigna mungo, 143 although we could not identify this protein by a BLAST search using
members of the other DSD classes as queries.

Figure 7. Phylogenetic analysis highlighting the distinct classes of DSDs. Only the N-terminal
(DSD) domain of the bacterial two-domain proteins were used in generating the tree, which
was created using Phylogeny.fr 144.

Importantly, our findings suggest that there may be many exceptions to common
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notion that Gram-positive and Gram-negative bacteria utilize different quinate pathway
enzymes. Although Pseudomonas belongs to the same Gram-negative gamma-proteobacteria
group as Acinetobacter, the analysis presented here indicates that several members of the
Pseudomonas genus in fact use quinate catabolic enzymes that are similar to those from fungi
and that are most closely related to those found in Gram-positive bacteria. These enzymes
include the novel two-domain DSD, which a BLAST analysis suggests is conserved as the sole
DSD in a number of Gram-negative and Gram-positive species. The presence of a putative PQQdependent Q/SDH in P. putida KT2440, as well as the existence of proteins related to
Acinetobacter DSD in the P. putida GB-1 and W619 strains (Table 4) suggests that some
pseudomonads may more accurately contain a mosaic of quinate pathway enzymes, with some
bearing resemblance to those found in other Gram-negative species and others showing
similarity to those from Gram-positive bacteria and fungi. Finally, while our analysis only
considered enzymes that participate in quinate degradation, the true diversity of proteins
involved in this process is likely to be even greater considering that several quinate pathway
regulatory proteins 145, 146 and transporters 147-149 also exist.
A novel structural environment for DSD activity.
We explored the diversity of quinate catabolic enzymes by structurally and
biochemically characterizing a representative of the novel two-domain DSD class, PP_2554 from
P. putida. The crystal structure of PP_2554 demonstrates that the protein is clearly composed
of two discrete structural domains, which differentiates it from fungal DSDs and the
siderophore biosynthesis-associated AsbF. DSD activity resides in the N-terminal domain of

PP_2554, which forms a TIM barrel that is similar to the structure of AsbF, but with a
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number of differences among secondary structural elements, particularly in the vicinity of
PP_2554 α9 (Figure 5A). Structural modeling studies using Phyre2 150 suggest that fungal DSDs
from A. nidulans and N. crassa are also likely to adopt a TIM barrel fold (data not shown).
A number of quinate pathway enzymes show a clear evolutionary relationship with
enzymes involved in the biosynthesis of the aromatic amino acid precursor, chorismite.102, 151
This finding is not surprising given that the chorismate biosynthetic pathway and the quinate
pathway share the substrates, shikimate, dehydroshikimate, and dehydroquinate. While type I
DHQs, which are often associated with chorismate biosynthesis, share the TIM barrel
architecture, they have mechanistically diverged from PP_2554 in that they are not metaldependent enzymes.122 Analysis by the Dali server 152 reveals that the overall fold of the
PP_2554 N-terminal domain may in fact be more similar to a number of sugar isomerases,
enzymes which like PP_2554, utilize a metal cofactor.153 These findings may suggest a more
direct evolutionary origin for the PP_2554 N-terminal domain in sugar metabolism. Likewise,
our structural modeling exercises predict that the central portion of the membrane-associated
A. calcoaceticus DSD forms a right-handed β-helix resembling the periplasmic alginate
epimerase, AlgG (PDB ID: 4NK6), and the β-xylosidase, XylC (PDB ID: 3VSV), suggesting another
possible evolutionary link between quinate catabolism and carbohydrate processing. It has also
been shown previously that PQQ-dependent Q/SDHs are closely related in their primary
sequences to PQQ-dependent glucose dehydrogenases.101
Out kinetic analysis of PP_2554 revealed that the enzyme is activated by a variety of
divalent cations with a preference for Co2+. Fungal DSDs 109, 128 and AsbF orthologs 125, 126 are

also metal-dependent enzymes capable of using a range of divalent cations. While AsbF
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from B. anthracis favors Mn2+, 126 the corresponding protein from B. thuringiensis shows a slight
preference for Mg2+ over Co2+ and Mn2+, 125 In contrast to these enzymes, the structurally
unrelated membrane-associated DSD from G. oxydans does not appear to require a metal for
its activity.154
We determined that PP_2554 catalyzes the conversion of dehydroshikimate to
protocatechuate with a kcat that is two orders of magnitude greater than those reported for the
AsbF enzymes from B. anthracis 126 and B. thuringiensis 125 (Table S1). The specific activity of
PP_2554, 135.4 ± 7.0 µmol/min/mg, is much closer to the published values for the fungal DSDs
from A. nidulans (261 µmol/min/mg) 128 and N. crassa (257 µmol/min/mg) 109, 155 (Table S1).
With respect to the PP_2554 substrate, dehydroshikimate, we determined a KM of ~300 µM.
This value is similar to those reported for other DSDs, which generally fall between ~100 µM
and ~650 µM (Table S1). Although both the PP_2554 N-terminal domain and AsbF belong to the
TIM barrel protein family and catalyze the same overall reaction, these enzymes contain very
few of the same active site residues outside of those involved in binding the metal cofactor. In
fact, we identified only a single histidine (PP_2554 His168) that is shared between the substrate
binding sites of two proteins (Figure 5B, C). Notably, we found that the proposed catalytic
group from AsbF, His144, corresponds with Leu136 in the structure of PP_2554, while mutation
of the nearby PP_2554 His168, another possible catalytic group, resulted only in a moderate
decrease in turnover (Table 4). We also observed broad differences in the size and placement
of secondary structures surrounding the active sites of the two enzymes, including the
substitution of a long AsbF α-helix with the shorter PP_2554 α-helices, α9 and α13’, the latter

contributed by the second molecule in the PP_2554 dimer (Figure 5A). The novel active site 156
features present in the PP_2554 N-terminal domain suggests that the enzyme may have a
distinct mode of binding its substrate and potentially a different catalytic mechanism than AsbF.
Given the absence of many of the AsbF active site residues in the sequences of fungal DSDs
(Figure 5C), it stands to reason that the fungal enzymes may also utilize a different substrate
binding mode and catalytic mechanism.
Enigmatic nature of the PP_2554 C-terminal domain.
The most unusual structural feature of PP_2554 is the presence of its large C-terminal
domain, which is clearly the result of a gene fusion event. The latter domain belongs to the
VOC family of structural folds, which is associated with a large number of enzymes, including
glyoxylase, fosfomycin resistance protein, HPPD, and several extradiol dioxygenases.130 The
compact interlocking of the individual domains in the PP_2554 dimer may suggest that the Nand C-terminal modules are functionally interdependent (Figure 4A). However, we have shown
that the N-terminal domain still retains in vitro DSD activity in the absence of the C-terminal
half of the protein (Table 4). We were also able to detect protocatechuate production in
quinate-fed E. coli cells expressing only the N-terminal domain of PP_2554
(data not shown). In addition, expression of the truncated protein permits growth of the
P. aeruginosa PAO1 1433 knock-out strain on quinate or shikimate (Figure 2). The fact that cells
expressing the truncated protein grew slower than those expressing the full-length protein may
suggest that the C-terminal domain of PP_2554 is required for optimal DSD activity, a finding
that is consistent with the 2.7-fold reduction in the turnover rate of the truncated variant
compared to the full-length protein (Table 4). However, these effects could also be due to a

reduction in the structural stability of the truncated protein, or in the case of the P.
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aeruginosa studies, to differences in the expression levels of the truncated and full-length
constructs. In any case, our results demonstrate that the C-terminal domain is not an absolute
requirement for the DSD activity of PP_2554, a conclusion that is in line with the fact that DSDs
from fungi lack the C-terminal HPPD-like domain entirely.
Since the PP_2554 C-terminal domain shares a highly similar three-dimensional fold as
well as a number of active site residues with bona fide HPPDs, we assessed whether PP_2554
has HPPD activity. However, we did not detect this activity using a coupled assay, an oxygen
liberation-based method, or by HPLC analysis. We also did not observe any color change
(browning) of the media when PP_2554 was expressed in E. coli cells provided with excess
tyrosine. Such a color change is associated with the formation of orchronic
pigment/pyomelanin from autooxidation and polymerization of homogentisate (the product of
the HPPD-catalyzed reaction) and has been reported during the expression of true HPPD
enzymes in E. coli cultures supplemented with tyrosine.135, 136, 156, 157 We hypothesize that the
lack of HPPD activity for PP_2554 may be related to the residue substitutions and/or
differences in the position of secondary structures we have identified in the predicted PP_2554
C-terminal active site compared to genuine HPPDs (Figure 6).
We also tested whether PP_2554 is capable of functioning as a PCD, a logical potential
activity considering that protocatechuate is produced by the N-terminal half of the protein.
However, this activity also appears to be absent. The apparent lack of PCD activity is supported
by the fact that quinate-fed E. coli cells expressing PP_2554 accumulate protocatechuate
without apparent further degradation of the compound (Figure 3A). In addition to these

findings, it should be noted that P. putida KT2440 already encodes a bona fide PCD, the two- 158
subunit PcaGH (PP_4655, PP_4656),158 as well as another protein (PP_3433) with much
Higher sequence identity to the verified HPPD from P. fluorescens.
Without an obvious enzymatic activity, the PP_2554 C-terminal domain is enigmatic.
The fact that the C-terminal domain active site has retained a metal-binding 2-His-1-carboxylate
facial triad may suggest that the domain has a catalytic activity, although its substrate remains
to be identified. An alternative hypothesis is that the domain is merely a vestigial structural
feature that has been retained to support to the N-terminal half of the protein via interactions
seen in the PP_2554 dimer (Figure 4A). Another possibility is that the C-terminal domain plays
a role in regulating the DSD activity of the N-terminal domain. The apparent ‘open’
conformation of the C-terminal domain and the presence of disordered secondary structures
(Figure 6A) suggests that the domain is somewhat flexible, and could conceivably undergo a
conformational change when a ligand is bound in its active site. A ligand-induced
conformational change could be conducted along structural elements that closely pass the Nterminal active site, such as α13, to alter the DSD activity of the protein. Although this function
is speculative, regulation of DSD activity is likely to be important for maintaining adequate
amounts of dehydroshikimate are available for chorismate biosynthesis. In fungi, substrate
channeling between the domains of the pentafunctional AROM complex, which catalyzes five
reactions in the biosynthesis of chorismate, is proposed to limit the loss of intermediates of
chorismate biosynthesis to the quinate pathway.159, 160 In contrast, the bacterial enzymes
required to produce chorismate are separate monofunctional proteins. Hence, one may
anticipate that bacteria have evolved different means of regulating flux through the two

competing pathways. It is an intriguing possibility that the C-terminal domain of PP_2554, 159
which is conspicuously absent from fungal DSDs, functions in this capacity.
PP_2554 acts at a branchpoint of catabolic and anabolic pathways.
Due to shared usage of the substrate, dehydroshikimate, DSDs may compete with the
biosynthetic SDH, AroE, involved in chorismate production.161 The AroE enzyme from C.
glutamicum (an organism which also encodes an ortholog of PP_2554) exhibits a kcat of ~330 s-1
and a KM for dehydroshikimate of ~200 µM.116 For the AroE enzyme from P. putida KT2440, we
previously measured a kcat of ~300 s-1 and a KM for shikimate of ~200 µM, albeit it for the
enzyme’s reverse reaction (shikimate to dehydroshikimate).121 These values are similar to those
that we have determined for the conversion of dehydroshikimate to protocatechuate by
PP_2554 (kcat ~ 150 s-1, KM ~ 300 µM). Based on these findings, PP_2554 may be capable of
redirecting a considerable amount of dehydroshikimate toward protocatechuate production
that would otherwise be destined for chorismate biosynthesis.
The ability of DSDs to act as a partition between catabolic and anabolic routes has a
number of fortuitous applications. Heterologous expression of DSDs in non-quinate-degrading
organisms has been used to generate a variety of valuable protocatechuate-derived molecules
including catechol 90 and vanillin.91, 92 DSD has also been used as part of an engineered scheme
to produce the compound, muconate, by co-expression of the enzyme alongside
protocatechuic acid decarboxylase and catechol 1,2-dioxygenase.94, 96 Muconate can
subsequently be converted by hydrogenation to adipic acid, an important chemical used in
making plastic that is normally produced by more environmentally damaging processes. Using
the DSD from the dung mold, P. anserina, recent studies have shown that muconate can be

generated in this manner in the common yeast, Saccharomyces cerevisiae (Curran et al.,
2012; Weber et al., 2012). Weber et al. also demonstrated that AsbF from B. thuringienesis
could be used for this purpose.95 Based on the high level of DSD activity of PP_2554, we
envision that this protein could similarly have applications in the microbe-based synthesis of
protocatechuate and useful downstream compounds.
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